Page last updated: 2024-12-08

rocuronium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441290
CHEMBL ID1201244
CHEBI ID8884
SCHEMBL ID29958
MeSH IDM0171457

Synonyms (46)

Synonym
BIDD:GT0360
HY-17033
AB01274786-01
zemuron
org-9426
143558-00-3
rocuronium
RBR ,
C07556 ,
DB00728
1-(17-(acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium
NCGC00167433-01
HMS2090E03
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate
CHEBI:8884 ,
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
rocuronium cation
rocuronium ion
CHEMBL1201244
unii-wre554rfez
wre554rfez ,
rocuronium [mi]
rocuronium [who-dd]
pyrrolidinium, 1-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-
EPITOPE ID:174837
CS-0733
1-[(1s,2s,4s,5s,7s,10r,11s,13s,14r,15s)-14-(acetyloxy)-5-hydroxy-2,15-dimethyl-4-(morpholin-4-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)pyrrolidin-1-ium
gtpl4003
SCHEMBL29958
AB01274786-02
DTXSID6048339 ,
YXRDKMPIGHSVRX-OOJCLDBCSA-N
AB01274786_03
SR-05000001500-1
sr-05000001500
1-[(2|a,3|a,5|a,16|a,17|a)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)pyrrolidinium
TQP0579
Q185331
BRD-K43305603-004-02-8
NCGC00167433-05
androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-(2-propen-1-yl)-1-pyrrolidiniumyl)-, 17-acetate, (2beta,3alpha,5alpha,16beta,17beta)-
17alpha-(acetyloxy)-3alpha-hydroxy-2beta-(morpholin-4-yl)-16alpha-[1-(prop-2-en-1-yl)pyrrolidin-1-ium-1-yl]-5beta,8alpha,14beta-androstane
AKOS040736692
pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-
dtxcid1028314
rocuronio

Research Excerpts

Overview

Rocuronium bromide is a neuromuscular blocker in widespread use in anaesthesia, emergency and intensive care. Rocuronium is a muscle relaxant with increased use due to its binding relation with the reversal agent sugammadex.

ExcerptReferenceRelevance
"Rocuronium is a non-depolarising muscle relaxant that is primarily metabolised by the liver."( Diaphragm ultrasound to evaluate the antagonistic effect of sugammadex on rocuronium after liver surgery in patients with different liver Child-Pugh grades: study protocol for a prospective, double-blind, non-randomised controlled trial.
Chen, R; Chen, X; Lin, Y; Sun, S; Sun, Y; Xia, H; Yao, C; Yao, S, 2022
)
1.67
"Rocuronium bromide is a commonly used NMB agent."( Comparison of two pharmacokinetic-pharmacodynamic models of rocuronium bromide during profound neuromuscular block: analysis of estimated and measured post-tetanic count effect.
Amorim, P; Couto, M; Esteves, S; Marco-Ariño, N; Mendes, J; Nunes, CS; Troconiz, IF; Vide, S, 2022
)
1.68
"Rocuronium bromide is a neuromuscular blocker in widespread use in anaesthesia, emergency and intensive care. "( Comparison of the onset and offset times of two available formulations of rocuronium bromide in an animal model.
Cave, G; Harvey, MG; Hopgood, G; O'Beirn, S; Speedy, LM, 2023
)
2.58
"Rocuronium is a neuromuscular blocking agent mainly used in anesthetic procedures. "( Findings of the neuromuscular blocking agent rocuronium in blood from deceased subjects several months after exposure: A report of two cases.
Brede, WR; Frost, J; Gjerde, S; Gundersen, POM; Pleym, H; Slørdal, L, 2023
)
2.61
"Rocuronium is a muscle relaxant with increased use, because of the binding relation with the reversal agent sugammadex. "( Rocuronium Continuous Infusion for Profound Neuromuscular Blockade: A Systematic Review and Meta-analysis.
Amorim, P; Couto, M; Mendes, J; Nunes, C; Vide, S,
)
3.02
"Rocuronium is a muscle relaxant with increased use due to its binding relation with the reversal agent sugammadex. "( Systematic Review on Rocuronium Continuous Infusion for Deep Neuromuscular Blockade.
Amorim, P; Couto, JG; Couto, M; Mendes, J; Nunes, CS; Vide, S, 2021
)
2.38
"Rocuronium is an aminosteroid nondepolarizing neuromuscular blocker that is widely used for anesthesia and intensive care. "( Rocuronium Has a Suppressive Effect on Platelet Function via the P2Y12 Receptor Pathway In Vitro That Is Not Reversed by Sugammadex.
Fukuda, K; Kawamoto, S; Murata, Y, 2020
)
3.44
"Rocuronium (ROC) is a neuromuscular blocker mainly eliminated by biliary excretion dependent on organic anion transporting polypeptide 1A2 (OATP1A2) hepatocellular uptake. "( The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.
Abumansur, JT; Coelho, EB; Correia, BV; Costa, ACC; de Moraes, NV; Lanchote, VL; Lauretti, GR, 2017
)
2.14
"Rocuronium is a non-depolarizing neuromuscular blocking agent which is associated with injection pain and induces withdrawal movement of the injected hand or arm or generalized movements of the body after intravenous injection. "( Comparison of randomized preemptive dexketoprofen trometamol or placebo tablets to prevent withdrawal movement caused by rocuronium injection.
Aydın, GB; Caparlar, CO; Ergil, J; Polat, R; Sayın, M, 2014
)
2.05
"Rocuronium bromide is a drug of choice for general anaesthesia in patients with traumatic cerebral compression."( [Rocuronium bromide as component of general anaesthesia in patients with traumatic cerebral compression].
Berezina, VV; Gribkov, AV; Kravets, LIa; Sheludiakov, AIu,
)
1.76
"Rocuronium (ROC) is a neuromuscular blocking agent used in surgical procedures which is eliminated primarily by biliary excretion. "( Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics.
de Moraes, NV; Filgueira, GC; Lanchote, VL; Lauretti, GR; Lopes, BC, 2014
)
2.22
"Rocuronium is a nondepolarizing neuromuscular blocking agent used in anesthesia induction and is associated with considerable discomfort and burning pain during injection, which is reported to occur in 50-80% of patients. "( The effect of intravenous paracetamol for the prevention of rocuronium injection pain.
Aypar, U; Canbay, O; Erden, IA; Uzun, S, 2014
)
2.09
"Rocuronium is an acceptable alternative when succinylcholine is contraindicated for facilitating the endotracheal intubation. "( Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis.
Dong, J; Gao, L; Lu, W; Xu, Z; Zheng, J, 2014
)
2.08
"Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that causes rapid muscle relaxation after intravenous injection. "( Structural characterization of a degradation product of rocuronium using nanoelectrospray-high resolution mass spectrometry.
Harms, G; Hayen, H; Volmer, DA; Wegener, O, 2015
)
2.11
"Rocuronium bromide (Rb) is a rapid onset, intermediate-acting neuromuscular blocking agent that is suitable for continuous administration. "( Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia.
Enohata, K; Kamikawaji, T; Kanmura, Y; Matsunaga, A; Moriyama, T; Nagata, O; Uchino, E, 2015
)
2.15
"Rocuronium is a neuromuscular blocking agent acting as a competitive antagonist of acetylcholine. "( Interaction of rocuronium with human liver cytochromes P450.
Adamus, M; Anzenbacher, P; Anzenbacherova, E; Bachleda, P; Jourova, L; Spicakova, A; Ulrichova, J, 2015
)
2.21
"Rocuronium bromide is a routinely used muscle relaxant in anaesthetic practice. "( Pharmacological and non-pharmacological interventions for reducing rocuronium bromide induced pain on injection in children and adults.
Ali, Z; Kalaivani, M; Prabhakar, H; Singh, GP; Smith, MA, 2016
)
2.11
"Rocuronium is a useful alternative when succinylcholine is contraindicated."( Rocuronium vs. succinylcholine in the emergency department: a critical appraisal.
Keim, SM; Mallon, WK; Shoenberger, JM; Walls, RM, 2009
)
2.52
"Rocuronium is a steroid-type, synthetic, non-depolarizing neuromuscular blocker of medium duration."( A comparative study between one and two effective doses (ED95) of rocuronium for tracheal intubation.
Barrucand, L; Costa, J; de Miranda, LC; Verçosa, N,
)
1.09
"Rocuronium is an aminosteroid non-depolarizing neuromuscular relaxant, which is metabolized in the liver and excreted through bile. "( Is neuromuscular relaxation of rocuronium prolonged in patients with obstructive jaundice?
Bao, Y; Lu, Z; Wang, Z; Yu, W, 2011
)
2.1
"Rocuronium at 0.06 mg/kg is an overdose for precurarization. "( A randomized trial to identify optimal precurarizing dose of rocuronium to avoid precurarization-induced neuromuscular block.
Fukano, N; Ishikawa, K; Mizutani, H; Ogawa, S; Saeki, S; Suzuki, T, 2011
)
2.05
"Rocuronium bromide is a muscle relaxant used in general anesthesia, inhibiting cholinergic neurotransmission of neuromuscular junction. "( [Interaction of donepezil with rocuronium].
Pautola, L; Reinikainen, M, 2012
)
2.11
"Rocuronium is a widely accepted alternative, but its duration could contribute to delay at surgery end."( Impact of rocuronium vs succinylcholine neuromuscular blocking drug choice for laparoscopic pyloromyotomy: is there a difference in time to transport to recovery?
Amin, A; Applegate, RL; Felema, B; Ghazal, E; Wu, A, 2013
)
1.51
"Rocuronium is a commonly used nondepolarizing paralytic agent but its prolonged duration of action must be weighed against the risk of side effects associated with succinylcholine."( Controversies in rapid sequence intubation in children.
Dayan, P; Levin, S; Roskind, C; Schnadower, D; Smith-Lockridge, A; Tyler, S; Zelicof-Paul, A, 2005
)
1.05
"Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. "( A clinical study of the effects of rocuronium in isoflurane-anaesthetized cats.
Auer, U; Mosing, M, 2006
)
2.05
"Rocuronium is an alternative to mivacurium for short procedures, without the risk of unexpected prolonged relaxation due to a possible defect in plasma cholinesterase."( A comparison of intubation conditions and time-course of action with rocuronium and mivacurium for day case anaesthesia.
Lois, F; Pendeville, PE; Scholtes, JL, 2007
)
1.3
"Rocuronium is an effective nondepolarizing muscle relaxant in horses under isoflurane anaesthesia. "( Observations on the muscle relaxant rocuronium bromide in the horse--a dose-response study.
Auer, U; Mosing, M; Uray, C, 2007
)
2.06
"Rocuronium is a new nondepolarizing muscle relaxant with a rapid onset and intermediate duration of action. "( Pharmacokinetics of rocuronium in children aged 4-11 years.
Fisher, DM; Vuksanaj, D, 1995
)
2.06
"Rocuronium is a new, intermediate-acting, nondepolarizing relaxant with rapid onset of action leading to both good and very good intubation conditions. "( [Mechanomyographic and electromyographic studies of endotracheal intubation with 2 different rocuronium dosages].
Benad, G; Hofmockel, R; Kabott, A, 1994
)
1.95
"Rocuronium is a new nondepolarizing neuromuscular blocking agent with a rapid onset but with intermediate duration of action. "( Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination.
Naguib, M, 1994
)
2.03
"Rocuronium is a new nondepolarizing neuromuscular blocking drug. "( The pharmacology of rocuronium bromide (ORG 9426).
Wicks, TC, 1994
)
2.05
"Rocuronium (ORG 9426) is a new nondepolarizing neuromuscular blocking agent with a rapid onset and an intermediate duration of action. "( Continuous intravenous infusion of rocuronium (ORG 9426) in patients receiving balanced, enflurane, or isoflurane anesthesia.
Fragen, RJ; Ling, D; Shanks, CA, 1993
)
2.01
"Rocuronium is a new aminosteroidal muscle relaxant, the main feature of which is a low potency compared to other aminosteroidal muscle relaxants. "( Dose-response and time-course of action of rocuronium bromide.
Mirakhur, RK, 1995
)
2
"Rocuronium is a new steroid muscle relaxant possibly eliminated through the liver."( Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study.
Desmonts, JM; Kleef, U; Lavaut, E; Servin, FS, 1996
)
1.35
"Rocuronium is a newly released steroidal nondepolarizing muscle relaxant with an intermediate duration of action."( Failure of neuromuscular blockade reversal after rocuronium in a patient who received oral neomycin.
Bailey, PL; Hasfurther, DL, 1996
)
1.27
"Rocuronium is a steroidal non-depolarising neuromuscular blocking agent chemically related to vecuronium."( [New muscle relaxants].
Buzello, W; Diefenbach, C, 1996
)
1.02
"Rocuronium is a new non-depolarising steroidal muscle relaxant with a short onset time. "( [Intubation requirements after rocuronium and succinylcholine].
Gervais, HW; Kleemann, PP; Latorre, F; Stanek, A, 1996
)
2.02
"Rocuronium is a new nondepolarizing muscle relaxant for which a fast onset has been described. "( [Intubation conditions and the development of neuromuscular blockade with rocuronium in endoscopic ORL surgery].
Leuwer, M; Lüllwitz, E; Piepenbrock, S; Schultze-Florey, T; Zuzan, O, 1997
)
1.97
"Rocuronium is a recently introduced nondepolarising neuromuscular blocking agent with a rapid onset and intermediate duration of action. "( Tracheal intubation conditions after one minute: rocuronium and vecuronium, alone and in combination.
England, AJ; Feldman, SA; Margarson, MP, 1997
)
1.99
"Rocuronium is a new nondepolarizing muscle relaxant. "( Comparison of neuromuscular action of rocuronium, a new steroidal non-depolarizing agent, with vecuronium.
Chao, A; Fan, SZ; Lin, PL; Liu, CC; Shin, SC; Tai, YT, 1997
)
2.01
"Rocuronium is an intermediate-acting muscle relaxant as vecuronium with good to excellent intubation condition."( Comparison of neuromuscular action of rocuronium, a new steroidal non-depolarizing agent, with vecuronium.
Chao, A; Fan, SZ; Lin, PL; Liu, CC; Shin, SC; Tai, YT, 1997
)
1.29
"Rocuronium is a new nondepolarizing neuromuscular blocking agent (NDNMBA) that has recently been introduced for clinical use. "( [Rocuronium].
Alvarez-Gómez, JA, 1997
)
2.65
"Rocuronium is a non-depolarising neuromuscular blocking agent structurally related to vecuronium. "( [Rocuronium for anesthesia induction in elective procedures. Time course of muscular blockade and intubation after administration of 2-compartment ED95 (0.6 mg/kg) and dose reduction (0.4 mg/kg)].
Fuchs-Buder, T; Schlaich, N; Ziegenfuss, T, 1999
)
2.66
"Rocuronium is a recently synthesized non-depolarizing neuromuscular blocking agent (NMBA) that has been demonstrated to have a faster onset of action than any other non-depolarizing NMBA. "( Rocuronium for rapid sequence intubation of emergency department patients.
Laurin, EG; Panacek, EA; Rantapaa, AA; Sakles, JC,
)
3.02
"Rocuronium is a non-depolarizing neuromuscular blocking agent which has a rapid onset and intermediate duration of action. "( Effects of priming with pancuronium or rocuronium on intubation with rocuronium in children.
Bai, SJ; Cohen, SP; Kim, JR; Lee, SK; Nam, YT; Shin, YS, 1999
)
2.02
"Rocuronium is a non-depolarizing neuromuscular blocking agent with intermediate duration of action and without significant cumulative properties, suitable for continuous infusion. "( The influence of halothane, isoflurane and sevoflurane on rocuronium infusion in children.
Lapczynski, T; Wierzejski, W; Woloszczuk-Gebicka, B, 2001
)
2

Effects

Rocuronium has an onset of action more rapid than other non-depolarizing neuromuscular blocking agents. It is unclear whether it and succinylcholine give equivalent intubating conditions during rapid-sequence induction of anaesthesia.

Rocuronium has been reported to have minimal haemodynamic effects. It provides conditions more suitable for rapid tracheal intubation. Rocuronium bromide has been evaluated as a mydriatic agent in birds.

ExcerptReferenceRelevance
"Rocuronium has a higher rate of IgE-mediated anaphylaxis compared with vecuronium, a result that is statistically significant and clinically important. "( Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011.
Bunning, DL; Clarke, RC; Platt, PR; Sadleir, PH, 2013
)
1.83
"Rocuronium, which has a short onset time and is free of hyperkalemic effects, could be considered for rapid-sequence induction of anesthesia in patients with burns. "( Neuromuscular pharmacodynamics of rocuronium in patients with major burns.
Bae, J; Han, T; Kim, H; Kim, K; Martyn, JA, 2004
)
2.05
"Rocuronium has an intermediate duration of action and produces its maximum effect within two minutes which is much more rapid than any other non-depolarizing relaxant and this is probably a result of its poor potency."( Newer neuromuscular blocking agents.
Bevan, DR, 1994
)
1.01
"Rocuronium has a short onset time and an intermediate duration of action."( Muscle paralysis by rocuronium during halothane, enflurane, isoflurane, and total intravenous anesthesia.
Crul, JF; Oris, B; Sabbe, MB; Van Aken, H; Van Egmond, J; Vandermeersch, E, 1993
)
1.33
"Rocuronium has an onset of action more rapid than other non-depolarizing neuromuscular blocking agents, but it is unclear whether it and succinylcholine give equivalent intubating conditions during rapid-sequence induction of anaesthesia. "( A large simple randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anaesthesia along with propofol.
Andrews, JI; Kumar, N; Olkkola, KT; Roest, GJ; van den Brom, RH; Wright, PM, 1999
)
2.02
"Rocuronium has a similar pharmacokinetic profile to vecuronium but its onset of action is more rapid and duration of action slightly shorter."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
1.02
"Rocuronium bromide has been evaluated as a mydriatic agent in birds, but the species applied were limited and the dose and effect were variable."( Application of topical rocuronium bromide dosing by ocular size in four species of wild birds.
Han, JI; Jung, S; Kim, N; Rhim, H, 2023
)
2.66
"Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively."( Interaction of rocuronium with human liver cytochromes P450.
Adamus, M; Anzenbacher, P; Anzenbacherova, E; Bachleda, P; Jourova, L; Spicakova, A; Ulrichova, J, 2015
)
1.49
"Rocuronium has been suggested as an alternative to succinylcholine for intubation."( Rocuronium versus succinylcholine for rapid sequence induction intubation.
Lee, JS; Mount, VA; Newton, EK; Perry, JJ; Tran, DT; Wells, GA, 2015
)
2.58
"Rocuronium has rapid onset at higher doses, but with a prolonged duration of action."( Optimal anesthetic regimen for ambulatory laser microlaryngeal surgery.
Baek, SK; Cho, JE; Huh, H; Jung, KY; Lee, HW; Lim, HH; Lim, HJ; Park, SJ; Yoon, SZ, 2017
)
1.18
"Rocuronium has been suggested to create intubating conditions similar to suxamethonium."( [Does rocuronium displace the position of suxamethonium?].
Iwasaki, H; Sasakawa, T, 2008
)
1.55
"Rocuronium has been associated with muscle weakness when administered in prolonged infusions. "( The effect of rocuronium, sugammadex, and their combination on cardiac muscle and diaphragmatic skeletal muscle cells.
Bostan, H; Bostan, M; Kalkan, Y; Temiz, A; Tomak, Y; Tumkaya, L; Turan, A; Turut, H; Yalçin, A; Yilmaz, A, 2012
)
2.18
"Rocuronium has a higher rate of IgE-mediated anaphylaxis compared with vecuronium, a result that is statistically significant and clinically important. "( Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011.
Bunning, DL; Clarke, RC; Platt, PR; Sadleir, PH, 2013
)
1.83
"Rocuronium has been widely used as an alternative to succinylcholine during the induction of anesthesia."( Rocuronium-induced generalized spontaneous movements cause pulmonary aspiration.
Hsu, JC; Huang, SJ; Lui, JT; Lui, PW; Yang, CY, 2002
)
2.48
"Rocuronium has been suggested to create intubating conditions similar to succinylcholine."( Rocuronium versus succinylcholine for rapid sequence induction intubation.
Lee, J; Perry, J; Wells, G, 2003
)
2.48
"Rocuronium (ORG 9426) has been shown to have an onset of action more rapid than other nondepolarizing neuromuscular blocking agents and to provide intubating conditions similar to those of succinylcholine 60-90 s after administration. "( Rocuronium combined with i.v. lidocaine for rapid tracheal intubation.
Aşik, Y; Okten, F; Yörükoglu, D, 2003
)
3.2
"Rocuronium, which has a short onset time and is free of hyperkalemic effects, could be considered for rapid-sequence induction of anesthesia in patients with burns. "( Neuromuscular pharmacodynamics of rocuronium in patients with major burns.
Bae, J; Han, T; Kim, H; Kim, K; Martyn, JA, 2004
)
2.05
"Rocuronium has been said to have an initially rapid onset of action followed by a slower final approach to maximum effect, the supporting data showing only that time to 75% of blockade is more rapid. "( [Rocuronium: onset time or speed of action?].
Steinberg, D,
)
2.48
"Rocuronium has been suggested as an alternative to succinylcholine for intubation."( Rocuronium versus succinylcholine for rapid sequence induction intubation.
Lee, JS; Perry, JJ; Sillberg, VA; Wells, GA, 2008
)
2.51
"Rocuronium has properties that may make it suitable for rapid-sequence intubation. "( Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anesthetized patients.
Cantineau, JP; d'Honneur, G; Duvaldestin, P; Porte, F, 1994
)
2.03
"Rocuronium has an intermediate duration of action and produces its maximum effect within two minutes which is much more rapid than any other non-depolarizing relaxant and this is probably a result of its poor potency."( Newer neuromuscular blocking agents.
Bevan, DR, 1994
)
1.01
"Rocuronium has a short onset time and an intermediate duration of action."( Muscle paralysis by rocuronium during halothane, enflurane, isoflurane, and total intravenous anesthesia.
Crul, JF; Oris, B; Sabbe, MB; Van Aken, H; Van Egmond, J; Vandermeersch, E, 1993
)
1.33
"Rocuronium has been reported to have minimal haemodynamic effects. "( The haemodynamic effects of rocuronium and vecuronium are different under balanced anaesthesia.
Hecker, RB; Stevens, JB; Talbot, JC; Walker, SC, 1997
)
2.03
"Rocuronium has minimal side effects, provides conditions more suitable for rapid tracheal intubation, and is associated with a shorter clinical duration than atracurium. "( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
1.99
"Rocuronium has an onset of action more rapid than other non-depolarizing neuromuscular blocking agents, but it is unclear whether it and succinylcholine give equivalent intubating conditions during rapid-sequence induction of anaesthesia. "( A large simple randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anaesthesia along with propofol.
Andrews, JI; Kumar, N; Olkkola, KT; Roest, GJ; van den Brom, RH; Wright, PM, 1999
)
2.02
"Rocuronium has a similar pharmacokinetic profile to vecuronium but its onset of action is more rapid and duration of action slightly shorter."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
1.02
"Rocuronium has mild vagolytic effects and does not release histamine, even when administered in large doses."( Newer neuromuscular blocking agents: how do they compare with established agents?
Beaufort, TM; Fuchs-Buder, T; Sparr, HJ, 2001
)
1.03

Actions

Rocuronium is known to cause mast cell mobilization, hypersensitivity, and pancreatitis. Rocuronium can produce optimal intubating conditions without the serious complications that can accompany succinylcholine.

ExcerptReferenceRelevance
"Rocuronium is known to cause mast cell mobilization, hypersensitivity, and pancreatitis."( Effect of sugammadex on rocuronium induced changes in pancreatic mast cells.
Altuner, D; Bedir, R; Bostan, H; Erdivanli, B; Kalkan, Y; Tomak, Y; Tumkaya, L; Turan, A; Yalcin, A; Yilmaz, A, 2015
)
1.45
"Rocuronium can produce optimal intubating conditions without the serious complications that can accompany succinylcholine."( Newer agents for rapid sequence intubation: etomidate and rocuronium.
Baum, CR; Ching, KY, 2009
)
1.32
"Rocuronium did not produce significant changes in the measured cardiovascular parameters."( Observations on the muscle relaxant rocuronium bromide in the horse--a dose-response study.
Auer, U; Mosing, M; Uray, C, 2007
)
1.34

Treatment

Rocuronium pretreatment given just before induction of anaesthesia with propofol reduces fasciculations and succinylcholine-induced myalgia. Pretreatment with rocuronium and d-tubocurarine was superior to cisatracurium. Rocuronium priming, pret treatment with ephedrine, and pretreatment with magnesium sulphate were all effective in accelerating the onset time of ro Curonium.

ExcerptReferenceRelevance
"Rocuronium priming, pretreatment with ephedrine, and pretreatment with magnesium sulphate were all effective in accelerating the onset time of rocuronium, and furthermore their efficacies were similar. "( Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis.
Dong, J; Gao, L; Lu, W; Xu, Z; Zheng, J, 2014
)
2.08
"Rocuronium pretreatment given just before induction of anaesthesia with propofol reduces fasciculations and succinylcholine-induced myalgia."( A rapid precurarization technique using rocuronium.
Finucane, B; Gupta, S; Kearney, R; Mayson, T; Reid, S; Tsui, BC, 1998
)
2.01
"Rocuronium pretreatment was more effective in reducing fasciculations than was vecuronium pretreatment, but both were equally effective in preventing myalgia on postoperative day 1. "( Comparison of rocuronium and vecuronium pretreatment for prevention of fasciculations, myalgia and biochemical changes following succinylcholine administration.
Chang, SH; Cho, H; Kim, JH; Lee, HW; Lim, HJ; Yoon, SM, 1999
)
2.11
"Pretreatment with rocuronium effectively reduces the biochemical changes associated with succinylcholine-induced muscle fasciculations. "( Biochemical changes following succinylcholine administration after pretreatment with rocuronium at different intervals.
Farhat, K; Jaffery, N; Pasha, AK, 2014
)
0.96
"Pretreatment with rocuronium and d-tubocurarine was superior to cisatracurium in preventing succinylcholine-induced fasciculations. "( Effects of pretreatment with cisatracurium, rocuronium, and d-tubocurarine on succinylcholine-induced fasciculations and myalgia: a comparison with placebo.
Cross, S; Hailey, A; Joshi, GP; Thompson-Bell, G; Whitten, CC, 1999
)
0.9

Toxicity

Rocuronium is as safe and efficacious as vecuronium for CIP in the pediatric ED. Adverse respiratory events were significantly less frequent in the roCuronium group.

ExcerptReferenceRelevance
" Any adverse effects of metabolites are also potential problems."( Safety aspects of non-depolarizing neuromuscular blocking agents with special reference to rocuronium bromide.
Mirakhur, RK, 1994
)
0.51
" Intubation conditions 60 sec after administration of muscle relaxant and immediate cardiovascular disturbances or adverse events during the hospital stay were noted by blinded observers."( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
0.54
" The incidence of adverse events and the cardiovascular profiles for the two drugs were similar, although one patient receiving atracurium experienced transient flushing of the head and neck."( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
0.54
" Presence of injection pain, sense of paralysis, SpO2 less than 95% during induction, and any unexpected adverse event were also recorded."( Effectiveness and safety of rocuronium-hypnotic sequence for rapid-sequence induction.
Chung, YT; Yeh, LT, 2001
)
0.6
"Rocuronium is as safe and efficacious as vecuronium for CIP in the pediatric ED."( Safety and efficacy of rocuronium for controlled intubation with paralytics in the pediatric emergency department.
Abramo, TJ; Goto, CS; Mendez, DR; Wiebe, RA, 2001
)
2.06
" We hypothesized that the Food and Drug Administration Adverse Event Reporting System could be used to confirm whether there has been an unusual incidence of anaphylactic events for rocuronium in the United States (U."( The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of food and drug administration reporting of adverse events.
Bhananker, SM; Bishop, MJ; O'Donnell, JT; Salemi, JR, 2005
)
0.79
" Sugammadex was safe and well tolerated."( Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.
Larsen, PB; Norrild, K; Ostergaard, D; Prins, ME; Sorgenfrei, IF; Stensballe, J; Viby-Mogensen, J, 2006
)
0.71
" No adverse effects were found except a case of local erythema on a forearm."( [Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients].
Iwao, Y; Ozaki, M; Saeki, S; Suzuki, T; Takeda, J, 2006
)
0.56
" No serious adverse events were reported during this trial."( A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block.
Drover, D; Groudine, SB; Lien, C; Roberts, K; Soto, R, 2007
)
0.54
" Sugammadex was safe and well tolerated."( Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Beaufort, AM; Proost, JH; Rietbergen, H; Saldien, V; Sparr, HJ; Velik-Salchner, C; Vermeyen, KM; Wierda, JM, 2007
)
0.64
" No serious adverse events related to sugammadex were reported."( Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer, HD; Driessen, JJ; Heeringa, M; Kerkkamp, H; Klimek, M; Marcus, MA, 2007
)
0.72
"No serious adverse events (AEs) were reported."( Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
Cammu, G; De Kam, PJ; Decoopman, M; Demeyer, I; Foubert, L; Peeters, PA; Smeets, JM, 2008
)
0.56
" No sugammadex-related serious adverse events were reported."( Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.
Driessen, JJ; Flockton, EA; Heeringa, M; Hunter, JM; Snoeck, MM; Staals, LM, 2008
)
0.35
"The Leipzig fast-track protocol for cardio-anesthesia including the central elements of switching opiate therapy to remifentanil and switching patient recovery to a special post-anesthesia recovery and care unit, shortened therapy times, is safe and economically effective."( [Leipzig fast-track protocol for cardio-anesthesia. Effective, safe and economical].
Ender, J; Fassl, J; Funkat, AK; Häntschel, D; Scholz, M; Sommer, M; Wittmann, M, 2009
)
0.35
" Three serious adverse events, one in each treatment group, considered to be possibly drug-related according to the investigator, were cases of mild QTc (Bazett) interval prolongation."( Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery.
Abels, EA; Blobner, M; Dahl, V; Heier, T; Hollmann, MW; Pendeville, PE, 2009
)
0.6
"The aim of this study was to compare intubating conditions and adverse events after sevoflurane induction in infants, with or without the use of rocuronium or alfentanil."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.57
" The secondary outcome criteria were respiratory (Sp(O₂) <90%, laryngospasm, closed vocal cords preventing intubation, bronchospasm) and haemodynamic adverse events (heart rate and mean arterial pressure variations ≥30% control value)."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.37
" Adverse respiratory events were significantly less frequent in the rocuronium group: 0% vs 33% in the placebo group and 30% in the alfentanil group (P=0."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.6
"3 mg kg⁻¹ rocuronium to 8% sevoflurane improved intubating conditions and decreased the frequency of respiratory adverse events."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.77
" Adverse events were reported in 87."( Safety and Efficacy of Rocuronium With Sugammadex Reversal Versus Succinylcholine in Outpatient Surgery-A Multicenter, Randomized, Safety Assessor-Blinded Trial.
de Bie, J; Egan, TD; Jahr, JS; Pavlin, J; Philip, BK; Rowe, E; Sabo, D; Soto, R; Woo, T,
)
0.44
" No adverse events or evidence of recurrence of neuromuscular block were observed."( Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial.
Alvarez-Gomez, JA; Caparros, MP; de Oliveira Junior, IS; de Souza, CM; Garcia, NN; Tardelli, MA; Tedesco, H, 2015
)
0.64
" There was no any one case of adverse events for the entire period of 24-hour surveillance, the drug has no cumulative effect."( [EFFICACY AND SAFETY OF ROCURONIUM BROMIDE PRODUCED IN THE RUSSIAN FEDERATION: A SINGLE-BLIND RANDOMIZED CLINICAL TRIAL].
Bragina, SV; Karpun, NA; Lugovoy, AV; Ovezov, AM; Prokoshev, PV; Timoshin, SS,
)
0.44
" Two reviewers independently selected the trials; extracted data on reversal times, incomplete reversals of NMB, and adverse events (AEs); and assessed the trials' methodological quality and evidence level."( Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
Carron, M; Ori, C; Tellaroli, P; Zarantonello, F, 2016
)
0.43
" The safe preparation of medications during resuscitation requires attention, time and resources, and can be a source of medication error."( Predrawn prehospital medications are microbiologically safe for up to 48 hours.
Foster, A; Garner, A; Gutierrez, CH; Kitcher, J; Soeyland, T; Vidler, S, 2018
)
0.48
"Predrawing of the eight studied medications for urgent prehospital procedures appears to be a microbiologically safe practice with syringe dwell times up to 48 hours."( Predrawn prehospital medications are microbiologically safe for up to 48 hours.
Foster, A; Garner, A; Gutierrez, CH; Kitcher, J; Soeyland, T; Vidler, S, 2018
)
0.48
" No serious adverse effects were happened in this study."( Safety, tolerability, and pharmacokinetics of adamgammadex sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers.
Jiang, Y; Liu, J; Xiang, S; Zhang, W; Zhang, Y; Zhao, W, 2020
)
0.77
" Specifically, this study assessed the impact of sugammadex on cardiac adverse events (AEs) and other prespecified AEs of clinical interest."( A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants.
Blobner, M; Broussard, DM; Herring, WJ; Lin, L; Lombard, JF; Lutkiewicz, J; Mukai, Y; Wang, A; Watkins, M, 2021
)
0.62
" The incidence of adverse events did not differ significantly between the groups."( Safety and efficacy of an automated anesthesia delivery system for total intravenous anesthesia with propofol, remifentanil, and rocuronium: a non-inferiority randomized controlled trial versus manually controlled anesthesia.
Matsuki, Y; Nagata, O; Ogino, Y; Shigemi, K, 2022
)
0.93
" This study aimed to explore sugammadex safety issues in the real world and determine the spectrum of adverse reactions."( Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database.
Chen, C; Chen, X; Guo, X; Lyu, Q; Xu, J; Ye, P; Ye, X; Zhang, H; Zheng, Y, 2023
)
0.91
"All sugammadex-related adverse events reported in VigiBase between 2010 and 2019 were classified by group queries according to the Medical Dictionary for Regulatory Activities."( Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database.
Chen, C; Chen, X; Guo, X; Lyu, Q; Xu, J; Ye, P; Ye, X; Zhang, H; Zheng, Y, 2023
)
0.91
"Overall, 16 219 410 adverse events were reported and 2032 were associated with sugammadex."( Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database.
Chen, C; Chen, X; Guo, X; Lyu, Q; Xu, J; Ye, P; Ye, X; Zhang, H; Zheng, Y, 2023
)
0.91
" CONCLUSIONS Sugammadex administration is safe and effective for SPK transplantation recipients."( Safety and Efficacy of 4 mg·kg⁻¹ Sugammadex for Simultaneous Pancreas-Kidney Transplantation Recipients: A Prospective Randomized Trial.
He, R; Tang, J; Xu, S; Zhang, L, 2023
)
0.91

Pharmacokinetics

Rocuroniu (Stanpump) was given to 72 patients scheduled for orthopaedic surgery. Pharmacokinetic analysis showed no significant differences for rocuronium during the 3 anesthetic techniques.

ExcerptReferenceRelevance
" All other pharmacodynamic parameters were similar."( A comparison of the pharmacodynamics of rocuronium and vecuronium during halothane anaesthesia.
Baird, WL; Booth, MG; Bryden, FM; Marsh, B; Robertson, EN, 1992
)
0.55
" A population-based pharmacokinetic analysis (NONMEM) was used to determine typical values, standard errors, and interindividual variability for the pharmacokinetic parameters and to determine whether these values differed between control and renal transplant patients."( Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation.
Bragg, P; Caldwell, JE; Fisher, DM; Gruenke, LD; Miller, RD; Segredo, V; Sharma, ML; Szenohradszky, J, 1992
)
0.61
"To determine the pharmacodynamic characteristics of three incremental doses of ORG 9426 used for endotracheal intubation in patients."( Pharmacodynamic effects of three doses of ORG 9426 used for endotracheal intubation in humans.
Dubois, MY; Kataria, BK; Lapeyre, G; Lea, D; Tran, DQ,
)
0.13
" Pharmacokinetic variables were calculated by iterative linear least square regression analysis."( The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.
Agoston, S; Kleef, UW; Kloppenburg, WD; Lambalk, LM; Wierda, JM, 1991
)
0.28
" With ORG 9616, mean elimination half-life was slower and mean residence time longer in cats with renal pedicle ligation."( The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat.
Agoston, S; Caldwell, JE; Canfell, PC; Castagnoli, KP; Khuenl-Brady, K; Miller, RD, 1990
)
0.28
" The half-life of transport between plasma and biophase (effect compartment) was significantly shorter at the adductor laryngeal muscles (2."( Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans.
Barre, J; Debaene, B; Meistelman, C; Plaud, B; Proost, JH; Wierda, JM, 1995
)
0.56
"The agreement between evoked adductor pollicis mechanomyogram and first dorsal interosseous evoked electromyogram (EMG) was evaluated during a pharmacodynamic study of rocuronium and vecuronium."( The agreement between adductor pollicis mechanomyogram and first dorsal interosseous electromyogram. A pharmacodynamic study of rocuronium and vecuronium.
Engbaek, J; Hangaard, N; Roed, J; Viby-Mogensen, J, 1994
)
0.69
" Pharmacokinetic differences between groups were determined using a population-based pharmacokinetic analysis (NONMEM)."( The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease.
Caldwell, J; Fisher, D; Gruenke, L; Magorian, T; Miller, R; Segredo, V; Sharma, M; Szenohradszky, J; Wood, P, 1995
)
0.54
"The existing human pharmacokinetic studies have been reviewed and compared with data derived from animals."( Pharmacokinetics and pharmacokinetic/dynamic relationship of rocuronium bromide in humans.
Hommes, FD; Proost, JH; Schiere, S; Wierda, JM, 1994
)
0.53
" Pharmacokinetic analysis showed no significant differences for rocuronium during the 3 anesthetic techniques."( Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics.
Hennis, PJ; Leclercq, MG; Smeulers, NJ; van den Broek, L; van Santen, GJ; Wierda, JM,
)
0.67
" Data were fitted to both a pharmacokinetic and a pharmacodynamic model by using a two-compartment open model and an effect compartment model."( Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis.
D'Honneur, G; De Hys, C; Duvaldestin, P; Gomeni, R; Khalil, M; Slavov, V, 1994
)
0.55
" The elimination half-life was 87."( Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis.
D'Honneur, G; De Hys, C; Duvaldestin, P; Gomeni, R; Khalil, M; Slavov, V, 1994
)
0.55
" The pharmacokinetic data were best described by a three-exponential equation."( Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure.
Brady, M; Cooper, RA; Fitzpatrick, KT; Maddineni, VR; Mirakhur, RK; Wierda, JM, 1993
)
0.53
"The effects of age on the pharmacokinetic and pharmacodynamic responses to rocuronium (Org 9426) were studied in 20 elderly (> 70 yr) and 20 younger control patients (< 60 yr) during N2O/O2, fentanyl anesthesia."( Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients.
Matteo, RS; Ornstein, E; Ostapkovich, N; Schwartz, AE; Stone, JG, 1993
)
0.78
" A reduced clearance and prolonged elimination half-life of pancuronium and vecuronium have been demonstrated."( The pharmacokinetics of rocuronium bromide in hepatic cirrhosis.
Hunter, JM, 1995
)
0.6
" The pharmacokinetic data were best described by a three-exponential equation."( Pharmacokinetics of rocuronium bromide in patients with and without renal failure.
Cooper, RA; Maddineni, VR; Mirakhur, RK; Wierda, JM, 1995
)
0.61
"Steroid muscle relaxants often display pharmacodynamic changes in patients with cirrhosis because of alterations in elimination processes."( Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study.
Desmonts, JM; Kleef, U; Lavaut, E; Servin, FS, 1996
)
0.63
" Blood samples drawn during the procedure and after the last maintenance dose allowed pharmacokinetic analysis in six cirrhotic patients and six control subjects."( Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study.
Desmonts, JM; Kleef, U; Lavaut, E; Servin, FS, 1996
)
0.63
"Rocuronium pharmacodynamics are moderately altered by cirrhosis, possible because of pharmacokinetic alterations."( Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study.
Desmonts, JM; Kleef, U; Lavaut, E; Servin, FS, 1996
)
2.07
" A two-exponential equation was used to describe the pharmacokinetic data."( Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia.
Maddineni, VR; McCoy, EP; Mirakhur, RK; Proost, JH; Wierda, JM, 1996
)
0.62
" Due to its chemical relationship to other aminosteroidal neuromuscular blocking agents such as pancuronium bromide or vecuronium, rocuronium is expected to display pharmacokinetic behaviour similar to that of its predecessors."( Clinical pharmacokinetics of rocuronium bromide.
Khuenl-Brady, KS; Sparr, H, 1996
)
0.79
" Pharmacokinetic models were fit to rocuronium concentrations versus time data using a mixed-effects population approach."( Pharmacokinetics of rocuronium during the three stages of liver transplantation.
Fisher, DM; Hein, HA; Marcel, RJ; Miller, RD; Ramsay, KJ; Ramsay, MA; Sharma, M, 1997
)
0.9
" A pharmacokinetic and pharmacodynamic model was fitted to the data for each patient."( The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ; van Miert, MM, 1997
)
0.56
" Pipecuronium resembles pancuronium in its pharmacokinetic and neuromuscular blocking profile, but is devoid of cardiovascular effects."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
0.3
" Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15."( Pharmacokinetics of rocuronium bromide in obese female patients.
Benzer, A; Giesinger, S; Keller, C; Kleinsasser, A; Pühringer, FK, 1999
)
0.63
" The influence of CO on pharmacokinetic and pharmacodynamic parameters of rocuronium in patients was evaluated using a recirculatory pharmacokinetic model."( Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output.
Boer, F; Bovill, JG; Burm, AG; Kuipers, JA; Olofsen, E, 2001
)
0.79
" For drugs with a fast onset of effect, a recirculatory model, which includes CO, can give a good description of the relation between concentration and effect, in contrast to a conventional compartmental pharmacokinetic model."( Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output.
Boer, F; Bovill, JG; Burm, AG; Kuipers, JA; Olofsen, E, 2001
)
0.56
" Rocuronium is strongly favored as a promising pharmacodynamic probe for predicting allograft liver function because it is predominantly eliminated via the liver and its putative metabolites are not active."( Neuromuscular paralysis as a pharmacodynamic probe to assess organ function during liver transplantation.
Baker, B; Gao, L; Ramzan, I, 2000
)
1.22
"Using the pharmacodynamic model without plasma concentrations described by Bragg et al, an individual approach resulted in highly variable parameters for rocuronium."( Population pharmacodynamic modeling without plasma concentrations of rocuronium in children.
Nava-Ocampo, AA; Velázquez-Armenta, EY, 2002
)
0.75
" Pharmacokinetic and pharmacodynamic parameters were determined."( Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia.
Donati, F; Dragne, A; Plaud, B; Varin, F, 2002
)
1.76
"No differences in rocuronium pharmacokinetic parameters were observed between both groups."( Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia.
Donati, F; Dragne, A; Plaud, B; Varin, F, 2002
)
2.09
" Therefore, the potentiating effect of isoflurane is of pharmacodynamic origin only, as explained by an increased sensitivity at the neuromuscular junction."( Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia.
Donati, F; Dragne, A; Plaud, B; Varin, F, 2002
)
1.76
" Pharmacokinetic modeling revealed no significant differences between myasthenic and control pigs."( Pharmacokinetic-pharmacodynamic modeling of rocuronium in case of a decreased number of acetylcholine receptors: a study in myasthenic pigs.
De Baets, MH; De Haes, A; Houwertjes, MC; Proost, JH; Stassen, MH; Wierda, JM, 2003
)
0.58
"We aimed to evaluate whether area under the curve (AUC) analysis of pharmacodynamic data can be used to compare pharmacokinetic models taken from the literature, during a target controlled infusion (TCI) of rocuronium."( Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model.
Hoffmann, VL; Saldien, V; Vermeyen, KM, 2003
)
0.79
"Seventy-two patients scheduled for orthopaedic surgery received a TCI of rocuronium (Stanpump) based on one of four pharmacokinetic models: those described by Szenohradszky, Alvarez-Gomez, Wierda, and Cooper."( Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model.
Hoffmann, VL; Saldien, V; Vermeyen, KM, 2003
)
0.84
" AUC(PE)-AUC(OE) was significantly larger in the Szenohradszky model when compared with all other pharmacokinetic models."( Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model.
Hoffmann, VL; Saldien, V; Vermeyen, KM, 2003
)
0.61
"It was possible to use AUC analysis for identification of the pharmacokinetic model that best predicted the pharmacodynamic characteristics of our patients."( Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model.
Hoffmann, VL; Saldien, V; Vermeyen, KM, 2003
)
0.61
"We investigated the pharmacodynamic effects of rocuronium on morbidly obese patients."( The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients.
Gullo, A; Leykin, Y; Lomangino, G; Lucca, M; Marzano, B; Pellis, T, 2004
)
0.87
" Two- and three-exponential equations were used to describe the pharmacokinetic data in each group and these were compared to each other using the Wilcoxon signed rank sum test as was the pharmacodynamic data."( Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure.
Booij, LH; Driessen, JJ; Robertson, EN, 2005
)
0.59
" Blood was sampled over 6 hr and pharmacokinetic variables were calculated by plasma concentrations of Org 9426."( [Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients].
Iwao, Y; Ozaki, M; Saeki, S; Suzuki, T; Takeda, J, 2006
)
0.56
"The efficacy of neuromuscular block, stable pharmacokinetic behavior and excellent safety of Org 9426 were also confirmed in Japanese surgical patients."( [Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients].
Iwao, Y; Ozaki, M; Saeki, S; Suzuki, T; Takeda, J, 2006
)
0.56
"05) and terminal elimination half-life was longer (P<0."( Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide.
Bennett, HL; Dahaba, AA; Metzler, H; Moskowitz, DM; Oettl, K; Perelman, SI; Reibnegger, G; Shander, A, 2006
)
0.54
" A population pharmacokinetic model using NONMEM (GloboMax LLC, Hanover, MD) was applied."( Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Beaufort, AM; Proost, JH; Rietbergen, H; Saldien, V; Sparr, HJ; Velik-Salchner, C; Vermeyen, KM; Wierda, JM, 2007
)
0.64
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The objective of this study was to identify the pharmacokinetic and/or pharmacodynamic origin of these alterations."( Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy.
Forst, J; Ihmsen, H; Muenster, T; Schmitt, HJ; Schwilden, H; Viethen, V, 2009
)
0.64
" In five patients of the DMD group, pharmacokinetic modelling was performed from arterial rocuronium concentrations."( Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy.
Forst, J; Ihmsen, H; Muenster, T; Schmitt, HJ; Schwilden, H; Viethen, V, 2009
)
0.87
" For both the DMD and the control group, the time course of neuromuscular block could be described by a sigmoid E(max) model using the estimated pharmacokinetic parameters of the DMD group."( Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy.
Forst, J; Ihmsen, H; Muenster, T; Schmitt, HJ; Schwilden, H; Viethen, V, 2009
)
0.64
"No pharmacokinetic change was noted when rocuronium was administered via TCI."( Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients.
Bi, SS; Guo, XY; Lu, W; Wang, HL; Yang, BX; Yang, L; Zhang, LP, 2010
)
0.91
"An integrated population pharmacokinetic-pharmacodynamic model was developed with the following aims: to simultaneously describe pharmacokinetic behaviour of sugammadex and rocuronium; to establish the pharmacokinetic-pharmacodynamic model for rocuronium-induced neuromuscular blockade and reversal by sugammadex; to evaluate covariate effects; and to explore, by simulation, typical covariate effects on reversal time."( Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.
Kerbusch, T; Kleijn, HJ; van den Heuvel, MW; Zollinger, DP, 2011
)
0.79
"Rocuronium concentration prediction using pharmacokinetic (PK) models would be useful for controlling rocuronium effects because neuromuscular monitoring throughout anesthesia can be difficult."( The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen.
Iwasaki, H; Kazama, T; Masui, K; Sasakawa, T, 2016
)
2.12
" The pharmacokinetic parameters were calculated by non-compartmental analysis."( Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery.
de Moraes, NV; Lanchote, VL; Lauretti, GR; Matsumoto, JA; Varrique, RM, 2016
)
0.7
" Rocuronium pharmacokinetic parameters were estimated by non-compartmental analysis."( The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.
Abumansur, JT; Coelho, EB; Correia, BV; Costa, ACC; de Moraes, NV; Lanchote, VL; Lauretti, GR, 2017
)
1.61
" This work describes a noninvasive approach for estimation of post-tetanic count (PTC) based on two pharmacokinetic (PK) models, the Saldien and the De Haes models."( Comparison of two pharmacokinetic-pharmacodynamic models of rocuronium bromide during profound neuromuscular block: analysis of estimated and measured post-tetanic count effect.
Amorim, P; Couto, M; Esteves, S; Marco-Ariño, N; Mendes, J; Nunes, CS; Troconiz, IF; Vide, S, 2022
)
0.96
" Nevertheless, the prediction of clinical neuromuscular endpoints by means of Pharmacokinetic (PK) and Pharmacodynamic (PD) modelling has the potential to complement monitoring and improve perioperative neuromuscular management."( Neuromuscular end-point predictive capability of published rocuronium pharmacokinetic/pharmacodynamic models: An observational trial.
Barbe, K; Carvalho, H; Cools, W; D'Haese, J; Eleveld, DJ; Flamée, P; Geerts, L; Poelaert, J; Ramirez, D; Struys, MMRF; Verdonck, M; Wylleman, J, 2023
)
1.15

Compound-Compound Interactions

Sugammadex alone or in combination with rocuronium or veCuronium is not associated with QTc prolongation.

ExcerptReferenceRelevance
" To achieve quality anesthesia and successful, fast recovery with minimal morbidity without the use of volatile anesthetic, the choice of drug combination has to be centered on one rapid- and short-acting hypnotic, opioid and non-depolarizing muscle relaxant."( The optimal pediatric induction dose of propofol in combination with reduced-dose rocuronium and alfentanil for day-case tonsillectomy in children.
Bartolek, D; Bartolek, F; Cavrić, G; Jakobović, J; Lajtman, Z; Zdravcević-Sakić, K, 2007
)
0.57
"This thorough corrected QT (QTc) study evaluated the effect of sugammadex alone and in combination with rocuronium or vecuronium on the individually corrected QTc interval (QTcI)."( Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J, 2010
)
0.81
"Based on the results of this study of healthy subjects, it can be concluded that sugammadex alone or in combination with rocuronium or vecuronium is not associated with QTc prolongation."( Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J, 2010
)
0.8
" We report a case of a 45-year-old woman with DM who underwent laparotomy for uterine cancer under general anesthesia combined with epidural anesthesia."( [Successful management of a patient with myotonic dystrophy under total intravenous anesthesia with propofol, remifentnil and rocuronium bromide, combined with epidural anesthesia].
Hirai, A; Nakanishi, T; Nishihama, M; Shimosaka, M; Uchikado, M; Uehara, A, 2010
)
0.57
"Seventy-four patients undergoing TURBT were randomly allocated to receive either glycopyrrolate 10 μg/kg (glycopyrrolate group, n = 37) or atropine 15 μg/kg (atropine group, n = 37) in combination with neostigmine 25 μg/kg at the end of surgery for reversal of neuromuscular blockade."( Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study.
Kim, HC; Lim, SM; Park, HP; Seo, H, 2015
)
0.64
" The present study was conducted in order to evaluate neuronal effects of SUG alone and in combination with both ROC and VEC."( Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium.
Aldasoro, C; Aldasoro, M; Gimeno-Raga, M; Guerra-Ojeda, S; Iradi, A; Jorda, A; Marchio, P; Mauricio, MD; Obrador, E; Valles, SL; Vila, JM, 2017
)
0.71
" We aimed to compare general anesthesia (GA) and general anesthesia combined with caudal block (GA + CA) in laparoscopic-assisted Soave pull-through of HD."( General versus general anaesthesia combined with caudal block in laparoscopic-assisted Soave pull-through of Hirschsprung disease: a retrospective study.
Fang, Y; He, Y; Lin, Y; Lin, Z; Liu, M; Shen, Y; Wu, D; Yan, L; Zhang, B; Zhang, L, 2021
)
0.62
"General anesthesia combined with caudal block can shorten the duration of operation, and provide more stable intraoperative hemodynamics and better postoperative analgesia."( General versus general anaesthesia combined with caudal block in laparoscopic-assisted Soave pull-through of Hirschsprung disease: a retrospective study.
Fang, Y; He, Y; Lin, Y; Lin, Z; Liu, M; Shen, Y; Wu, D; Yan, L; Zhang, B; Zhang, L, 2021
)
0.62
" The effects of moderate neuromuscular blockade combined with transverse abdominal plane block (TAPB) on surgical space conditions during laparoscopic surgery have not been described."( The effects of moderate neuromuscular blockade combined with transverse abdominal plane block on surgical space conditions during laparoscopic colorectal surgery: a randomized clinical study.
Dong, R; Ke, F; Shen, Z; Wu, C; Zhang, L, 2022
)
0.72
" The intervention group was treated with moderate neuromuscular blockade (train-of-four (TOF) count between 1 and 3) combined with TAPB (M group), while the control group was treated with deep neuromuscular blockade (D group), with a TOF count of 0 and a post-tetanic count (PTC) ≥1."( The effects of moderate neuromuscular blockade combined with transverse abdominal plane block on surgical space conditions during laparoscopic colorectal surgery: a randomized clinical study.
Dong, R; Ke, F; Shen, Z; Wu, C; Zhang, L, 2022
)
0.72
"Moderate neuromuscular blockade combined with TAPB applied to laparoscopic colorectal cancer surgery can provide surgical space conditions similar to those of deep neuromuscular blockade."( The effects of moderate neuromuscular blockade combined with transverse abdominal plane block on surgical space conditions during laparoscopic colorectal surgery: a randomized clinical study.
Dong, R; Ke, F; Shen, Z; Wu, C; Zhang, L, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" A mixed-effects population pharmacokinetic analysis was applied to these values to determine bioavailability, absorption rate constant, and time to peak Cp with intramuscular administration."( Bioavailability of intramuscular rocuronium in infants and children.
Brown, R; Fisher, DM; Lau, M; Luks, A; Reynolds, LM; Sharma, M, 1997
)
0.58
"With intramuscular administration, rocuronium's bioavailability averaged 82."( Bioavailability of intramuscular rocuronium in infants and children.
Brown, R; Fisher, DM; Lau, M; Luks, A; Reynolds, LM; Sharma, M, 1997
)
0.86

Dosage Studied

We studied the dose-response relationships of each drug and their combination with rocuronium in 200 ASA I or II patients during propofol-fentanyl-nitrous oxide-oxygen anaesthesia. The dosage of ro Curonium was significantly higher than that in the group M (P < 0.9% saline (placebo) in combination with ketamine and roCuronium)

ExcerptRelevanceReference
" The influence of prior suxamethonium administration on the potency of Org 9426 was studied also by constructing a dose-response curve."( Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium.
Boules, Z; Clarke, RS; Cooper, R; Mirakhur, RK, 1992
)
0.52
" Spontaneous twitch recovery from 10% to 25% was similar in all dosage groups (5 +/- 1 minutes to 6 +/- 4 minutes)."( Pharmacodynamic effects of three doses of ORG 9426 used for endotracheal intubation in humans.
Dubois, MY; Kataria, BK; Lapeyre, G; Lea, D; Tran, DQ,
)
0.13
" Dose-response curves were constructed using a single-dose method."( Estimation of the potency of ORG 9426 using two different modes of nerve stimulation.
Cooper, RA; Elliott, P; McCarthy, GJ; Mirakhur, RK, 1992
)
0.28
" We determined the dose-response relationship of ORG-9426 in 62 children (aged 1-5 yr) during nitrous oxide-halothane anesthesia by means of log-probit transformation and least-squares linear regression of the initial dose and response."( Effects of bolus administration of ORG-9426 in children during nitrous oxide-halothane anesthesia.
Brandom, BW; Cook, DR; Sarner, JB; Woelfel, SK, 1992
)
0.28
"The dose-response relationship of Org 9426, its time course of action and the reversibility of the residual block by neostigmine have been investigated in 100 patients undergoing various anaesthetic techniques."( Dose-response relationship and time course of action of Org 9426. A new muscle relaxant of intermediate duration evaluated under various anaesthetic techniques.
Agoston, S; De Wit, AP; Hennis, PJ; Lambalk, LM; Wierda, JM, 1991
)
0.28
"To determine average dose requirements and pharmacodynamic characteristics before general clinical use, the dose-response curve, onset time, and recovery time for the neuromuscular relaxant ORG 9426 were determined in 72 adult patients given doses of 120, 160, 200, or 240 micrograms/kg after establishment of a steady-state expired isoflurane concentration of approximately 1%."( Clinical responses to ORG 9426 during isoflurane anesthesia.
Begin, M; Ginsberg, B; Glass, PS; Gorback, MS; Quill, TJ, 1991
)
0.28
" We studied the dose-response relationships of each drug and their combination with rocuronium in 200 ASA I or II patients during propofol-fentanyl-nitrous oxide-oxygen anaesthesia."( Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids.
Bakhamees, HS; el-Bakry, AK; Magboul, MA; Naguib, M; Samarkandi, AH, 1995
)
0.72
" It was the aim of our study to investigate the onset of action, the intubation conditions and the course of relaxation using two different dosage regimes."( [Mechanomyographic and electromyographic studies of endotracheal intubation with 2 different rocuronium dosages].
Benad, G; Hofmockel, R; Kabott, A, 1994
)
0.51
"The dose-response relationship and time course of neuromuscular block following bolus injections of rocuronium was determined in four groups of nine patients each under nitrous oxide-narcotic anaesthesia."( Dose-response relationship of rocuronium bromide during intravenous anaesthesia.
Bischoff, A; Buzello, W; Diefenbach, C; Grond, S; Mellinghoff, H, 1994
)
0.79
" Diazepam displaced the dose-response curve to the right in four cats."( Interaction between rocuronium bromide and some drugs used during anaesthesia.
Anderson, KA; Muir, AW; Pow, E, 1994
)
0.61
"In the first study, the dose-response relations of rocuronium, mivacurium, and their combination were studied in ASA physical status 1 or 2 patients during thiopental-fentanyl-N2O anesthesia."( Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination.
Naguib, M, 1994
)
0.84
" The dose-response relationships for neostigmine and edrophonium were studied during antagonism of neuromuscular block induced by rocuronium bromide."( Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-induced neuromuscular blockade.
Abdulatif, M; al-Ghamdi, A; Naguib, M, 1993
)
0.72
"The dose-response curves for neostigmine- and edrophonium-assisted antagonism of rocuronium bromide neuromuscular blockade for the single twitch and TOF ratio were not parallel."( Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-induced neuromuscular blockade.
Abdulatif, M; al-Ghamdi, A; Naguib, M, 1993
)
0.74
"We determined the dose-response relationship, the onset time, the duration, and the recovery time of a rocuronium neuromuscular block under four anesthesia techniques."( Muscle paralysis by rocuronium during halothane, enflurane, isoflurane, and total intravenous anesthesia.
Crul, JF; Oris, B; Sabbe, MB; Van Aken, H; Van Egmond, J; Vandermeersch, E, 1993
)
0.82
"kg-1 was administered to determine dose-response curves."( Pharmacodynamic behaviour of rocuronium in the elderly.
Balendran, P; Bevan, DR; Donati, F; Fiset, P; Law-Min, JC; Ratcliffe, A, 1993
)
0.58
"We determined dose-response curves and spontaneous recovery of neuromuscular function following a single ED95 dose of rocuronium in 10 infants (1-11 months old), 20 children (2-12 years old) and 20 adults (20-40 years old) during nitrous oxide-oxygen-thiopentone-alfentanil anaesthesia."( Dose-response and time-course of effect of rocuronium bromide in paediatric patients.
Erkola, O; Juvakoski, M; Meretoja, OA; Rautoma, P; Taivainen, T, 1995
)
0.76
" Dose-response curves were established, and ED50 was calculated."( Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study.
Desmonts, JM; Kleef, U; Lavaut, E; Servin, FS, 1996
)
0.63
" Individual variability in response to rocuronium is great, and dosage should be carefully titrated to that required."( Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study.
Desmonts, JM; Kleef, U; Lavaut, E; Servin, FS, 1996
)
0.9
" Neuromuscular function was recorded by adductor pollicis emg and a cumulative log-probit dose-response curve of rocuronium was established."( Rocuronium in infants, children and adults during balanced anaesthesia.
Erkola, O; Juvakoski, M; Meretoja, OA; Rautoma, P; Taivainen, T, 1996
)
1.95
" We have examined the dose-response relationships for neostigmine antagonism of 90% rocuronium-induced neuromuscular block in children and adults, during nitrous oxide-1 MAC of isoflurane anaesthesia."( Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults.
Abdulatif, M; al-Ghamdi, A; el-Sanabary, M; Mowafi, H, 1996
)
0.76
"In order to compare an acceleromyograph (TOF-Guard) with a mechanomyograph (Grass FT03), the dose-response relationship of rocuronium was simultaneously determined in both arms of 15 children aged 3-11 years during anaesthesia with thiopentone, alfentanil and nitrous oxide."( A comparison of acceleromyography and mechanomyography for determination of the dose-response curve of rocuronium in children.
Baker, RD; Hopkinson, JM; McCluskey, A; Meakin, G, 1997
)
0.72
"To determine differences from dose-response and time-course of rocuronium between male and female patients, 60 adult patients (30 male and 30 female), ASA grade I, aged 17-52 yr, undergoing elective plastic surgery were studied."( Dose-response and time course of effect of rocuronium in male and female anesthetized patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS, 1997
)
0.8
"The dose-response and concentration-response relation of rocuronium infusion was studied in 20 adult surgical patients during propofol-nitrous oxide and isoflurane (1 MAC)-nitrous oxide anaesthesia."( Dose-response and concentration-response relation of rocuronium infusion during propofol-nitrous oxide and isoflurane-nitrous oxide anaesthesia.
Kansanaho, M; Olkkola, KT; Wierda, JM, 1997
)
0.79
"To evaluate the influence of sevoflurane on the dose-response relationship and on the time-course of the effect of rocuronium, 60 adult patients undergoing elective plastic surgery were randomly allocated to either the control or the sevoflurane group."( Dose-response and time-course of the effect of rocuronium bromide during sevoflurane anaesthesia.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS, 1998
)
0.77
" The relation between dose and response for rocuronium in the two groups was determined by the cumulative dose-response technique."( Influence of acute normovolaemic haemodilution on the relation between the dose and response of rocuronium bromide.
An, G; Liao, X; Luo, LK; Tong, SY; Xue, FS, 1998
)
0.78
" Following equi-effective dosing (T1 > 95%) the duration to 25% T1 recovery, recovery index (25/75), and TOF0."( Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia.
Ledowski, T; Linstedt, U; Proppe, D; Sitzlack, D; Wulf, H, 1998
)
0.58
"(1) To compare the dose-response relations of rocuronium and vecuronium in healthy adult patients anesthetized with nitrous oxide-oxygen-fentanyl-thiopental; and (2) to evaluate the time-course of action of two drugs following equipotent doses."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.79
" The dose-response relations of rocuronium and vecuronium were determined by the cumulative dose-response technique."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.82
" The cumulative dose-response curve of vecuronium was shifted to the left in a parallel fashion compared with that of rocuronium."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.74
" After obtaining individual dose-response curves for rocuronium, bolus doses of rocuronium were given to maintain neuromuscular block at 90-99% for 60 min."( Smoking increases the requirement for rocuronium.
Rautoma, P; Svartling, N, 1998
)
0.82
" In these patients appropriate dosing of muscle relaxants and adequate monitoring of the neuromuscular blockade are required."( Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy.
Bittner, R; Finsterer, J; Sporn, P; Stratil, U, 1998
)
0.6
"We compared the dose-response relationships of cisatracurium, mivacurium, atracurium, vecuronium and rocuronium and examined the interactions of cisatracurium with mivacurium, atracurium, vecuronium and rocuronium in humans by isobolographic and fractional analyses."( Neuromuscular interaction between cisatracurium and mivacurium, atracurium, vecuronium or rocuronium administered in combination.
Chon, SU; Chun, YS; Kim, KS; Suh, JK, 1998
)
0.74
"We compared the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium after chronic isepamicin therapy for 7 days in 56 anesthetized rabbits."( Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Chung, CW; Jun, JH; Kim, KS; Lee, KH; Shim, JC, 1999
)
0.75
"We studied the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium during chronic isepamicin therapy in rabbits."( Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Chung, CW; Jun, JH; Kim, KS; Lee, KH; Shim, JC, 1999
)
0.75
" The ED50 of each neuromuscular blocker was determined from cumulative log dose-response regression lines (n = 14)."( Adenosine potentiation of neuromuscular blocking agents in guinea-pigs.
Dan, K; Foldes, FF; Kornak, P; Nagashima, H; Nitahara, K; Vizi, ES, 2000
)
0.31
"This study was done to determine the safety, efficacy, dosing requirements, and spontaneous recovery profiles of prolonged infusions of rocuronium bromide in the critically ill."( Multicenter trial of prolonged infusions of rocuronium bromide in critically ill patients: effects of multiple organ failure.
Circeo, LE; Reeves, ST, 2001
)
0.77
"Seventy-eight subjects were randomly assigned to receive one of four dosing combinations for intubation and neuromuscular maintenance: rocuronium for intubation and maintenance, rocuronium for intubation and pancuronium for maintenance, pancuronium for intubation and rocuronium for maintenance, or pancuronium for both."( Impact of the initial doses of rocuronium and pancuronium on subsequent maintenance for neuromuscular block.
Fitzgerald, PC; Fragen, RJ; Johnson, JO; Kern, SE; van Zeeland, M, 2001
)
0.8
" At this time the volatile agent administration was stopped or propofol dosage reduced in half the patients in each group (n = 20 in each group)."( Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol.
Breslin, DS; Hayes, AH; Mirakhur, RK; Reid, JE, 2001
)
0.61
" Dose-response relationships of rocuronium under both anaesthetic regimes were assessed using a generalised linear model based on the maximum-likelihood-technique."( [Sevoflurane augments the degree and speeds the onset of rocuronium evoked neuromuscular blockade in children].
Eikermann, M; Peters, J; Renzing-Köhler, K, 2001
)
0.84
"To compare the characteristics of the dose-response relationship and the time course of action between atracurium and rocuronium in adult patients anesthetized with N2O-O2-fentanyl-thiopene."( A comparative study of the dose-response and time course of recovery of atracurium and rocuronium.
An, G; Liao, X; Liu, J; Xue, F; Zhang, Y, 2000
)
0.74
" The dose-response relationship of atracurium and rocuronium was determined by the cumulative dose-response technique."( A comparative study of the dose-response and time course of recovery of atracurium and rocuronium.
An, G; Liao, X; Liu, J; Xue, F; Zhang, Y, 2000
)
0.78
"According to the dose-response curves established by a least squares linear regression, the potency ratio of atracurium to rocuronium was 1:1."( A comparative study of the dose-response and time course of recovery of atracurium and rocuronium.
An, G; Liao, X; Liu, J; Xue, F; Zhang, Y, 2000
)
0.74
" Drug dosing according to total body weight (TBW) can cause exaggerated effects and dosing by lean body mass (LBM) may provide a more consistent response despite the increased weight."( Prolonged neuromuscular block after rocuronium in postpartum patients.
Chan, KL; Chan, MT; Gin, T; Yuen, PM, 2002
)
0.59
" Anesthetic management and muscle relaxant maintenance dosing were standardized."( Impact of shorter-acting neuromuscular blocking agents on fast-track recovery of the cardiac surgical patient.
Avram, MJ; Marymont, JH; Murphy, GS; Rosengart, TK; Szokol, JW; Vender, JS, 2002
)
0.31
" We compared the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium in 56 anesthetized rabbits immobilized in a plaster cast for 2, 4, and 6 wk."( The duration of immobilization causes the changing pharmacodynamics of mivacurium and rocuronium in rabbits.
Cho, SY; Jeon, JW; Kim, KS; Koh, MS; Shim, JH; Suh, JK, 2003
)
0.76
" During hypothermic extracorporeal circulation and postperfusion period, the dosage of the myorelaxant substantially decreased."( [Rocuronium (esmerone) in anesthesia during surgery under extracorporeal circulation].
Chernov, VA; Ermolenko, AE; Il'nitskiĭ, VV; Kozlov, IA; Vershuta, DV,
)
1.04
" At this time, sevoflurane or the propofol dosage was reduced in each group (n = 20 in each group)."( Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia.
Cheong, MA; Kim, KS; Lee, HJ; Lee, JM, 2004
)
0.58
" In a control group of six normal-weight female patients admitted for laparoscopic surgery, rocuronium was dosed on the basis of their real body weight."( The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients.
Gullo, A; Leykin, Y; Lomangino, G; Lucca, M; Marzano, B; Pellis, T, 2004
)
0.83
" The aim of this study was to explore the efficacy, dose-response relation and safety of Org 25969 for reversal of a prolonged rocuronium-induced neuromuscular block."( Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.
Adams, J; Giovannelli, M; Hermens, Y; Mirakhur, RK; Moppett, I; Shields, M, 2006
)
0.76
" This study investigated the dose-response relation, safety, and pharmacokinetics of sugammadex to reverse rocuronium-induced block."( Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.
Larsen, PB; Norrild, K; Ostergaard, D; Prins, ME; Sorgenfrei, IF; Stensballe, J; Viby-Mogensen, J, 2006
)
0.93
" Dose-response curves were created using log-dose-probit transformation."( Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosage.
An, G; Bennett, HL; Bornemann, H; Dahaba, AA; Hager, B; Huang, L; List, WF; Metzler, H; Moskowitz, DM; Perelman, SI; Rehak, PH; Shander, A; Wilfinger, G; Xiao, Z, 2006
)
0.61
" Larger studies are required for determining dosage recommendations for different geographic regions."( Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosage.
An, G; Bennett, HL; Bornemann, H; Dahaba, AA; Hager, B; Huang, L; List, WF; Metzler, H; Moskowitz, DM; Perelman, SI; Rehak, PH; Shander, A; Wilfinger, G; Xiao, Z, 2006
)
0.61
" In the dose-response groups, using the mechanomyograph, neuromuscular block of six consecutive incremental doses of rocuronium 50 microg kg(-1), followed by 300 microg kg(-1), was evaluated."( Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide.
Bennett, HL; Dahaba, AA; Metzler, H; Moskowitz, DM; Oettl, K; Perelman, SI; Reibnegger, G; Shander, A, 2006
)
0.75
"ANH resulted in a shift to the left of rocuronium dose-response curve."( Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide.
Bennett, HL; Dahaba, AA; Metzler, H; Moskowitz, DM; Oettl, K; Perelman, SI; Reibnegger, G; Shander, A, 2006
)
0.81
" This study explored the dose-response relation of sugammadex given as a reversal agent at reappearance of the second muscle twitch after rocuronium- and vecuronium-induced block."( Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Cammu, G; Demeyer, I; Hans, P; Heeringa, M; Morias, K; Suy, K; van Duijnhoven, WG, 2007
)
0.83
" A dose-response relation was observed with sugammadex for reversal of both rocuronium- and vecuronium-induced neuromuscular block."( Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Cammu, G; Demeyer, I; Hans, P; Heeringa, M; Morias, K; Suy, K; van Duijnhoven, WG, 2007
)
0.86
"9 after dosing at 3, 5, and 15 min decreased from 52."( Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Beaufort, AM; Proost, JH; Rietbergen, H; Saldien, V; Sparr, HJ; Velik-Salchner, C; Vermeyen, KM; Wierda, JM, 2007
)
0.64
" The repeated times and the total dosage of rocuronium in H group were significantly more than that in E group (P<0."( Hyperthyroidism patients have shorter onset and duration time of rocuronium than euthyroidism patients.
Feng, SW; Ge, YL; He, LL; Song, XJ; Wang, YG; Yang, JJ, 2007
)
0.84
" Inadequate dosage may lead to reparalysis."( Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia.
Donati, F, 2008
)
0.35
"We conducted a dose-response study in 16 rats and a recovery study in 8 rats."( Different recovery of the train-of-four ratio from rocuronium-induced neuromuscular blockade in the diaphragm and the tibialis anterior muscle in rat.
Osawa, T, 2008
)
0.6
" This behavior persisted despite changing the inference (Bayesian or likelihood), underlying dose-response model (though slightly improved using the power model), and the number of patients enrolled at each dose level."( Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Chevret, S; Resche-Rigon, M; Zohar, S, 2008
)
0.35
" Using a power model for dose-response improves some behavior if the trial is started at the first dose level and includes at least three to five patients at the starting dose before applying the CRM allocation rule."( Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Chevret, S; Resche-Rigon, M; Zohar, S, 2008
)
0.35
"A dose-response relation was demonstrated in children (n = 22), adolescents (n = 28), and adults (n = 26), but not infants because of the small sample size (n = 8)."( Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
Hermens, Y; Hofmockel, R; Meretoja, O; Mirakhur, RK; Plaud, B; Raft, J; Stoddart, PA; van Kuijk, JH, 2009
)
0.73
"Pharmacokinetic studies in obese patients suggest that dosing of rocuronium should be based on ideal body weight (IBW)."( Should dosing of rocuronium in obese patients be based on ideal or corrected body weight?
Claudius, C; Jenstrup, MT; Lund, J; Meyhoff, CS; Rasmussen, LS; Sørensen, AM; Viby-Mogensen, J, 2009
)
0.93
"In obese patients undergoing gastric banding or gastric bypass, rocuronium dosed according to IBW provided a shorter duration of action without a significantly prolonged onset time or compromised conditions for tracheal intubation."( Should dosing of rocuronium in obese patients be based on ideal or corrected body weight?
Claudius, C; Jenstrup, MT; Lund, J; Meyhoff, CS; Rasmussen, LS; Sørensen, AM; Viby-Mogensen, J, 2009
)
0.93
" Many studies have demonstrated a dose-response relationship with sugammadex for reversal of neuromuscular blockade in patients induced and maintained under propofol anesthesia."( A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Claudius, C; Debaene, B; Duvaldestin, P; Heeringa, M; Klein, J; Kuizenga, K; Saldien, V; Servin, F, 2010
)
0.59
"We designed this randomized, open-label, dose-response trial to explore the dose-response relationship of sugammadex for the reversal of deep neuromuscular blockade induced by rocuronium or vecuronium under propofol-induced and sevoflurane-maintained anesthesia."( A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Claudius, C; Debaene, B; Duvaldestin, P; Heeringa, M; Klein, J; Kuizenga, K; Saldien, V; Servin, F, 2010
)
0.78
" The onset depends on the dosage used."( Rapid sequence intubation: a review of recent evidences.
Di Filippo, A; Gonnelli, C, 2009
)
0.35
"In a first and second phases of the study, rocuronium dose-response curves were constructed for patient groups as follows: 2 mixed-gender groups, 2 female groups, and 2 male groups."( [Influence of gender on the potency and course of action of rocuronium bromide].
Steinberg, D, 2009
)
0.86
" Some statisticians now consider this approach outmoded and assert that non-linear regression (NLR) is the preferred way to analyse sigmoidal dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.36
"We analysed raw data for succinylcholine, rocuronium, rapacuronium, and cisatracurium from previously published studies using both LRA and NLR to determine the ED(50) and ED(95) values and the respective slopes of the dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.62
" In myotonic dystrophy type 1 patients, the dose-response curve obtained with acceleromyography was steeper and right-shifted compared with that obtained using mechanomyography."( Comparison of mechanomyography and acceleromyography for the assessment of rocuronium induced neuromuscular block in myotonic dystrophy type 1.
Booij, LHDJ; Robertson, EN; Van Egmond, J; Vanlinthout, LEH, 2010
)
0.59
"4%, either in varying doses (for dose-response measurements; 60 patients) or a fixed dose of 600 μg."( Potency and recovery characteristics of rocuronium mixed with sodium bicarbonate.
Kim, KS; Lee, HJ; Shin, IC; Suh, JK; Sung, IH; Yeon, JT, 2010
)
0.63
"8 min for repeat dosing <25 min vs 38."( Repeat dosing of rocuronium 1.2 mg kg-1 after reversal of neuromuscular block by sugammadex 4.0 mg kg-1 in anaesthetized healthy volunteers: a modelling-based pilot study.
Cammu, G; De Graeve, K; de Kam, PJ; Foubert, L; Grobara, P; Morias, K; Peeters, P; Suy, K; van den Heuvel, M, 2010
)
0.7
"Sugammadex shows a dose-response relationship for reversal of neuromuscular block (NMB) during propofol anaesthesia."( Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
Demeyer, I; Gordon, M; Heeringa, M; Ingimarsson, J; Klarin, B; Pühringer, FK; Sparr, HJ; van Duijnhoven, W, 2010
)
0.63
"Succinylcholine and rocuronium are equivalent with regard to first-attempt intubation success in the ED when dosed according to the ranges used in this study."( Comparison of succinylcholine and rocuronium for first-attempt intubation success in the emergency department.
Erstad, BL; Patanwala, AE; Sakles, JC; Stahle, SA, 2011
)
0.97
"Simulations of the therapeutic dosing regimens demonstrated limited impact of age, renal function and sevoflurane use, as predicted reversal time in typical subjects was always <2 min."( Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.
Kerbusch, T; Kleijn, HJ; van den Heuvel, MW; Zollinger, DP, 2011
)
0.59
"To date, the dosing of sugammadex is based on real body weight without taking fat content into account."( Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients.
Bogaert, T; De Kock, M; Dillemans, B; Haspeslagh, M; Mulier, JP; Van Lancker, P, 2011
)
0.37
" This occurs because of dosing choices for neuromuscular blocking agents and anticholinesterases as well as insensitivity of typically used monitors of depth of NMB."( Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents.
Lien, CA, 2011
)
0.37
" Hence, the dosing interval of rocuronium should be adjusted using neuromuscular monitoring when maintaining intense neuromuscular block, especially in older patients."( The effects of age on maintenance of intense neuromuscular block with rocuronium.
Aono, M; Furuya, T; Hirose, N; Kashiwai, A; Kato, J; Konishi, J; Ogawa, S; Suzuki, T, 2012
)
0.9
"Below clinical utility, such adjustments may be used to explore cofactors influencing interindividual and intraindividual variability in NMB dose-response relationship."( Influence of real-time Bayesian forecasting of pharmacokinetic parameters on the precision of a rocuronium target-controlled infusion.
Billard, V; Debaene, B; Devys, JM; Motamed, C, 2012
)
0.6
" When dosage of rocuronium reached 20 mg, train-of-four count reached 1 and his trachea was intubated without coughing or moving."( [Anesthetic management for a patient with amyotrophic lateral sclerosis; the neuromuscular monitoring was useful to determine appropriate dosages of rocuronium].
Iwabuchi, Y; Kumagai, M; Miyata, M; Nagata, H; Suzuki, K; Wakimoto, M, 2012
)
0.92
" A variety of medications have been used for RSI, with potential for inadequate or excessive dosing as well as complications including hypotension and the need for redosing."( A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients.
Anderson, S; Ballow, SL; Chang, M; Kaups, KL, 2012
)
0.38
" The dosing of postintubation sedative and analgesic infusions were compared 30 min after initiation between the two groups."( Comparison of rocuronium and succinylcholine on postintubation sedative and analgesic dosing in the emergency department.
Goddard, LA; Korinek, JD; Patanwala, AE; Sakles, JC; St John, AE; Thomas, RM, 2014
)
0.76
"03 mg/kg dosage could be useful for very short ophthalmic procedures."( Effects of rocuronium bromide on globe position and respiratory function in isoflurane-anesthetized dogs: a comparison between three different dosages.
Barsotti, G; Breghi, G; Briganti, A; Di Nieri, C; Portela, DA, 2015
)
0.81
" Pulmonary function tests were performed before and after neuromuscular blocking drug dosing and again after albuterol administration."( The effect of cisatracurium and rocuronium on lung function in anesthetized children.
Fine, GF; Jooste, EH; Motoyama, EK; Mutich, R; Walczak, SA; Yang, CI, 2013
)
0.67
" The dosage of rocuronium was 10 mg."( [Anesthesia for pneumothorax surgery in a patient with type II chronic respiratory failure associated with inclusion body myositis].
Igari, Y; Ito, Y; Nagaya, K, 2014
)
0.76
"Sugammadex could reverse rocuronium-induced neuromuscular blockade in a dose-response manner even in the patients treated with magnesium sulfate."( [Reversal of rocuronium-induced neuromuscular blockade with sugammadex in patients for cesarean delivery treated with magnesium sulfate].
Aiba, J; Kakumoto, M; Mimura, F; Sakurai, Y; Uchida, M; Yamaguchi, M, 2014
)
1.08
" Denervation time and stage and the type of neuromuscular blocker and dosage should be taken into consideration when using these drugs in patients with nerve injury."( Receptor analysis of differential sensitivity change to succinylcholine induced by nerve injury in rat gastrocnemius.
Jiang, JH; Li, ST; Song, JC; Yang, B, 2015
)
0.42
"Adult patients undergoing abdominal surgery received rocuronium, followed by randomized allocation to sugammadex (2 or 4 mg kg(-1)) or usual care (neostigmine/glycopyrrolate, dosing per usual care practice) for reversal of neuromuscular blockade."( Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
Brueckmann, B; de Bie, J; Eikermann, M; Grobara, P; Kwo, J; Lee, J; Li, MK; Maktabi, M; McGovern, F; Pino, R; Sabouri, AS; Sasaki, N; Staehr-Rye, AK; Woo, T, 2015
)
0.67
" The dose-response relationship of rocuronium was determined with a single-bolus technique (0."( Effects of single-shot and steady-state propofol anaesthesia on rocuronium dose-response relationship: a randomised trial.
Blobner, M; Fink, H; Schaller, SJ; Stäuble, CG; Stäuble, RB; Unterbuchner, C, 2015
)
0.93
" Since the dosing guidelines for the timing and dose of reversal agents are based on the TOF count derived from the TOF-Watch SX, a manually assessed TOF count may lead to inadequate dosing and/or premature administration of reversal agents."( Comparison of train-of-four count by anesthesia providers versus TOF-Watch® SX: a prospective cohort study.
Bhananker, SM; Cain, KC; Ramaiah, R; Sellers, BA; Thilen, SR; Treggiari, MM, 2015
)
0.42
"The dose-response relationship of drugs to reverse vecuronium-, rocuronium-, and cisatracurium-induced neuromuscular block (NMB) was evaluated in vitro (competition binding assays and urine analysis), ex vivo (n = 34; phrenic nerve hemidiaphragm preparation), and in vivo (n = 108; quadriceps femoris muscle of the rat)."( Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.
Ayata, C; Blobner, M; Diaz-Gil, D; Eikermann, M; Eikermann-Haerter, K; Foerster, U; Ganapati, S; Haerter, F; Isaacs, L; Moreno Duarte, I; Simons, JC; Zhang, B, 2015
)
0.66
"Sixty-four patients were included: 31 patients received sugammadex at a dosage based on their real weight (RW) and 33 patients received a lower dose (based on ideal weight [IW])."( Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: In support of dose reduction.
Alami, Y; Badaoui, R; Cabaret, A; Dupont, H; Lorne, E; Popov, I; Zogheib, E, 2016
)
0.43
"The aim of this dose-finding study was to evaluate the dose-response relationship of sugammadex and neostigmine to reverse a commonly observed level of incomplete recovery from rocuronium-induced neuromuscular block, that is, a train-of-four ratio (TOFR) ≥0."( Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,.
Baumüller, E; Blobner, M; Fink, H; Kaufhold, N; Schaller, SJ; Stäuble, CG; Ulm, K, 2016
)
0.63
" Rocuronium-neostigmine combination is a safe alternative if appropriately dosed (0."( Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial.
Bittner, EA; Cusin, C; Doran, ME; Eikermann, M; Guchelaar, HJ; MacDonald, TO; Mirzakhani, H; Nozari, A; Welch, CA, 2016
)
1.6
"A PK model developed from data obtained after single-bolus dosing can predict Cp values during bolus and continuous infusion."( The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen.
Iwasaki, H; Kazama, T; Masui, K; Sasakawa, T, 2016
)
0.68
"Opioids are integral part of anesthesia induction, but information on optimal dosing is limited."( Dose requirements of alfentanil to eliminate autonomic responses during rapid-sequence induction with thiopental 4 mg/kg and rocuronium 0.6 mg/kg.
Abou-Arab, MH; Heier, T; Rostrup, M, 2016
)
0.64
" Succinylcholine dosing was titrated to an appropriate level to avoid prolonged apnea in subsequent ECT treatments."( Electroconvulsive Therapy Considerations for Transgendered Patients.
Adams, DC; Balla, A; Grondin, LS; O'Donnell, SE; Tran, BK; Tsai, MH, 2017
)
0.46
" Also, preoperative adjustment of statin dosage may be recommended."( Laparoscopic partial nephrectomy in a patient on simvastatin : Delayed recovery from neuromuscular blockade.
Abd El-Hakeem, EE; Almazlom, SA; Alsayyad, AJ; Kaki, AM, 2017
)
0.46
" The T1, clinical duration (time from end of bolus injection to recovery of twitch tension to 25% of control), recovery index (time from 25% to 75% of recovery of T1), and dosage were recorded."( Administration of rocuronium based on real body weight versus fat-free mass in patients with lymphedema.
Binjiang, Z; Hu, X; Jing, Z; Liu, P; Muheremu, A, 2017
)
0.79
" NMBA dosing was reported descriptively."( Effect of patient weight on first pass success and neuromuscular blocking agent dosing for rapid sequence intubation in the emergency department.
Patanwala, AE; Sakles, JC, 2017
)
0.46
" SDX dosage is set according to the state of neuromuscular blockade determined with a neuromuscular monitoring device."( Method for Prediction of Efficacy of Sugammadex Administered to Recover from Rocuronium-Induced Neuromuscular Blockade in Gynecological Laparoscopic Surgery Cases.
Hoshino, T; Imaura, M; Kimura, K; Omura, K; Takahashi, H; Yamada, Y, 2018
)
0.71
" We tested whether a protocol for the management of neuromuscular block that specified appropriate dosing and optimal neostigmine reversal was associated with a reduction in postoperative residual neuromuscular block."( Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine.
Bhananker, SM; Cain, KC; Ng, IC; Thilen, SR; Treggiari, MM, 2018
)
0.84
" The goal of our study was to investigate the real-world practice pattern of dosing of neuromuscular blocking agents (NMBA), utilizing the amount of NMBA used during the course of a case, adjusted for patient weight and case duration, as a surrogate measure of depth of NMB."( Investigation of intraoperative dosing patterns of neuromuscular blocking agents.
Beutler, SS; Gimlich, R; Palsen, S; Urman, RD; Wu, A; Yang, HK, 2019
)
0.51
" First pass success can be increased by ensuring correct dosing for overweight patients and employing the use of video laryngoscope."( Nursing Considerations When Using Neuromuscular Blocking Agents to Assist With Intubation: A Review of Literature.
Blauvelt, G; Burdick, K; Cannon, EJ,
)
0.13
" The dose-response curve of rocuronium in Dexa1 was shifted to the right compared to controls, but curves in Dexa3 and Dexa7 were not significantly different."( Effect of protracted dexamethasone exposure and its withdrawal on rocuronium-induced neuromuscular blockade and sugammadex reversal: an ex vivo rat study.
Choi, HR; In, J; Kim, YB; Lee, IO; Lim, BG; Oh, SK; Park, S; Yang, HS, 2019
)
1.04
" Multivariable analysis showed that only the dosage of rocuronium based on ideal body weight had a positive correlation with prolonged spontaneous recovery time (P = 0."( Cautionary findings for motor evoked potential monitoring in intracranial aneurysm surgery after a single administration of rocuronium to facilitate tracheal intubation.
Bebawy, JF; Hayashi, H; Hemmer, LB; Koht, A, 2021
)
1.08
" There are limited data on the use and dosing of continuous infusion (CI) rocuronium in critically ill patients outside of the operating room."( An Evaluation of Continuous Infusion Rocuronium for Sustained Neuromuscular Blockade in Critically Ill Adults.
Groetzinger, LM; Hutchins, AT; Rivosecchi, RM, 2021
)
1.13
"8 min), which was compounded by high rocuronium dosing (2."( Prolonged neuromuscular block after rocuronium administration in laparoscopic pyloromyotomy patients: A retrospective bayesian regression analysis.
Austin, TM; Fiedorek, CS; Fiedorek, MC; Gilbertson, LE; Lam, H; Trinh, TA, 2021
)
1.17
" Therefore, consideration of appropriate rocuronium dosing or the use of sugammadex should be considered."( Prolonged neuromuscular block after rocuronium administration in laparoscopic pyloromyotomy patients: A retrospective bayesian regression analysis.
Austin, TM; Fiedorek, CS; Fiedorek, MC; Gilbertson, LE; Lam, H; Trinh, TA, 2021
)
1.16
" In the second phase, the same dosage was instilled twice in the span of 10 min into both eyes (OU) of four pigeons (eight eyes)."( Efficacy of topical rocuronium bromide as a mydriatic agent in domestic pigeons (Columba livia).
Jeong, D; Jeong, Y; Kang, S; Lee, E; Park, S; Seo, K; Susanti, L, 2021
)
0.94
"This randomized, double-blind trial evaluated sugammadex-mediated recovery time from rocuronium- or vecuronium-induced moderate (M-) or deep (D-) neuromuscular block in morbidly obese adults dosed by actual (ABW) or ideal body weight (IBW)."( Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Blobner, M; DeAngelis, M; Herring, WJ; Horrow, JC; Li, W; Lombard, J; Speek, M, 2021
)
1.06
"ABW-based sugammadex dosing yields faster reversal without re-curarization, supporting ABW-based sugammadex dosing in the morbidly obese, irrespective of the depth of neuromuscular block or NMBA used."( Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Blobner, M; DeAngelis, M; Herring, WJ; Horrow, JC; Li, W; Lombard, J; Speek, M, 2021
)
0.83
" Its clinical use in children is reviewed, potential applications in the palliative care arena discussed, and dosing algorithms presented."( Sugammadex to Reverse Neuromuscular Blockade Prior to Withdrawal of Life Support.
Gee, SW; Guider, W; Humphrey, L; Lemus, R; Tobias, JD, 2021
)
0.62
" There was a significant difference between groups with a different dosage administered at the same time (F ratio = 28."( Earlier and lower dose administration of sugammadex: A randomised placebo-controlled trial.
Duranteau, O; Engelman, E; Fernandez, W; Tabolcea, I; Tuna, T; Van Obbergh, L, 2021
)
0.62
"Rocuronium dosed ≥1."( The association of rocuronium dosing and first-attempt intubation success in adult emergency department patients.
April, MD; Arana, AA; Brown, CA; Fix, ML; Levin, NM, 2021
)
2.39
" La régression logistique a démontré que lorsque la laryngoscopie directe était utilisée et comparée à la gamme de dosage standard de 1,0-1,1 mg/kg, la probabilité ajustée de réussite de la première tentative était significativement plus élevée dans le groupe ≥ 1,4mg/kg à 1,9 (IC 95 % 1,3-2,7) par rapport aux autres gammes de dosage, RC 0,9 (IC 95 % 0,7-1,2) pour < 1,0 mg/kg et RC 1,2 (IC 95 % 0,9-1,7) pour le groupe 1,2-1,3 mg/kg."( The association of rocuronium dosing and first-attempt intubation success in adult emergency department patients.
April, MD; Arana, AA; Brown, CA; Fix, ML; Levin, NM, 2021
)
0.95
" Therefore, the influence of neuromuscular blockers essential for spinal anaesthesia on IONM is worthy of our attention, but no randomized study has evaluated the dose-response effect."( Effects of rocuronium dosage on intraoperative neurophysiological monitoring in patients undergoing spinal surgery.
Hu, H; Li, T; Wang, W; Yan, R; Yang, W; Zhang, X, 2022
)
1.11
"9% saline (placebo) in combination with ketamine and rocuronium, according to a weight-based dosing schedule."( Fentanyl versus placebo with ketamine and rocuronium for patients undergoing rapid sequence intubation in the emergency department: The FAKT study-A randomized clinical trial.
Aneman, A; Burns, B; Buttfield, A; Ferguson, I; Harris, IA; Milligan, J; Reid, C; Shepherd, S, 2022
)
1.24
" The dosage of rocuronium in the group D was significantly higher than that in the group M (P < 0."( The effects of moderate neuromuscular blockade combined with transverse abdominal plane block on surgical space conditions during laparoscopic colorectal surgery: a randomized clinical study.
Dong, R; Ke, F; Shen, Z; Wu, C; Zhang, L, 2022
)
1.07
"Total body weight-based dosing of rocuronium might prolong the neuromuscular relaxation effect in patients with a small amount of skeletal muscle."( Influence of the amount of skeletal muscle mass on rocuronium-induced neuromuscular block.
Doo, AR; Ko, S; Lee, JH; Lee, Y, 2022
)
1.25
" The dosage of the active principle was measured using high-pressure liquid chromatography coupled with ultraviolet detection."( Impact of Ambient Temperature on 5 Emergency Drugs Aboard an Emergency Medical Car Over a 1-Year Period.
Marson, C; Roschel, K; Schneider, S; Stammet, P; Welter, C, 2022
)
0.72
"To conduct a meta-analysis to compare different dosing scalars of sugammadex in a morbidly obese population for reversal of neuromuscular blockade (NMB)."( Appropriate dosing of sugammadex for reversal of rocuronium-/vecuronium-induced muscle relaxation in morbidly obese patients: a meta-analysis of randomized controlled trials.
Lee, M; Liao, JQ; Lin, TY; Lu, CW; Shih, D, 2022
)
0.98
"gov, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar were searched for relevant randomized controlled trials (RCTs) comparing lower-dose sugammadex using ideal body weight (IBW) or corrected body weight (CBW) as dosing scalars with standard-dose sugammadex based on total body weight (TBW) among morbidly obese people after NMB."( Appropriate dosing of sugammadex for reversal of rocuronium-/vecuronium-induced muscle relaxation in morbidly obese patients: a meta-analysis of randomized controlled trials.
Lee, M; Liao, JQ; Lin, TY; Lu, CW; Shih, D, 2022
)
0.98
" The reversal time was significantly longer in patients receiving sugammadex with dosing scalar based on IBW than in patients receiving sugammadex with dosing scalar based on TBW (mean difference 55."( Appropriate dosing of sugammadex for reversal of rocuronium-/vecuronium-induced muscle relaxation in morbidly obese patients: a meta-analysis of randomized controlled trials.
Lee, M; Liao, JQ; Lin, TY; Lu, CW; Shih, D, 2022
)
0.98
" This study aims to compare the dosage of the neuromuscular blocking agents (NMBA) rocuronium and the need for reversion by sugammadex between those methods."( Effect of quantitative versus qualitative neuromuscular blockade monitoring on rocuronium consumption in patients undergoing abdominal and gynecological surgery: a retrospective cohort study.
Blum, LV; Iken, S; Lotz, G; Piekarski, F; Raimann, FJ; Steeger, E; Zacharowski, K; Zinn, S, 2023
)
1.36
"Rocuronium is widely used in surgery as a neuromuscular relaxant, but it has been difficult to accurately control its specific dosage in clinical operation."( Rapid detection of rocuronium based on host/guest complex between a pyrene derivative and sugammadex.
Cheng, H; Song, J; Yao, Z, 2022
)
2.49
" In this study we propose PTA analysis to optimize sugammadex dosing in children."( Population Pharmacokinetic-Pharmacodynamic Modeling and Probability of Target Attainment Analysis of Rocuronium and Sugammadex in Children Undergoing Surgery.
Bartkowska-Śniatkowska, A; Ber, J; Bienert, A; Grzelak, J; Grześkowiak, E; Grześkowiak, M; Jarosz, K; Książkiewicz, M; Malec, M; Rosada-Kurasińska, J; Wiczling, P, 2023
)
1.13
" The developed model was used to simulate pharmacokinetic-pharmacodynamic profiles for different patient groups and dosing regimens before the PTA analysis was performed to translate these simulations into a clinically useful measure."( Population Pharmacokinetic-Pharmacodynamic Modeling and Probability of Target Attainment Analysis of Rocuronium and Sugammadex in Children Undergoing Surgery.
Bartkowska-Śniatkowska, A; Ber, J; Bienert, A; Grzelak, J; Grześkowiak, E; Grześkowiak, M; Jarosz, K; Książkiewicz, M; Malec, M; Rosada-Kurasińska, J; Wiczling, P, 2023
)
1.13
" One significant change is the drug dosage regimen; 1 μg/kg fentanyl, 2 mg/kg ketamine, and 2 mg/kg rocuronium is recommended as the main drug dosing regimen for both medical and trauma patients."( The Prehospital Emergency Anaesthetic in 2022.
Broomhead, R; Dawson, J; Morton, S; Sherren, P; Wareham, G,
)
0.35
" Rocuronium, when dosed appropriately, provides neuromuscular blockade as quickly and effectively as succinylcholine but was previously avoided due to its prolonged duration of action which precluded neurologic examination."( Traumatic brain injury and RSI is rocuronium or succinylcholine preferred?
Dao, AQ; Kuza, C; Mohapatra, S; Moon, TS, 2023
)
2.1
"9 correlated positively with the dosage of rocuronium, indicating that recovery time of rocuronium was also dose-dependent in dogs anesthetized with alfaxalone."( ED
Chen, IY; Daimaruya, N; Itami, T; Sano, T; Sugita, C; Wei, Y; Yamashita, K, 2023
)
1.17
" Additional prospective studies are needed to determine optimal induction agent selection and dosing in patients presenting with shock or sepsis."( Pharmacotherapy optimization for rapid sequence intubation in the emergency department.
Brown, CS; Engstrom, K; Lyons, N; Mattson, AE; Rech, MA, 2023
)
0.91
"The use of a protocol that specifies rocuronium dosing and selective use of sugammadex versus neostigmine based on qualitative assessment of TOF count and fade allowed us to achieve an incidence of PRNB of 3% (95% CI, 1-7) at PACU arrival."( Evaluation of a Protocol for the Management of Maintenance and Reversal of Rocuronium Block Using Neostigmine or Sugammadex.
Bhananker, SM; Cain, KC; Kruse, TN; Liang, T; Thilen, SR; Treggiari, MM, 2023
)
1.41
" The levels of interleukin-6 (IL-6), interleukin-8 (IL-8), C-reactive protein (CRP), procalcitonin, tumor necrosis factor-α (TNF-α), numeric rating scales, dosage of propofol, dexmedetomidine and rocuronium, as well as the numeric rating scales score and analgesic complications were monitored in the 2 groups."( Effect of esketamine on inflammatory factors in opioid-free anesthesia based on quadratus lumborum block: A randomized trial.
Dai, J; Li, J; Li, S; Zheng, R, 2023
)
1.1
" There is, however, a paucity of data regarding its dosing profile in infants and children younger than 2 years."( Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age.
Cates, AC; Clifton, JC; Freundlich, RE; Lorinc, AN, 2024
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
neuromuscular agentA drug used for its actions on skeletal muscle.
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
androstane
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
quaternary ammonium ionA derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
morpholinesAny compound containing morpholine as part of its structure.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency4.54790.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID218977-logED50 value for chick biventer determined.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID219378Inhibition of stimulated vagus nerve-induced bradycardia in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID681149TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID219391Recovery time (25-75 %) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219383Inhibitory potency in anesthetized cats, and Onset time is reported2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219390Onset time was measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679155TP_TRANSPORTER: inhibition of TBuMA uptake in Xenopus laevis oocytes2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides.
AID679213TP_TRANSPORTER: inhibition of Rocuronium uptake in Xenopus laevis oocytes2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID126970Duration (90%) measured for NMB activity in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID679150TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Oct, Volume: 291, Issue:1
Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations.
AID679002TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Oct, Volume: 291, Issue:1
Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations.
AID219380Inhibition of superior cervical nerve-induced contractions of the nictitating membrane in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681150TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID127134Onset time was measured for NMB activity in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID127145Recovery time (25-75 %) measured for NMB activity in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID679003TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Oct, Volume: 291, Issue:1
Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID126649Inhibitory potency in anesthetized rhesus monkeys; ND means not determined2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID218864Dose causing 50% block of muscle twitch in isolated chick biventer cervicis muscle (Decrease in baseline tension)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID21877Calculated partition coefficient (clogP)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID219389Duration (90%) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,043)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.05)18.7374
1990's346 (16.94)18.2507
2000's544 (26.63)29.6817
2010's842 (41.21)24.3611
2020's310 (15.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.89 (24.57)
Research Supply Index7.98 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index144.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (81.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials766 (35.51%)5.53%
Reviews152 (7.05%)6.00%
Case Studies408 (18.92%)4.05%
Observational60 (2.78%)0.25%
Other771 (35.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (249)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction [NCT02546843]66 participants (Actual)Interventional2015-12-31Completed
A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT) [NCT03532178]Phase 244 participants (Actual)Interventional2019-01-01Completed
The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent During Laparoscopic Colorectal Surgery [NCT03890406]88 participants (Actual)Interventional2019-04-01Completed
Paravertebral Nerve Blocks in Neonates and Infants Undergoing Repair of Aortic Coarctation, A Pilot Study [NCT03408340]Phase 430 participants (Anticipated)Interventional2018-07-18Recruiting
A Multi-center, Randomized, Assessor-blinded, Placebo Controlled, Phase II, Parallel Dose-finding Trial in Male Subjects of ASA 1-2 to Assess the Efficacy, Safety and Pharmacokinetics of 5 Doses of Org 25969 When Administered After 0.6 mg.Kg-1 Esmeron® at [NCT03519854]Phase 299 participants (Actual)Interventional2002-12-01Completed
International Multicenter Single Blind Randomized Clinical Study to Compare Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgical Procedures Under General Anesthesia [NCT03669484]Phase 3150 participants (Actual)Interventional2017-08-22Completed
Opioid-Free Shoulder Arthroplasty [NCT03540030]Phase 486 participants (Actual)Interventional2016-09-30Completed
A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in Morbidly Obese Subjects [NCT03346070]Phase 4207 participants (Actual)Interventional2018-01-01Completed
A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (A [NCT03346057]Phase 4344 participants (Actual)Interventional2017-12-20Completed
Evaluation of the Effectiveness and Safety of Endotracheal Intubation for Inhalational Anesthesia Without the Use of Muscle Relaxants or Analgesics [NCT03112564]91 participants (Actual)Interventional2013-03-01Completed
Partial Neuromuscular Blockade to Facilitate Lung and Diaphragm Protective Mechanical Ventilation in Intensive Care Unit Patients: a Randomized Controlled Pilot Study [NCT03646266]Phase 430 participants (Anticipated)Interventional2018-08-15Recruiting
Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery [NCT02812186]Phase 479 participants (Actual)Interventional2016-12-27Completed
Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade [NCT02118844]Phase 492 participants (Anticipated)Interventional2014-07-31Recruiting
Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting [NCT06102915]289 participants (Actual)Observational2023-08-01Completed
The Effectiveness of Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery [NCT02838134]Phase 4101 participants (Actual)Interventional2016-11-30Completed
Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol [NCT02054468]82 participants (Actual)Interventional2012-03-31Completed
A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures [NCT03138967]Phase 454 participants (Actual)Interventional2017-09-18Completed
Reducing High Respiratory Drive to Facilitate Supported Ventilation in ARDS Patients: a Pilot Study [NCT02064140]12 participants (Actual)Interventional2014-02-28Completed
Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine [NCT05909696]60 participants (Anticipated)Interventional2023-03-01Enrolling by invitation
Pilot Study - Assessing the Impact of Using a Neuromuscular Blocking Agent to Reduce Neuromuscular Junction Damage and Intermediate Syndrome in Organophosphorus (OP) Insecticide Poisoned Patients Requiring Ventilation [NCT02147054]Phase 2/Phase 345 participants (Actual)Interventional2014-05-31Completed
Anaesthesia With or Without Neuromuscular Blocking Agents in Intubation and Intraoperative Nerve-monitoring During Thyroid Surgery: a Feasibility and Safety Pilot Study. [NCT03910504]100 participants (Actual)Interventional2019-04-17Completed
A Randomized Controlled Double-blinded Trial Comparing the Effect of on Demand vs Deep Neuromuscular Relaxation on Rating of Surgical and Anesthesia Conditions in Patients Undergoing Thoraco-laparoscopic Esophagectomy [NCT02320734]Phase 466 participants (Actual)Interventional2015-02-28Completed
Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in Patients Undergoing Coronary Artery Bypass Grafting [NCT05423951]106 participants (Actual)Interventional2022-07-26Completed
Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery [NCT02285829]46 participants (Actual)Observational2015-02-11Completed
The Impact of Moderate Versus Deep Neuromuscular Blockade on Enhanced Recovery After Bariatric Anesthesia: A Randomized Double Blinded Clinical Trial [NCT04466943]110 participants (Anticipated)Interventional2020-01-01Active, not recruiting
Recording Sympathetic Nerve Activity From the Skin During Surgery Under General Anesthesia : a Pilot Study [NCT03658057]20 participants (Actual)Interventional2018-08-31Completed
Effect of Intraoperative Neuromuscular Blockade on Postoperative Sore Throat and Hoarseness in Patients Undergoing Spinal Surgery [NCT03397797]117 participants (Actual)Observational2017-09-01Completed
Ventilation by Mask Before and After the Administration of Neuromuscular Blockade: a Non-inferiority Trial [NCT02237443]Phase 4210 participants (Actual)Interventional2014-08-31Completed
Correlation Between Trend of Four Values and Bispectral Index Values During General Anaesthesia for Breast Surgery. [NCT05681611]8 participants (Actual)Observational2023-03-03Completed
Effect of Atracurium and Rocuronium on the State and Response Entropy During Isoflurane Anesthesia [NCT05097508]Early Phase 140 participants (Actual)Interventional2020-06-20Completed
A Multicenter, Open Label, Phase IIIa Trial to Evaluate the Efficacy and Safety of Org 25969 When Used at the End of a Surgical Procedure to Reverse the Neuromuscular Block Induced by Rocuronium Following Routine Anesthesia [NCT00298831]Phase 3224 participants (Actual)Interventional2005-10-27Completed
Comparative Study of Single Port Thoracoscopic Bullectomy Under Nonintubated Local and Sedation Anesthesia Versus Intubated General Anesthesia for Primary Spontaneous Pneumothorax. [NCT02109510]40 participants (Actual)Interventional2012-11-30Completed
Evaluation of Duration of Curarisation (Surgical Efficacy) and Pharmacokinetics of Neuromuscular Block After a Single Dose of Rocuronium in Geriatric Patients (Age ≥ 80 Years ) Compared to a Younger Population (Age < 50 Years). [NCT03551652]28 participants (Anticipated)Observational2020-05-15Recruiting
The Influence of the Neuromuscular Blockade on Mask Ventilation; a Placebo Controlled, Randomized Trial With Three Different Dosages of Rocuronium (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg) [NCT02318810]300 participants (Actual)Interventional2015-03-31Completed
Efficacy of Magnesium Sulfate Added to Bupivacaine in Suprascapular Nerve Block on Duration of Analgesia Following Shoulder Arthroscopy: a Prospective Randomized Controlled Study [NCT03602469]60 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Effect of the Sheath of Rectus Abdominis Block Combined With the Transverse Plane Block on the Condition in Laparoscopic Gynecological Surgery. [NCT04850404]42 participants (Anticipated)Interventional2021-07-31Not yet recruiting
The Effect of Lean Body Weight-adjusted Rocuronium Dose on Intubation Conditions: a Prospective Observational Study [NCT05476952]180 participants (Actual)Observational2023-01-30Completed
Comparison of Standard rapi̇d Sequential Intubation Protocol With Rocuronium Priming Technique in Patients Registering to the Emergency Department and With Indication of Elective Intubation [NCT05343702]52 participants (Actual)Observational [Patient Registry]2021-07-15Completed
Reduction of Rocuronium-induced Injection Pain With Aspiration of Blood [NCT06150001]120 participants (Anticipated)Interventional2023-12-31Not yet recruiting
[NCT02266056]72 participants (Actual)Interventional2014-08-31Completed
Comparison of Two Neuromuscular Transmission Monitors Based on Acceleromyography: TOF-Watch SX® and TOFScan® [NCT02880787]142 participants (Anticipated)Interventional2014-11-30Recruiting
Effect of Intraoperative Muscle Relaxation Depth on Postoperative Sore Throat and Hoarseness After General Anesthesia [NCT03391700]206 participants (Anticipated)Interventional2017-08-01Recruiting
Effect of Neuromuscular Blockade on Surgical Conditions and Patient Reported Comfort Scores in Total Hip Replacement Arthroplasty [NCT03369782]Phase 40 participants (Actual)Interventional2017-12-15Withdrawn(stopped due to refocusing of research priorities)
The Impact of Anesthesia on the Absorption of Glycine in Operative Hysteroscopy: a Randomized Controlled Trial [NCT01124383]95 participants (Actual)Interventional2008-08-31Completed
Interventional Bronchoscopy Under Noninvasive Ventilation for Central Airway Stenosis [NCT02289586]40 participants (Anticipated)Interventional2014-07-31Recruiting
The Appearance of Electromyography on the Anaesthesia Monitor. [NCT01142635]Phase 430 participants (Anticipated)Interventional2009-04-30Completed
Effect of Neuromuscular Blockade Protocol on Perioperative Outcomes of Robotic Laparoscopic Surgery [NCT03726372]192 participants (Anticipated)Interventional2018-11-10Not yet recruiting
Effect of Rocuronium and Sugammadex Under Sevoflurane and Desflurane Anesthesia in Children [NCT03795259]148 participants (Actual)Interventional2018-12-28Completed
Effects of Propofol Titration at Different Speeds on Hemodynamics and Stress During General Anesthesia Induction [NCT04595591]276 participants (Actual)Interventional2020-10-23Completed
Deep vs Moderate Neuromuscular Blockade on Surgical Conditions and Quality of Recovery in Day Case Laparoscopic Cholecystectomy [NCT03881423]Phase 480 participants (Actual)Interventional2017-04-01Completed
Recovery From Optimal Neuromuscular Blockade in the Critically Ill: Randomized Control Trial [NCT03791801]50 participants (Anticipated)Interventional2019-09-01Recruiting
Paraspinal Muscle Relaxation in Spine Surgery: Comparison of the Effect of Neuromuscular Blocking Agent Rocuronium Between Extremity- and Paraspinal Musculature [NCT03318718]25 participants (Actual)Interventional2016-02-01Completed
The Effects of Remifentanil and Remifentanil-Alfentanil Administration on Emergence Agitation After Brief Ophthalmic Surgery in Children [NCT02486926]102 participants (Actual)Interventional2012-11-30Completed
Standardised Drug Provocation Testing in Perioperative Hypersensitivity [NCT06065137]Phase 450 participants (Anticipated)Interventional2023-10-31Not yet recruiting
A Randomized, Parallel Design, Single-center Study to Compare of Surgical Condition and Postoperative Complications With Moderate and Deep Neuromuscular Blockade in Laparoscopic Gastrectomy [NCT02601508]80 participants (Anticipated)Interventional2015-11-30Not yet recruiting
The Prospective Randomized Comparison of the Onset Time of Rocuronium in Patients Undergoing Emergency and Elective Surgery [NCT02634255]Phase 350 participants (Anticipated)Interventional2015-12-31Not yet recruiting
Cognitive Functions After TIVA With Dexmedetomidine [NCT02631135]Phase 440 participants (Actual)Interventional2008-01-31Completed
The Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety During Laparoscopic Surgery: a Multicenter Strategy Study [NCT04124757]922 participants (Anticipated)Interventional2020-02-11Recruiting
The Analgesic Efficacy and Safety of Oxycodone Hydrochloride Versus Fentanyl After Total Hip Arthroplasty: A Randomized Triple-Blind Trial [NCT05602519]Phase 472 participants (Actual)Interventional2022-11-10Completed
Comparison of Onset and Duration of Rocuronium Induced Neuromuscular Block Between 2nd Trimester Pregnant and Non-pregnant Women [NCT02797860]90 participants (Actual)Observational2016-06-30Completed
Effectiveness of an Optimisation Strategy for Emergency Tracheal Intubation on Postintubation Morbidity: A Cluster Randomized Controlled Trial [NCT05539391]1,500 participants (Anticipated)Interventional2023-01-14Recruiting
Influence of Sepsis, Age and SLCO1A2 Genetic Polymorphisms on Rocuronium Pharmacokinetics-pharmacodynamics in ASA I-III Surgical Patients [NCT02399397]Phase 436 participants (Actual)Interventional2014-02-28Completed
The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy [NCT02036827]Phase 4108 participants (Actual)Interventional2013-12-31Completed
Comparison of Operating Conditions, Postoperative Recovery and Overall Satisfaction Between Deep and Restricted Neuromuscular Blockade for Spinal Surgery Under General Anesthesia [NCT02724111]Phase 490 participants (Actual)Interventional2016-05-15Completed
The Impact of Deep Versus Moderate Neuromuscular Block on Respiratory System Mechanics and Metabolic Changes During Laparoscopic Cholecystectomy a Double-Blind Randomized Clinical Trial. [NCT02469831]Phase 240 participants (Actual)Interventional2014-10-31Completed
Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery [NCT02079337]Phase 414 participants (Actual)Interventional2013-11-30Completed
Deep Versus Moderate Neuromuscular Blockade During Total HIP Replacement Surgery to Improve POstoperative Quality of Recovery and Immune Function: a Randomized Controlled Study [NCT05562999]Phase 4100 participants (Anticipated)Interventional2022-11-18Recruiting
Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients -a Single-center, Randomized ,Double-blinded and Controlled Trial [NCT02134093]Phase 4120 participants (Anticipated)Interventional2014-07-31Not yet recruiting
The Effect of Precurarization With Rocuronium on the Incidence and Severity of Succinylcholine-Induced Fasciculations and Myalgias in a High Volume ERCP Center [NCT04581395]Phase 3300 participants (Actual)Interventional2020-10-02Completed
Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery [NCT05619848]Early Phase 187 participants (Actual)Interventional2022-10-25Completed
Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia [NCT02141737]Phase 4272 participants (Anticipated)Interventional2014-05-31Recruiting
Perioperative Cardiovascular Protection Conservative Effects of Esketamine Versus µ-opioid Receptor Agonists in Total Intravenous General Anesthesia: Study Protocol for a Randomized Controlled Pilot Trial [NCT04553536]1,000 participants (Anticipated)Interventional2020-11-02Recruiting
Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis. [NCT02194855]Phase 4100 participants (Actual)Interventional2015-01-01Completed
The Impact of the Menstrual Cycle on Injection Pain of Rocuronium [NCT02539706]100 participants (Actual)Interventional2014-01-06Completed
The Effect of Remifentanil on the Onset Time of Rocuronium in Total Intravenous Anesthesia [NCT01030510]126 participants (Actual)Interventional2009-12-31Completed
Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine [NCT00953550]Phase 461 participants (Actual)Interventional2009-09-30Completed
Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 Following a Single Intubating Dose in Adult Patients Undergoing Operation Under Sevoflurane or Propofol Anesthesia. [NCT00988520]Phase 338 participants (Actual)Interventional2003-05-31Completed
A Single Blinded Multicenter Randomized Study Comparing Intubating Conditions During Rapid Sequence Induction With Either Suxamethonium 1.0 mg/kg or Rocuronium 1.0 mg/kg in Elderly Patients (≥ 80 Years Old) [NCT04868409]Phase 490 participants (Anticipated)Interventional2021-08-12Recruiting
Interaction of Statins and Nondepolarizing Muscle Relaxants [NCT02222519]60 participants (Anticipated)Observational2014-10-31Recruiting
Continuous Neuromuscular Blocking Agent for out-of Hospital Cardiac Arrest; Multicenter Randomized Controlled Trial [NCT02790164]Phase 281 participants (Actual)Interventional2016-05-31Completed
Comparison of the Effect of Continuous Infusion and Bolus Doses of Rocuronium During Anesthesia for Lumbal Discectomy on Muscle Strength and Quality of Patient Recovery [NCT04236050]80 participants (Actual)Interventional2015-12-31Completed
The Neuromuscular Effect of Rocuronium in Patient Measuring Muscle Mass by Bioelectrical Impedance Analysis [NCT02657187]80 participants (Anticipated)Interventional2016-02-29Recruiting
Comparison of With or Without Use of Stylet for Endotracheal Intubation With McGrath Videolaryngoscope [NCT02642367]Phase 4140 participants (Actual)Interventional2016-01-31Completed
Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation in Patients With Moderate vs. Deep Neuromuscular Block [NCT02888067]Phase 112 participants (Actual)Interventional2017-07-01Terminated(stopped due to Slow recruitment)
Effect of Neuromuscular Blockade on the Insertion of ProSeal™ Laryngeal Mask Airway and Postoperative Pharyngolaryngeal Discomfort [NCT01035021]160 participants (Actual)Interventional2009-06-30Completed
Serum Tryptase Concentration During General Anaesthesia With Rocuronium [NCT04035707]126 participants (Actual)Interventional2009-06-25Completed
Pharmacokinetics of Rocuronium (1 mg/kg) for Deep Block : a Prospective Observational Study [NCT03545308]250 participants (Actual)Observational2017-08-25Completed
Best Practice With Rocuronium, Neostigmine, Sugammadex, and Subjective Monitoring. [NCT03543826]Phase 4201 participants (Actual)Interventional2018-05-21Completed
A Multi-center, Randomized, Assessor-blinded, Phase II, Parallel Dose-finding Trial in Subjects of ASA Class 1 - 3 to Assess the Efficacy and Safety of 5 Doses of Org 25969 When Administered at 1-2 PTCs After Administration of Zemuron® [NCT03519867]Phase 250 participants (Actual)Interventional2004-08-01Completed
Safety Control Study in Pediatric Inguinal Hernia Repair: Are Muscle Relaxants Necessary? Endotracheal Intubation vs Laryngeal Mask Airway [NCT02696837]80 participants (Actual)Interventional2016-03-31Completed
Deep Neuromuscular Blockade to Improve Postoperative Quality of Recovery in Ambulatory Gynaecologic Laparoscopy [NCT04105764]Phase 480 participants (Actual)Interventional2016-12-01Completed
A Multi-center, Randomized, Parallel-group, Comparative, Active-controlled, Safety-assessor Blinded Trial in Adult Subjects Comparing the Efficacy and Safety of Sugammadex (SCH 900616, ORG 25969) Administered at 1-2 PTC With Neostigmine Administered at Re [NCT00724932]Phase 3140 participants (Actual)Interventional2008-07-16Completed
Evaluation of EEG With Respect to the Change of Depth of Anesthesia [NCT02586441]Phase 440 participants (Anticipated)Interventional2015-11-30Not yet recruiting
[NCT02575443]60 participants (Actual)Interventional2015-09-30Completed
Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs. [NCT02698969]Phase 458 participants (Anticipated)Interventional2014-11-30Recruiting
Conventional Sedation Compaired With THRIVE Under General Anesthesia in Endotracheal Intubation by Fiberbronchoscope in Patients With Difficult Airways,A Randomized Controlled Study [NCT04924621]42 participants (Anticipated)Interventional2021-06-10Recruiting
[NCT02648503]Phase 4120 participants (Anticipated)Interventional2016-03-31Not yet recruiting
A Single Center, Open-Label Trial in Subjects With Severe Renal Impairment Evaluating the Dialysability of the Sugammadex-Rocuronium Complex [NCT00656799]Phase 36 participants (Actual)Interventional2008-04-30Completed
The Effect of Rocuronium as an Anesthetic Adjuvant in Peribulbar Anesthesia for Adult Strabismus Surgery: Randomized Controlled Double-blind Study [NCT04821817]50 participants (Anticipated)Interventional2021-04-03Recruiting
Effectiveness of Quadratus Lumborum Block After Nephrectomy [NCT03529201]105 participants (Actual)Interventional2018-05-07Completed
Effect of Magnesium Sulphate Pretreatment on the Onset and Duration of Intense and Deep Neuromuscular Block of Rocuronium Versus Cis-Atracurium in Pediatric Laparoscopic Surgery [NCT05736744]Phase 2/Phase 358 participants (Anticipated)Interventional2023-03-20Not yet recruiting
Perioperative Multimodal General Anesthesia Focusing on Specific CNS Targets in Patients Undergoing Cardiac Surgeries [NCT04016740]Early Phase 122 participants (Actual)Interventional2019-08-20Completed
Comparing Deep Neuromuscular Block and Moderate Neuromuscular Block in Patients Undergoing Laparoscopic Gynaecological Surgeries: Impact on Surgical Satisfaction of Operating Conditions and Patient Satisfaction [NCT02794714]Phase 40 participants (Actual)Interventional2016-06-30Withdrawn(stopped due to unresolved budget issues)
MgSO4 Combined With Rocuronium Priming [NCT01389791]100 participants (Anticipated)Interventional2011-05-31Recruiting
Comparison of General Anesthesia With Use of Muscle Relaxation and General Anesthesia Without Muscle Relaxation on Recovery of Muscle Strength of the Patients [NCT04760912]60 participants (Anticipated)Interventional2020-04-01Enrolling by invitation
The Use Of Solid Phase Micro Extraction For Metabolomic Profiling And Concomitant Measurements Of Rocuronium Bromide Levels In Recipients Of Orthotopic Liver Transplantations [NCT01404793]28 participants (Actual)Observational2011-09-30Completed
Comparative Study of Org 9426 With Vecuronium Bromide (Phase III) [NCT00970762]Phase 390 participants (Actual)Interventional2003-02-28Completed
Neuromuscular Blockade Improves Surgical Conditions [NCT00895778]57 participants (Actual)Interventional2009-03-31Completed
Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study [NCT01571908]Phase 2280 participants (Actual)Interventional2012-09-30Completed
Effect of Sevoflurane on the Onset Characteristics and Intubating Conditions of Rocuronium Under Routine Clinical Practice [NCT02785653]Phase 460 participants (Actual)Interventional2004-04-30Completed
Deep Versus Moderate Neuromuscular Blockade for Optimising Surgical Conditions Include Patient Benefits During Spinal Surgery: A Randomized Controlled Double Blinded Clinical Study [NCT02778945]Phase 460 participants (Anticipated)Interventional2016-09-01Recruiting
Priming Dose of Rocuronium and Milliamperage Value for Supramaximal Stimulation of NeuroMuscular Transmission Monitor [NCT05294523]300 participants (Anticipated)Interventional2021-12-20Recruiting
Influence of a Neuromuscular Block on Face Mask Ventilation Conditions During Induction of Anaesthesia [NCT01849211]120 participants (Actual)Interventional2013-04-30Completed
Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients [NCT01851005]120 participants (Actual)Interventional2013-05-31Completed
Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section [NCT01718236]Phase 4500 participants (Actual)Interventional2012-09-30Completed
Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 Following a Single Intubating Dose in Adult Subjects Undergoing Operation Under Sevoflurane or Propofol Anesthesia [NCT00984633]Phase 340 participants (Actual)Interventional2003-06-30Completed
Protocol for Eslax Intravenous Drug Use Investigation [NCT00902070]3,969 participants (Actual)Observational2007-11-30Completed
Pharmacodynamic Trial on Rocuronium in Obese Patients [NCT00540085]Phase 451 participants (Actual)Interventional2007-10-31Completed
The Effect of Rocuronium on the Response of CVI to Laryngoscopy [NCT00926718]80 participants (Anticipated)Interventional2009-06-30Recruiting
A Multi-Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Org 25969 and Placebo in Pediatric and Adult Subjects. [NCT00421148]Phase 394 participants (Actual)Interventional2005-05-30Completed
Phase 4 Study of Succinylcholine Versus Rocuronium as Neuromuscular Blocking Agent for Emergency Intubation in Intensive Care [NCT00355368]Phase 4420 participants (Actual)Interventional2006-08-31Completed
Comparing Intubating Conditions and Patient Satisfaction Using Succinylcholine or Low-dose Rocuronium for Rigid Bronchoscopy: A Randomized Study [NCT01902641]105 participants (Actual)Interventional2011-10-31Completed
A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the PACU/ICU [NCT01937767]Phase 290 participants (Actual)Interventional2013-08-31Completed
Comparing Intubating Conditions Using Succinylcholine or Rocuronium/Sugammadex for Rigid Bronchoscopy: a Randomized Study [NCT01996358]150 participants (Anticipated)Interventional2015-08-31Suspended
Succinylcholine vs Rocuronium for Prehospital Emergency Intubation : a Randomized Trial [NCT02000674]Phase 31,321 participants (Actual)Interventional2013-12-31Completed
A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and [NCT00552617]Phase 2100 participants (Actual)Interventional2005-09-20Completed
Intubation Conditions After Rapid Sequence Induction Using Different Doses of Rocuronium With Ephedrine Pretreatment: A Randomized Controlled Trial [NCT05725031]Phase 390 participants (Anticipated)Interventional2023-02-22Recruiting
A Phase 2, Randomized, Double-Blind, Active-Controlled, Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery [NCT05687253]Phase 280 participants (Actual)Interventional2022-10-25Completed
A Multicenter, Randomized, Parallel Group Comparative, Active-Controlled, Safety-assessor Blinded. Phase IIIa, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a Neuromuscular Block Induced by Maintenance Dosing of [NCT00473694]Phase 3182 participants (Actual)Interventional2005-11-28Completed
Influence of Skeletal Muscle Paralysis on Metabolism in Hypothermic Patients After Cardiac Arrest [NCT01683006]43 participants (Actual)Interventional2012-04-30Completed
Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy [NCT02669368]Phase 275 participants (Anticipated)Interventional2015-03-31Active, not recruiting
Best Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex [NCT03958201]Phase 4200 participants (Actual)Interventional2019-05-28Completed
Long-term Outcome After Radical Lymph Node Dissection of Malignant Melanoma. Comparison Between Regional Versus General Anesthesia With Respect to Impact of Perioperative Immunoediting and Validation of New Potential Predictive Biomarkers [NCT01588847]230 participants (Anticipated)Interventional2012-03-31Recruiting
Does the Choice of Administration Sequence of Propofol and Remifentanil Affect the ED50 and ED95 of Rocuronium for Rapid Sequence Induction of Anesthesia? [NCT02709473]Phase 484 participants (Actual)Interventional2016-03-31Completed
Atropine in Laparoscopic Gynaecological Surgery (The ALGOS Trial) A Randomised, Double Blind, Controlled Trial [NCT02769325]Phase 4150 participants (Anticipated)Interventional2016-05-31Not yet recruiting
Consumption of Rocuronium Under Etomidate-based Versus Propofol-based Maintenance of General Anesthesia Under Different Concentration of Sevoflurane- BIS Guided Clinical Trial in a Closed Loop Infusion System [NCT02711917]175 participants (Actual)Interventional2015-07-31Completed
The Effect of Different Doses of Ketamine on Tracheal Intubating Conditions Using Low Dose Rocuronium in Children [NCT02646709]Phase 460 participants (Anticipated)Interventional2016-01-31Not yet recruiting
A Single-blinded Multicenter Randomized Study Comparing Intubating Conditions After Either Rocuronium 0.6 mg/kg or Remifentanil 2 µg/kg in Elderly Patients [NCT04287426]Phase 478 participants (Actual)Interventional2020-03-11Completed
[NCT01532466]260 participants (Actual)Interventional2011-03-31Completed
Comparative Randomized Controlled Trial Study of General Balanced Anesthesia Based on Opioid and Opioid Sparing Balanced Anesthesia for Cholecystectomy Surgery Via Laparoscopy: Intraoperative and Postoperative Outcomes [NCT02953210]Phase 440 participants (Anticipated)Interventional2016-11-30Enrolling by invitation
A Multicenter, Randomized, Parallel Group, Comparative, Active-Controlled, Safety-Assessor Blinded, Phase IIIa, Trial, in Adult Subjects Comparing Recovery From 1.2 mg.Kg-1 Rocuronium Followed by 16 mg.Kg-1 Org 25969 at 3 Minutes With Recovery From 1.0 mg [NCT00474253]Phase 3115 participants (Actual)Interventional2006-02-10Completed
A Randomized Parallel Design Study to Compare the Impact of Intraoperative Deep Neuromuscular Blockade on Intraoperative NOL-guided Opioid Requirement and Postoperative Early Outcomes in Laparoscopic Colorectal Surgeries [NCT03910998]Phase 4100 participants (Anticipated)Interventional2019-05-30Recruiting
Efficacy of Neuromuscular Blockade Before Facemask Ventilation in Inducing General Anesthesia [NCT03270696]114 participants (Actual)Interventional2017-08-23Completed
Validation of Inspiratory Muscle Pressure Estimation and Automated Detection of Asynchronies in Patients Under Assisted Mechanical Ventilation [NCT05820347]50 participants (Actual)Interventional2022-08-26Completed
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]3,520 participants (Actual)Observational2011-11-30Completed
Comparison of Mg, Ketamine, Large Dose Rocuronium, and Priming on Intubating Condition in Rapid Sequence Intubation [NCT01479751]110 participants (Actual)Interventional2011-11-30Completed
The Effect of Orally Administered Metoprolol on the Frequency and Severity of Rocuronium Injection Pain [NCT05457751]200 participants (Actual)Observational2014-05-15Completed
A Randomized, Assessor-blind, Dose-ranging, Phase IIIB, Multicenter Trial Comparing the Intubating Conditions and Time Course of Block of Three Different Intubating Doses (0.45 mg/kg, 0.6 mg/kg, and 1.0 mg/kg) of Zemuron® in Pediatric and Adolescent Subje [NCT00124722]Phase 3207 participants (Actual)Interventional2004-12-31Completed
Requirement of Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest - a Pilot Study [NCT01719770]Phase 360 participants (Anticipated)Interventional2010-11-30Completed
Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block for Pain Management in Pediatric Patients With Developmental Dysplasia Sia of the Hip Joint, Randomized Controlled Trial [NCT05543109]85 participants (Anticipated)Interventional2022-09-29Enrolling by invitation
A Single-blinded Multicenter Randomized Interventional Study of Rocuronium 0.3 mg/kg, and 0.9 mg/kg Comparing Onset Time, Duration of Action and Effect on Intubating Conditions in Elderly Patients (≥ 80 Years). [NCT04512313]34 participants (Actual)Interventional2020-12-17Completed
Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery [NCT03939923]Phase 484 participants (Actual)Interventional2019-05-01Completed
The Effect of Esmolol on Pain Due to Rocuronium Injection Pain [NCT01824758]Phase 490 participants (Actual)Interventional2013-03-31Completed
A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety-assessor Blinded, Anesthesiologist-TOF-Watch® SX Blinded Trial Comparing T4/T1 Ratio at Time of Tracheal Extubation Using 4 mg/kg Sugammadex Administered at 1-2 PTCs or Bet [NCT00675792]Phase 3100 participants (Actual)Interventional2008-05-31Completed
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals - a Cross-sectional Study [NCT02914119]30,430 participants (Actual)Observational [Patient Registry]2016-10-01Completed
Does Adding Magnesium Sulphate to Low Dose Rocuronium Affects the Depth of Blockade in Cancer Patients Undergoing Direct Laryngoscope Surgical Procedures [NCT04510337]60 participants (Actual)Interventional2018-04-02Completed
Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade: a Randomized Controlled Study Assessing Propofol and Remifentanil Requirements and Quality of Recovery in Patients With a Standard Practice of N [NCT02484651]Phase 470 participants (Actual)Interventional2016-09-30Completed
[NCT01550354]114 participants (Actual)Interventional2012-02-29Completed
An Open-label, Randomized, Phase IIIB, Multicenter Trial to Evaluate the Pharmacodynamic Parameters of Intubation Bolus, and Bolus and Infusion Maintenance Doses of Zemuron® in Pediatric and Adolescent Subjects [NCT00124735]Phase 3149 participants (Actual)Interventional2004-10-31Completed
Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences [NCT05468671]Phase 434 participants (Actual)Interventional2021-01-04Completed
Evaluation of Surgical Condition During Laparoscopic Gynaecological Surgery in Patient With Moderate vs Deep Neuromuscular Block in Lower Pressure Pneumoperitoneum [NCT05689957]70 participants (Actual)Interventional2020-12-13Completed
Regional vs General Anesthesia in Patients With Hip Fracture Under Treatment With Clopidogrel [NCT03596060]150 participants (Anticipated)Interventional2017-10-20Recruiting
Effect of the Deep Neuromuscular Block on Postoperative Delirium in Elderly Patients Undergoing Lumbar Surgery [NCT05453929]230 participants (Anticipated)Interventional2021-09-16Enrolling by invitation
Optimizing Surgical Conditions: Intraabdominal Distance During Gynecologic Laparoscopic Surgery With and Without Muscle Relaxation (The Measurement Study) [NCT01933425]Phase 414 participants (Actual)Interventional2013-08-31Completed
Randomized Controlled Trial of Epidural-General Anesthesia Versus General Anesthesia for Open Pancreaticoduodenectomy: Influence on Complications and Overall Two Year Survival [NCT03434678]Phase 3133 participants (Actual)Interventional2018-01-30Active, not recruiting
Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized? [NCT02140593]Phase 4128 participants (Actual)Interventional2014-09-30Completed
A Prospective, Double-blind, Randomized, Crossover Design Study to Compare the Hemodynamic and Respiratory Variations During Laparoscopic Surgery in Patients With and Without Deep Neuromuscular Blockade. [NCT02025075]37 participants (Actual)Interventional2014-01-31Completed
Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial [NCT02495038]81 participants (Actual)Interventional2014-03-31Completed
The Impact of the Timing of Rocuronium After Induction With Propofol on Temporal Summation of Pain in Gynecologic Laparoscopic Surgery-prospective and Controlled Study. [NCT04547608]100 participants (Actual)Interventional2020-05-01Completed
Comparison Between Standalone Succinyl Choline and Rocuronium After Pretreatment With Dexmedetomidine, in Rapid Sequence Induction. [NCT04709315]Phase 3240 participants (Anticipated)Interventional2020-10-01Enrolling by invitation
A Prospective Randomized Double Blind Trial of the Efficacy of a Bilateral Lumbar Erector Spinae Block on the 24h Morphine Consumption After Posterior Lumbar Interbody Fusion Surgery. [NCT03825198]Phase 380 participants (Anticipated)Interventional2019-08-01Recruiting
Cukurova University Faculty of Medicine [NCT02360982]120 participants (Actual)Observational2012-03-31Completed
Assessment of Post-operative Residual Curarization (PORC) Incidence in Patients Undergoing Surgery With General Anaesthesia; Comparison Between Cisatracurium and Rocuronium. A Randomised, Single-blind Phase 4 Study. [NCT01651572]Phase 4120 participants (Actual)Interventional2012-07-31Completed
Comparison Between Ultrasound Guided Erector Spinae Block vs Thoracolumbar Interfascial Plane Block in Lumbar Spine Surgeries;Randomized Controlled Trial [NCT05596227]120 participants (Anticipated)Interventional2022-10-20Not yet recruiting
A Multicenter, Randomized, Parallel Group, Comparative, Safety-Assessor Blinded, Phase IIIa Trial in Adult Surgical Subjects Under General Anesthesia at Increased Risk for Pulmonary Complications [NCT00475215]Phase 386 participants (Actual)Interventional2005-10-27Completed
A Perspective, Multicentre, Randomized,Blind Study of Residual Curarization Incidence in China [NCT01690338]Phase 46,090 participants (Anticipated)Interventional2012-10-31Recruiting
Comparison Of Deep Versus Moderate Neuromuscular Blockade on Intra-Operative Blood Loss During Spinal Surgery, Randomized Double Blinded Clinical Trial [NCT05294926]Early Phase 188 participants (Anticipated)Interventional2022-04-01Not yet recruiting
A Prospective Randomized Clinical Trial Evaluating Surgical Conditions During Laparoscopic Bariatric Surgery With Deep Versus Moderate Neuromuscular Blockade [NCT02703909]Phase 4144 participants (Actual)Interventional2016-05-31Completed
The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial [NCT03039543]Phase 4108 participants (Actual)Interventional2017-06-01Completed
Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors. [NCT03063255]Phase 460 participants (Actual)Interventional2017-04-25Completed
Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions in Patients Undergoing Laparoscopic Renal Surgery [NCT03170661]Phase 498 participants (Actual)Interventional2017-06-14Completed
Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery. [NCT01631149]Phase 424 participants (Actual)Interventional2012-06-30Completed
Effects of Deep Versus Moderate Neuromuscular Blockade on Intraoperative Respiratory Mechanics in Patients Undergoing Laparoscopic Renal Surgery: a Prospective, Randomized, Parallel Design Study [NCT02185339]Phase 461 participants (Actual)Interventional2014-07-31Completed
Neuromuscular Blockade for Post-Cardiac Arrest Care [NCT02260258]Phase 283 participants (Actual)Interventional2014-10-31Completed
Preoxygenation With Optiflow™, a High Flow Nasal Cannula (HFNC), is Superior to Preoxygenation With Facemask in Morbidly Obese Patients Undergoing General Anesthesia [NCT03009877]0 participants (Actual)Interventional2018-07-31Withdrawn(stopped due to withdrawn prior to IRB approval)
A Randomized Controlled Trial to Compare the Effectiveness of Deep vs. Moderate Neuromuscular Blockade in Reducing Postoperative Pain and Intra-Abdominal Insufflation Pressure During Minimally Invasive Robotic Prostatectomy [NCT03808077]Phase 2130 participants (Anticipated)Interventional2019-01-14Recruiting
Evaluation of Residual Neuromuscular Blockade and of Late Recurarization in the Post Anesthesia Care Unit in Patients Undergoing Videolaparoscopic Cholecystectomy [NCT03831815]85 participants (Actual)Observational [Patient Registry]2017-11-03Completed
International Review Board of Gachon University Gil Hospital [NCT01436799]40 participants (Actual)Interventional2011-03-31Completed
Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery [NCT01748643]Phase 460 participants (Actual)Interventional2013-04-30Completed
Premedication for Non-Emergency Endotracheal Intubation In the NICU [NCT01749501]Phase 445 participants (Actual)Interventional2011-01-31Completed
Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study [NCT02414880]Phase 460 participants (Actual)Interventional2014-12-31Completed
Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection: A Prospective Randomized Trial [NCT02393664]Phase 2/Phase 3300 participants (Anticipated)Interventional2015-03-31Recruiting
Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes [NCT02589691]Phase 4412 participants (Anticipated)Interventional2015-12-23Recruiting
A Comparison of Surgical Conditions Between Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures. [NCT02451202]Phase 4102 participants (Actual)Interventional2016-06-30Completed
The Influence of the Magnitude of Neuromuscular Blockade on the Surgical Conditions During Laparoscopic Sleeve Gastrectomy [NCT01564576]40 participants (Anticipated)Interventional2012-04-30Not yet recruiting
Interventional Rigid Bronchoscopy Under General Anesthesia: Influence of the Muscle Relaxant, Succinylcholine or Rocuronium, on the Quality of the Surgical Procedure [NCT01579864]Phase 46 participants (Actual)Interventional2012-01-31Terminated(stopped due to recent publication (Ghezel-Ahmadi. Thorac Cardiovasc Surg. 2014 Nov 21))
Laryngeal Injuries After Anesthesia Induction With Sevoflurane and After Anesthesia Induction With Rocuronium. A Randomized, Prospective, Controlled Trial [NCT01591031]60 participants (Actual)Interventional2012-04-30Completed
Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft During Kidney Transplantation [NCT02827435]12 participants (Anticipated)Interventional2016-07-01Recruiting
Comparison of Effects of Low Dose Neuromuscular Blocker Added to Propofol Fentanyl Combination During Lma Procedures in Cystoscopy Patients [NCT03424356]96 participants (Anticipated)Interventional2017-01-04Recruiting
Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine : A Prospective Non-inferiority Randomized and Blind Trial [NCT06029049]Phase 4152 participants (Anticipated)Interventional2023-09-13Recruiting
Eliminating Use of Non Depolarizing Neuromuscular Blocking Agents to Reduce Postoperative Pulmonary Complications: A Multi-center, Randomized Control Trial [NCT03962725]Phase 43 participants (Actual)Interventional2019-08-07Terminated(stopped due to Study terminated due to lack of enrollment.)
Impact of Deep Neuromuscular Block Versus Inhalation and Total Intravenous Anesthesia (TIVA) on Laparoscopic Surgical Workspace Defined as Insufflated Pneumoperitoneum Volume. [NCT01930747]Phase 450 participants (Actual)Interventional2013-04-30Completed
Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies - the PATHFINDER II Study [NCT05279898]70 participants (Anticipated)Interventional2023-02-28Recruiting
Optimal Inspiratory Pressure for Facemask Pressure-controlled Ventilation in Children: Study Using Detection of Gastric Insufflation Using Ultrasonography of the Antrum and Epigastric Auscultation [NCT02471521]120 participants (Actual)Interventional2015-02-28Completed
An Observational Study of Rocuronium 0.6 mg/kg Comparing Onset Time, Duration of Action and Effect on Intubation Conditions in Younger (18 - 40 Years) and Elderly Patients (> 80 Years) [NCT03857750]32 participants (Actual)Observational2019-03-27Completed
A Double-blind, Randomized, Parallel Design to Compare the Effectiveness of Deep Versus Moderate Neuromuscular Blockade With Standard-pressure Pneumoperitoneum During Laparoscopic Gastrectomy on Postoperative Pain in Surgical Patients [NCT03266419]100 participants (Actual)Interventional2018-03-28Completed
Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure [NCT01722097]Phase 4110 participants (Actual)Interventional2012-11-30Completed
A Multi-Center, Randomized, Safety Assessor-Blinded, Placebo- Controlled, Phase II, Parallel Dose-Finding Trial in Subjects of ASA 1-3 to Assess the Efficacy and Safety of 5 Doses of Sugammadex Administered at 3 and 15 Minutes After Administration of 1.0 [NCT00535743]Phase 2174 participants (Actual)Interventional2004-03-04Completed
The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on the Anesthetic Condition With Fentanyl in Children Undergoing Adenotonsillectomy [NCT02467595]Phase 475 participants (Anticipated)Interventional2015-07-31Enrolling by invitation
Anesthetic Depth Using PLE (Phase Lag Entropy) [NCT03299621]35 participants (Anticipated)Interventional2017-11-13Recruiting
Effect to Gastrointestinal Barrier Function During Laparoscopic Gastrectomy With Deep vs Moderate Neuromuscular Blockade. [NCT03782233]83 participants (Actual)Interventional2019-01-01Completed
[NCT02400931]288 participants (Actual)Interventional2015-04-28Completed
Sugammadex and the Diaphragm: Recovery of Diaphragmatic Function and Neuromuscular Blockade. A Double-blind Randomized Controlled Trial [NCT01962298]Phase 375 participants (Actual)Interventional2013-10-31Completed
Effects of Intravenous Lidocaine Infusion on Stress Response in Patients Undergoing Abdominal Surgery During Perioperative Anesthesia and Its Correlation With Serum Orphanin FQ (N/OFQ) [NCT05899127]Phase 480 participants (Anticipated)Interventional2023-07-22Recruiting
Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles. [NCT02376595]10 participants (Actual)Observational2013-03-31Completed
The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy [NCT01450813]80 participants (Actual)Interventional2009-06-30Completed
Comparison of Two Induction Regimens Using Topical Lidocaine or Muscle Relaxant; Impact on Postoperative Sore Throat and Haemodynamics [NCT03031808]Phase 4100 participants (Anticipated)Interventional2017-10-31Recruiting
Effect of Partial Neuromuscular Blockade by Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea-before and After Three Month CPAP Treatment. A Non-randomized, Non-blinded Study. [NCT01672606]11 participants (Actual)Interventional2012-05-31Completed
The Difference in the Current Intensity for the Obturator Nerve Block According to the Presence or Absence of Neuromuscular Blockage [NCT05872451]30 participants (Anticipated)Interventional2023-07-01Recruiting
Randomized, Controlled, Parallel-Group, Double-Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Factorial Design in Patients Undergoing Laparoscopic Cholecyste [NCT01728584]Phase 4127 participants (Actual)Interventional2012-11-28Completed
A Multi -Center, Randomized, Parallel Group, Safety Assessor Blinded Trial Comparing Efficacy and Safety of 4.0 mg.Kg-1 Sugammadex , Administered at T1 3-10% After Continuous Infusion of Rocuronium, and Pharmacokinetics of Rocuronium, Between Subjects Rec [NCT00559468]Phase 352 participants (Actual)Interventional2006-12-07Completed
Reversal of Neuromuscular Blockade in Patients With Severe Renal Impairment [NCT03904550]Phase 249 participants (Actual)Interventional2019-12-10Completed
Regional Anesthesia Versus General Anesthesia in Patients Undergoing Laparoscopic Gynecological Surgery [NCT03830086]28 participants (Actual)Interventional2019-02-07Completed
Ultrasonographic Thyrohyoid Distance Measurement for Prediction of Difficult Intubation and Ultrasonographic Prediction of Pediatric Endotracheal Tube Size [NCT03013036]150 participants (Anticipated)Interventional2013-02-28Recruiting
Comparison of Hourly Rocuronium Consumption Using Continuous Infusion Versus Intermittent Bolus Injection: a Randomized Controlled Trial [NCT03060707]Phase 470 participants (Anticipated)Interventional2017-03-23Recruiting
The Effectiveness of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery in Preserving Innate Immune Homeostasis by Reducing Peritoneal Mesothelial Cell Injury. [NCT03572413]Phase 4100 participants (Actual)Interventional2018-10-24Completed
Comparison of Effectiveness of Different Airway Management Methods During Fiberoptic Bronchoscopy Assisted Percutaneous Tracheostomy [NCT04872881]Phase 452 participants (Anticipated)Interventional2021-05-01Not yet recruiting
Rocuronium ED50 for Excellent Laparoscopic Conditions for Cholecistectomy: Dose-finding Adaptative Clinical Trial [NCT03043157]Phase 330 participants (Actual)Interventional2017-02-15Completed
Effect of Anesthetic Choice (Sevoflurane Versus Desflurane) on Speed and Sustained Nature of Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block [NCT01199237]Phase 4107 participants (Actual)Interventional2010-08-31Completed
Optimal Control of Muscle Strength for Electroconvulsive Therapy: A Comparison of Succinylcholine Versus Rocuronium-induced Neuromuscular Blockade [NCT01441960]45 participants (Actual)Interventional2011-05-31Completed
A Double-blind, Randomized, Parallel Design Study to Compare Surgical Conditions for Fetus Delivery and Suture of the Uterus and Abdominal Wall in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine [NCT01941628]Phase 491 participants (Actual)Interventional2014-08-16Completed
Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil for Epinephrine Local Injection in Patient With Endoscopic Sinus Surgery Under General Anesthesia [NCT02464722]Phase 450 participants (Anticipated)Interventional2015-08-31Enrolling by invitation
MRI Measurement of the Effects of Moderate Versus Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopic Surgery in a Prospective Cohort Study. [NCT03287388]8 participants (Anticipated)Interventional2019-05-31Not yet recruiting
Optimization of Surgical Conditions During Laparoscopic Cholecystectomy With Deep or Moderate Neuromuscular Blockade [NCT01523886]Phase 449 participants (Actual)Interventional2012-03-31Completed
RECOVER Study: the Effect of Low- Versus Normal Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on the Early Quality of Recovery With Perioperative Care According to the Enhanced Recovery Principles [NCT03608436]Phase 4178 participants (Actual)Interventional2018-10-24Completed
Comparison of the Clinical Performances of Flexible Laryngeal Mask Airway in Pediatric Patients Under General Anesthesia With or Without Muscle Relaxant: a Randomized Controlled Non-inferiority Trial [NCT03487003]128 participants (Actual)Interventional2018-04-20Completed
The Influence of Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by μ-opioid Receptor Agonists [NCT03135795]Phase 4100 participants (Anticipated)Interventional2017-02-06Recruiting
Optimizing Surgical Conditions During Laparoscopic Umbilical, Incisional -and Linea Alba Herniotomy With Deep Neuromuscular Blockade [NCT02247466]Phase 437 participants (Actual)Interventional2015-02-28Completed
Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period [NCT02518789]Phase 4132 participants (Anticipated)Interventional2015-09-30Not yet recruiting
Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery [NCT03591289]Phase 40 participants (Actual)Interventional2018-02-28Withdrawn(stopped due to study never started up at site)
A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety Assessor Blinded Trial in Adult Subjects Comparing Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Subjects Undergoing Short Surgical Procedures in Out-patient S [NCT00751179]Phase 3161 participants (Actual)Interventional2008-11-30Completed
[NCT02109133]67 participants (Actual)Interventional2014-05-31Completed
A Double-blind, Randomized, Parallel Group Study to Compare Rocuronium Reversal With Sugammadex (Bridion®) Versus Neostigmine/Glycopyrrolate and the Incidence of Urinary Retention After Elective Ambulatory Posterior Lumbar Laminectomy [NCT05887375]Phase 4118 participants (Anticipated)Interventional2023-08-03Enrolling by invitation
Intubating Conditions at Various Levels of Neuromuscular Blockade [NCT05620108]170 participants (Anticipated)Interventional2022-11-28Enrolling by invitation
The Effect of Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium of Elderly Patients Undergoing Total Hip Arthroplasty [NCT02507609]82 participants (Actual)Interventional2015-09-08Completed
Effect of Deep Neuromuscular Blockade on Surgical Conditions and Recovery After Robotic Radical Prostatectomy: a Prospective Randomized Study [NCT02513693]Phase 480 participants (Anticipated)Interventional2015-07-31Recruiting
Combined General and Spinal Anesthesia vs. Combined General and Spinal Anesthesia With Neuromuscular Blockade for Operative Repair of Hip Fractures [NCT03226080]Phase 40 participants (Actual)Interventional2017-07-19Withdrawn(stopped due to Study terminated with IRB on 20Feb2019 due to lack of enrollment.)
"Randomized, Parallel Group, Controlled Trial to Compare Two Different NMB + Reversal Strategies in Adult Obese Patients Undergoing Laparoscopic Abdominal Surgery" [NCT02410590]Phase 40 participants (Actual)Interventional2015-07-31Withdrawn
Effect of Depth of Neuromuscular Block on Intraoperative Surgical Conditions as Determined by the Leiden Surgical Rating Scale in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery [NCT02553629]Phase 4109 participants (Actual)Interventional2015-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00124735 (4) [back to overview]Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 80%
NCT00124735 (4) [back to overview]Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 90%
NCT00124735 (4) [back to overview]Duration of Recovery of T4/T1 Ratio (TOF Fourth Twitch to First Twitch) 70%
NCT00124735 (4) [back to overview]Total Dose of Zemuron (Rocuronium) Administered
NCT00298831 (6) [back to overview]Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9
NCT00298831 (6) [back to overview]Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.8
NCT00298831 (6) [back to overview]Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.7
NCT00298831 (6) [back to overview]Clinical Assessments of Recovery - Check for General Muscle Weakness (GMW)
NCT00298831 (6) [back to overview]Clinical Assessments of Recovery - Participant Able to Perform 5-second Head Lift (5SHL)
NCT00298831 (6) [back to overview]Clinical Assessment of Recovery - Participant's Level of Consciousness
NCT00355368 (4) [back to overview]Number of Participants Exhibiting Desaturation >5%
NCT00355368 (4) [back to overview]Number of Participants With an Failed First Intubation Attempts
NCT00355368 (4) [back to overview]Time to Completion of Intubation
NCT00355368 (4) [back to overview]Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.
NCT00421148 (3) [back to overview]Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9
NCT00421148 (3) [back to overview]Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8
NCT00421148 (3) [back to overview]Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]Number of Participants Able to Perform a 5-second Head Lift
NCT00473694 (11) [back to overview]Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]Number of Participants Experiencing General Muscle Weakness
NCT00473694 (11) [back to overview]Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00474253 (7) [back to overview]Number of Participants Experiencing General Muscle Weakness
NCT00474253 (7) [back to overview]Number of Participants Able to Perform 5-Second Head Lift
NCT00474253 (7) [back to overview]Level of Consciousness: Number of Participants Awake and Oriented
NCT00474253 (7) [back to overview]Level of Consciousness: Number of Participants Arousable With Minimal Stimulation
NCT00474253 (7) [back to overview]Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation
NCT00474253 (7) [back to overview]Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
NCT00474253 (7) [back to overview]Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
NCT00475215 (11) [back to overview]Level of Consciousness Assessment 1: Prior to Transfer to the Recovery Room Following Extubation
NCT00475215 (11) [back to overview]Level of Consciousness Assessment 2: Prior to Discharge From the Recovery Room
NCT00475215 (11) [back to overview]Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.7 in Participants With or Having a Past History of Pulmonary Disease
NCT00475215 (11) [back to overview]Five-Second Head Lift Assessment 2: Prior to Discharge From the Recovery Room
NCT00475215 (11) [back to overview]Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.8 in Participants With or Having a Past History of Pulmonary Disease
NCT00475215 (11) [back to overview]Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.9 in Participants With or Having a Past History of Pulmonary Disease
NCT00475215 (11) [back to overview]General Muscle Weakness Assessment 1: Prior to Transfer to the Recovery Room Following Extubation
NCT00475215 (11) [back to overview]Percentage of Participants Experiencing ≥1 Adverse Event(s) (AE)
NCT00475215 (11) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an Adverse Event (AE)
NCT00475215 (11) [back to overview]General Muscle Weakness Assessment 2: Prior to Discharge From the Recovery Room
NCT00475215 (11) [back to overview]Five-Second Head Lift Assessment 1: Prior to Transfer to the Recovery Room Following Extubation
NCT00535743 (4) [back to overview]Number of Participants Experiencing an Adverse Event
NCT00535743 (4) [back to overview]Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.7
NCT00535743 (4) [back to overview]Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.8
NCT00535743 (4) [back to overview]Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9
NCT00552617 (3) [back to overview]Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8
NCT00552617 (3) [back to overview]Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
NCT00552617 (3) [back to overview]Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7
NCT00559468 (3) [back to overview]Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.8
NCT00559468 (3) [back to overview]Mean Time From Start Administration of Sugammadex to Recovery of Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
NCT00559468 (3) [back to overview]Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.7
NCT00656799 (19) [back to overview]Clearance of Rocuronium by Dialysis as Measured by the Reduction Ratio (RR)
NCT00656799 (19) [back to overview]Time From Start of Administration of Sugammadex to Recovery of T4/T1 Ratio to 0.9
NCT00656799 (19) [back to overview]Time From Start of Administration of Sugammadex to Recovery of T4/T1 Ratio to 0.7
NCT00656799 (19) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT00656799 (19) [back to overview]Number of Participants With Reoccurrence of Neuromuscular Blockade at Day 1
NCT00656799 (19) [back to overview]Number of Participants With Pregnancies at 30 Days Post-dose
NCT00656799 (19) [back to overview]Number of Participants With Pre-treatment Adverse Events (AEs)
NCT00656799 (19) [back to overview]Number of Participants With Medical Device (Near) Incidents
NCT00656799 (19) [back to overview]Number of Participants With Events Due to Possible Interaction of Sugammadex With Endo-/Exogenous Compounds Other Than Rocuronium
NCT00656799 (19) [back to overview]Time From Start of Administration of Sugammadex to Recovery of T4/T1 Ratio to 0.8
NCT00656799 (19) [back to overview]Vital Sign: Mean Systolic Blood Pressure
NCT00656799 (19) [back to overview]Vital Sign: Mean Diastolic Blood Pressure
NCT00656799 (19) [back to overview]Rate of Clearance of Sugammadex From Dialysate
NCT00656799 (19) [back to overview]Vital Sign: Mean Heart Rate
NCT00656799 (19) [back to overview]Rate of Clearance of Sugammadex From Blood
NCT00656799 (19) [back to overview]Rate of Clearance of Rocuronium From Dialysate
NCT00656799 (19) [back to overview]Rate of Clearance of Rocuronium From Blood
NCT00656799 (19) [back to overview]Number of Participants With Physical Examinations
NCT00656799 (19) [back to overview]Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR)
NCT00675792 (6) [back to overview]Number of Participants With Post-operative Complications
NCT00675792 (6) [back to overview]Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9
NCT00675792 (6) [back to overview]Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation
NCT00675792 (6) [back to overview]Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7
NCT00675792 (6) [back to overview]Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8
NCT00675792 (6) [back to overview]Number of Participants With Evidence of Possible Interaction of Sugammadex With Endogenous Compounds or Exogenous Compounds Other Than Rocuronium Bromide
NCT00724932 (32) [back to overview]Mean Heart Rate
NCT00724932 (32) [back to overview]Mean Diastolic Blood Pressure
NCT00724932 (32) [back to overview]Monitoring of Clinical Signs of Recovery According to Routine Anesthetic Procedures at the Trial Sites
NCT00724932 (32) [back to overview]Number of Female Participants or Partners of Male Participants Who Became Pregnant During Study
NCT00724932 (32) [back to overview]Number of Participants With Clinical Evidence of Reoccurrence of Neuromuscular Blockade or Residual Neuromuscular Blockade (Routine Oxygen Saturation by Pulse Oximetry and Breath Frequency Measurement)
NCT00724932 (32) [back to overview]Number of Participants With Events Due to a Possible Interaction of Sugammadex With Endogenous Compounds or With Exogenous Compounds Other Than Rocuronium
NCT00724932 (32) [back to overview]Number of Participants With Reoccurrence of Neuromuscular Blockade Based on the Train-of-Four- (TOF-) Watch® SX Recording (i.e. a Decline in T4/T1 Ratio From >=0.9 to <0.8 in at Least Three Consecutive TOF Values)
NCT00724932 (32) [back to overview]Number of Participants With Train-of-Four- (TOF-) Watch® SX and Arm Board Related Adverse Events
NCT00724932 (32) [back to overview]Time From Tracheal Extubation to Operating Room Discharge Ready
NCT00724932 (32) [back to overview]Time From Actual Operating Room Discharge to PACU Discharge Ready
NCT00724932 (32) [back to overview]Time From Operating Room Admission to Actual Operating Room Discharge
NCT00724932 (32) [back to overview]Time From Operating Room Admission to Operating Room Discharge Ready
NCT00724932 (32) [back to overview]Time From Operating Room Discharge Ready to Actual Operating Room Discharge
NCT00724932 (32) [back to overview]Time From Operating Room Discharge Ready to Actual PACU Discharge
NCT00724932 (32) [back to overview]Time From Operating Room Discharge Ready to Post Anesthetic Care Unit (PACU) Discharge Ready
NCT00724932 (32) [back to overview]Time From PACU Admit to Actual PACU Discharge
NCT00724932 (32) [back to overview]Time From Start of Administration of the Last Dose of Rocuronium to Recovery of the T4/T1 Ratio to 0.5, 0.6, 0.7, 0.8 and 0.9
NCT00724932 (32) [back to overview]Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8
NCT00724932 (32) [back to overview]Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
NCT00724932 (32) [back to overview]Time From Start of Administration of the Last Dose of Rocuronium to the Time of 1-2 PTC in the 4.0 mg.Kg-1 Sugammadex Group
NCT00724932 (32) [back to overview]Time From Start of Administration of the Last Dose of Rocuronium to the Time of Reappearance of T2 in the 50 μg.Kg-1 Neostigmine Group
NCT00724932 (32) [back to overview]Time From PACU Admit to PACU Discharge Ready
NCT00724932 (32) [back to overview]Time From Start of IMP Administration to Operating Room Discharge Ready
NCT00724932 (32) [back to overview]Time From Start of IMP Administration to Tracheal Extubation
NCT00724932 (32) [back to overview]Mean Systolic Blood Pressure
NCT00724932 (32) [back to overview]Number of Participants Who Experienced Pre-treatment Non-serious Adverse Events (AEs) and Post-treatment Non-serious AEs
NCT00724932 (32) [back to overview]Number of Participants Who Experienced Pre-treatment Serious Adverse Events (SAEs) and Post-treatment SAEs
NCT00724932 (32) [back to overview]Time From Start of IMP Administration to Actual Operating Room Discharge
NCT00724932 (32) [back to overview]Time From Actual Operating Room Discharge to Actual PACU Discharge
NCT00724932 (32) [back to overview]Time From Tracheal Extubation to Actual Operating Room Discharge
NCT00724932 (32) [back to overview]Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.5 and 0.6
NCT00724932 (32) [back to overview]Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups
NCT00751179 (11) [back to overview]Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine
NCT01199237 (5) [back to overview]Time From Anesthetic Discontinuation to First Ability to Swallow
NCT01199237 (5) [back to overview]Time From Potent Inhaled Anesthetic Discontinuation to First Response to Command (T1)
NCT01199237 (5) [back to overview]Nausea and Vomiting
NCT01199237 (5) [back to overview]Recovery of Ability to Swallow After Neostigmine/Glycopyrrolate Antagonism of Rocuronium Paralysis.
NCT01199237 (5) [back to overview]Nausea and Vomiting
NCT01436799 (1) [back to overview]Regional Cerebral Oxygen Satuation (rSO2)
NCT01441960 (3) [back to overview]Optimal Dose of Neuromuscular Blocking Agent During ECT
NCT01441960 (3) [back to overview]Compound Specific Differences in Time to Recovery From Neuromuscular Blockade
NCT01441960 (3) [back to overview]Differences in Seizure Duration Between Compounds
NCT01450813 (2) [back to overview]The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups
NCT01450813 (2) [back to overview]The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups
NCT01523886 (1) [back to overview]The Percentage of Patients With Optimal Surgical Space Conditions ( 1 at a 4-step Scale) Assessed at the Time During Surgery, When View Was Less
NCT01631149 (5) [back to overview]Nausea and Vomiting
NCT01631149 (5) [back to overview]Post-operative Pain
NCT01631149 (5) [back to overview]Surgical Rating Scale
NCT01631149 (5) [back to overview]Postoperative Sedation Score
NCT01631149 (5) [back to overview]Breathing
NCT01722097 (2) [back to overview]Shoulder Pain
NCT01722097 (2) [back to overview]Pain (Assessed on a 0-100 Visual Analouge Scale (VAS): 0 no Pain, 100 Worst Kind of Pain)
NCT01728584 (14) [back to overview]Number of Times Participant's Movements or Increased Muscle Tone Interfered With the Surgical Conditions During Laparoscopy: By Depth of NMB (Standard, Deep)
NCT01728584 (14) [back to overview]Score on Surgeon's Assessment of Overall Satisfaction With the Visibility of the Surgical Field: By Depth of NMB (Standard, Deep)
NCT01728584 (14) [back to overview]Score on Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions: By Treatment Arm
NCT01728584 (14) [back to overview]Score on Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions: By Depth of NMB (Standard, Deep) and Insufflation Pressure (Standard, Low)
NCT01728584 (14) [back to overview]Participant's Overall Average Pain Score in the First 24 Hours After Administration of Sugammadex: By Depth of NMB (Standard, Deep) and Insufflation Pressure (Standard, Low)
NCT01728584 (14) [back to overview]Participant's Overall Average Pain Score in the First 24 Hours After Administration of Sugammadex: By Treatment Arm
NCT01728584 (14) [back to overview]Number of Participants With Rescue Actions Performed During Surgery in Order to Improve Insufficient Surgical Conditions: By Treatment Arm
NCT01728584 (14) [back to overview]Score on Surgeon's Assessment of the Effect Participant's Movements During Surgery Had on the Overall Surgical Procedure: By Depth of NMB (Standard, Deep)
NCT01728584 (14) [back to overview]Score on Surgeon's Assessment of the Overall Adequacy of Insufflation Pressure During Surgery: By Depth of NMB (Standard, Deep)
NCT01728584 (14) [back to overview]Score on Surgeon's Assessment of the Overall Adequacy of Muscle Relaxation During Surgery: By Depth of NMB (Standard, Deep)
NCT01728584 (14) [back to overview]Number of Participants Using Pain/Analgesic Medication During Post Operative Period: By Treatment Arm
NCT01728584 (14) [back to overview]Participant's Daily Assessment of Overall Pain at Rest During Post Operative Period: By Treatment Arm
NCT01728584 (14) [back to overview]Participant's Daily Assessment of Provoked Pain During Post Operative Period: By Treatment Arm
NCT01728584 (14) [back to overview]Participant's Daily Assessment of Shoulder Pain During Post Operative Period: By Treatment Arm
NCT01748643 (6) [back to overview]Number of Intra-abdominal Pressure Rises > 18cmH2O
NCT01748643 (6) [back to overview]Peak Expiratory Flow
NCT01748643 (6) [back to overview]Duration of Surgery
NCT01748643 (6) [back to overview]Subjective Evaluation of the View on the Operating Field by the Surgeon
NCT01748643 (6) [back to overview]Forced Expiratory Volume in 1 Second
NCT01748643 (6) [back to overview]Forced Vital Capacity
NCT01749501 (2) [back to overview]Present the Percentage of Participants With an Excellent Ease of Intubation Rating
NCT01749501 (2) [back to overview]Timing of Entire Procedure (Stopwatch)and Recording Number of Attempts to Successful Intubation Recorded.
NCT01930747 (3) [back to overview]Effect of Anesthetics on the Abdominal Elastance (E) Measured During Insufflation of the Abdomen by
NCT01930747 (3) [back to overview]Adverse Events Difference Between the Three Groups
NCT01930747 (3) [back to overview]Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen
NCT01933425 (3) [back to overview]Surgical Conditions During Suturing of the Abdominal Fascia
NCT01933425 (3) [back to overview]Intraabdominal Distance (Centimeters)
NCT01933425 (3) [back to overview]Intraabdominal Distance (Centimeters)
NCT01941628 (3) [back to overview]Induction to Delivery Interval
NCT01941628 (3) [back to overview]Number of Participants With Newborn in Need of Respiratory Support
NCT01941628 (3) [back to overview]Peroperative and Postoperative Surgical Complication
NCT01962298 (2) [back to overview]Electric Activity of the Intercostal Muscles
NCT01962298 (2) [back to overview]Electric Activity of the Diaphragm (Microvolts)
NCT02025075 (4) [back to overview]Cerebral Oximetry (%)
NCT02025075 (4) [back to overview]Ejection Fraction (%)
NCT02025075 (4) [back to overview]Postoperative Pain
NCT02025075 (4) [back to overview]Regional Change in Air Content (Delta Z, %)
NCT02109133 (4) [back to overview]Post-operative Nausea
NCT02109133 (4) [back to overview]Incidence of Residual Neuromuscular Blockade
NCT02109133 (4) [back to overview]Maximum Intraocular Pressure During RALRP Under Deep Neuromuscular Blockade
NCT02109133 (4) [back to overview]Overall Surgical Condition
NCT02140593 (2) [back to overview]Surgical Rating Score
NCT02140593 (2) [back to overview]The Surgical Rating Score During Fascial Closure
NCT02185339 (9) [back to overview]Cardiac Index
NCT02185339 (9) [back to overview]Estimated Dead Space
NCT02185339 (9) [back to overview]Postoperative Pain
NCT02185339 (9) [back to overview]Pulmonary Shunt
NCT02185339 (9) [back to overview]Stroke Volume Variation
NCT02185339 (9) [back to overview]Surgical Condition
NCT02185339 (9) [back to overview]Thoracopulmonary Compliance
NCT02185339 (9) [back to overview]Arterial Oxygen Tension/Inspired Oxygen Fraction
NCT02185339 (9) [back to overview]Arterial to End-tidal Partial Pressure of Carbon Dioxide Difference
NCT02247466 (5) [back to overview]Continuous Abdominal Contractions
NCT02247466 (5) [back to overview]Insufflator Alarms
NCT02247466 (5) [back to overview]Operating Time
NCT02247466 (5) [back to overview]Suturing Time
NCT02247466 (5) [back to overview]Contractions
NCT02260258 (8) [back to overview]Change in Lactate Over 24 Hours
NCT02260258 (8) [back to overview]Change in Lactate Over 24 Hours: Effect Estimate
NCT02260258 (8) [back to overview]Muscle Weakness Score
NCT02260258 (8) [back to overview]Survival
NCT02260258 (8) [back to overview]Time ROSC to Target Temperature
NCT02260258 (8) [back to overview]Length of Intensive Care Unit (ICU) Stay
NCT02260258 (8) [back to overview]Mechanical Ventilation Duration
NCT02260258 (8) [back to overview]Number of Participants With Rankin Score ≤3
NCT02451202 (2) [back to overview]Time to Modified Aldrete's Score ≥ 9
NCT02451202 (2) [back to overview]Proportion of Patients Who Have a Clinically Acceptable Surgical Conditions
NCT02471521 (1) [back to overview]Inspiratory Pressure That Cause Gastric Insufflation
NCT02484651 (3) [back to overview]PQRS Results at 15 and 40 Minutes After Surgery (Taking Into Account the Patient Baseline Values of the PQRS Test Done on the Preanesthetic Visit)
NCT02484651 (3) [back to overview]BIS Signal Variability Using the Measured Standard Deviation During the Maintenance Phase of Anesthesia
NCT02484651 (3) [back to overview]Required Effect-site Concentrations of Propofol and Remifentanil
NCT02495038 (10) [back to overview]Operation Time
NCT02495038 (10) [back to overview]Non Invasive Blood Pressure,
NCT02495038 (10) [back to overview]Additional Rescue Doses Per Hour Ratio.
NCT02495038 (10) [back to overview]Anesthetic Time
NCT02495038 (10) [back to overview]Bispectral Index
NCT02495038 (10) [back to overview]Body Temperature
NCT02495038 (10) [back to overview]Duration 25% of Neuromuscular Blocking Agents(NMBAs)
NCT02495038 (10) [back to overview]Onset of Neuromuscular Blocking Agents(NMBAs)
NCT02495038 (10) [back to overview]Recovery Index of Neuromuscular Blocking Agents(NMBAs)
NCT02495038 (10) [back to overview]Peripheral Oxygen Saturation
NCT02553629 (5) [back to overview]Pain
NCT02553629 (5) [back to overview]Extubation
NCT02553629 (5) [back to overview]Mean Arterial Blood Pressure
NCT02553629 (5) [back to overview]Respiration
NCT02553629 (5) [back to overview]Surgical Rating
NCT02703909 (3) [back to overview]Postoperative Opioid Requirement
NCT02703909 (3) [back to overview]Surgeon Satisfaction Scale
NCT02703909 (3) [back to overview]Number and Percentage of Subjects With Success at Low (10 mm) Insufflation Pressure
NCT02724111 (8) [back to overview]The Degree of Bleeding
NCT02724111 (8) [back to overview]Adverse Events : The Postoperative Nausea and Vomiting Occurrence in Subject
NCT02724111 (8) [back to overview]Mean Value of Peak Inspiratory Pressure
NCT02724111 (8) [back to overview]Mean Value of Pressure of Back Muscle Retractor
NCT02724111 (8) [back to overview]Overall Satisfaction of Surgeons for the Surgical Condition
NCT02724111 (8) [back to overview]Recovery Time (Time to Reach Sedation Score 5 at Postanesthesia Care Unit (PACU).
NCT02724111 (8) [back to overview]The Muscle Tone
NCT02724111 (8) [back to overview]The Number of Body Movements
NCT02812186 (3) [back to overview]Abdominal Insufflation Pressure
NCT02812186 (3) [back to overview]Peak Airway Pressures
NCT02812186 (3) [back to overview]Surgical Rating Scale
NCT02838134 (13) [back to overview]Cumulative Use of Rocuronium
NCT02838134 (13) [back to overview]Conversion
NCT02838134 (13) [back to overview]Pain Scores
NCT02838134 (13) [back to overview]Surgical Conditions
NCT02838134 (13) [back to overview]Total Score of the Quality of Recovery-40 Questionnaire
NCT02838134 (13) [back to overview]Total Score of the Quality of Recovery-40 Questionnaire (QoR-40)
NCT02838134 (13) [back to overview]Warm Ischemia Time
NCT02838134 (13) [back to overview]Discharge Criteria
NCT02838134 (13) [back to overview]Postoperative Pain
NCT02838134 (13) [back to overview]Postoperative Complications
NCT02838134 (13) [back to overview]Length of Pneumoperitoneum
NCT02838134 (13) [back to overview]Intra-operative Complications
NCT02838134 (13) [back to overview]Estimated Blood Loss
NCT02914119 (2) [back to overview]Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA
NCT02914119 (2) [back to overview]Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively
NCT03039543 (5) [back to overview]Incidence of Postoperative Residual Curarization
NCT03039543 (5) [back to overview]Number of Participants Attaining a 5 (Optimal) Surgical Condition Score
NCT03039543 (5) [back to overview]Other Postoperative Adverse Events
NCT03039543 (5) [back to overview]Recovery Time (PACU Discharge)
NCT03039543 (5) [back to overview]the Incidence of Desaturation
NCT03063255 (3) [back to overview]Number Patients With Increased Risk of Falling
NCT03063255 (3) [back to overview]Number of Patients With Incidence of Leg Weakness
NCT03063255 (3) [back to overview]Number of Patients With Incidence of Intraoperative Adductor Spasm
NCT03138967 (3) [back to overview]PostOperative Complications
NCT03138967 (3) [back to overview]Muscle Recovery Time
NCT03138967 (3) [back to overview]Overall Recovery Time
NCT03170661 (6) [back to overview]Intraoperative Hemodynamic Conditions
NCT03170661 (6) [back to overview]Intraoperative Nociception Level
NCT03170661 (6) [back to overview]Leiden Surgical Rating Scale
NCT03170661 (6) [back to overview]Postoperative Measurements and Outcomes; Pain Scores
NCT03170661 (6) [back to overview]Postoperative Measurements and Outcomes; Saturation
NCT03170661 (6) [back to overview]Postoperative Measurements and Outcomes; Sedation Levels
NCT03266419 (2) [back to overview]Mean Visual Analogue Scale (VAS) Score for Wound Pain at Post Anesthesia Care Unit (PACU)
NCT03266419 (2) [back to overview]Minimum Effective Analgesic Dose (MEAD) of Oxycodone at Postoperative Care Unit (PACU)
NCT03346057 (6) [back to overview]Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
NCT03346057 (6) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
NCT03346057 (6) [back to overview]Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
NCT03346057 (6) [back to overview]Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.8: Geometric Mean Analysis
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.7: Geometric Mean Analysis
NCT03346070 (11) [back to overview]Percentage of Participants With Prolonged (>10 Minutes) Time to Recovery (TTR) of the Train Of Four (TOF) Ratio to ≥0.9
NCT03346070 (11) [back to overview]Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
NCT03346070 (11) [back to overview]Percentage of Participants Experiencing an Event of Clinical Interest (ECI) After Administration of Study Intervention
NCT03346070 (11) [back to overview]Percentage of Participants Experiencing an Adverse Event (AE) After Administration of Study Intervention
NCT03346070 (11) [back to overview]Percentage of Participants Experiencing a Serious Adverse Event (SAE) After Administration of Study Intervention
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.9: Secondary Geometric Mean Analysis
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis
NCT03346070 (11) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
NCT03346070 (11) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
NCT03519854 (8) [back to overview]Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9
NCT03519854 (8) [back to overview]Mean Heart Rate at Baseline
NCT03519854 (8) [back to overview]Mean Heart Rate at 30 Minutes Following Administration of Study Treatment
NCT03519854 (8) [back to overview]Mean Heart Rate at 2 Minutes Following Administration of Study Treatment
NCT03519854 (8) [back to overview]Mean Corrected QT Interval (QTc) at Baseline
NCT03519854 (8) [back to overview]Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment
NCT03519854 (8) [back to overview]Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment
NCT03519854 (8) [back to overview]Number of Participants Experiencing an Adverse Event
NCT03519867 (2) [back to overview]Percentage of Participants Experiencing ≥1 Adverse Events (AEs)
NCT03519867 (2) [back to overview]Time From Start of Administration of MK-8616 to Recovery T4/T1 Ratio to 0.9
NCT03532178 (2) [back to overview]Recovery Time of T1 to 90% Baseline
NCT03532178 (2) [back to overview]Number of Participants With Treatment or Emergent Adverse Events of the Drugs
NCT03540030 (16) [back to overview]Additional Post Op Pain
NCT03540030 (16) [back to overview]Simple Shoulder Test
NCT03540030 (16) [back to overview]Simple Shoulder Test
NCT03540030 (16) [back to overview]Post Op Pain
NCT03540030 (16) [back to overview]ASES
NCT03540030 (16) [back to overview]Morphine Use
NCT03540030 (16) [back to overview]Falls
NCT03540030 (16) [back to overview]Falls
NCT03540030 (16) [back to overview]Nausea
NCT03540030 (16) [back to overview]Nausea
NCT03540030 (16) [back to overview]Pain Satisfaction
NCT03540030 (16) [back to overview]Pain Satisfaction
NCT03540030 (16) [back to overview]Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore
NCT03540030 (16) [back to overview]Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore
NCT03540030 (16) [back to overview]Constipation
NCT03540030 (16) [back to overview]Constipation
NCT03543826 (4) [back to overview]Incidence of Postoperative Severe Residual Neuromuscular Blockade at Time of Tracheal Extubation
NCT03543826 (4) [back to overview]Incidence of Postoperative Severe Residual Neuromuscular Blockade at Time of Arrival to the Post-anesthesia Care Unit.
NCT03543826 (4) [back to overview]Incidence of Postoperative Residual Neuromuscular Blockade at Time of Tracheal Extubation.
NCT03543826 (4) [back to overview]Incidence of Postoperative Residual Neuromuscular Blockade at Time of Arrival to the Post-anesthesia Care Unit.
NCT03782233 (18) [back to overview]Relative Abundance of Intestinal Microbiota
NCT03782233 (18) [back to overview]16s rRNA Sequencing of Postoperative Feces
NCT03782233 (18) [back to overview]Total Number of Operational Taxonomic Units (OUTs) of Intestinal Microbiota
NCT03782233 (18) [back to overview]Duration of Surgery
NCT03782233 (18) [back to overview]Duration of Postoperative Hospital Stay
NCT03782233 (18) [back to overview]Duration of CO2 Pneumoperitoneum
NCT03782233 (18) [back to overview]Plasma Concentration of Diamine Oxidase (DAO) Before the Surgery
NCT03782233 (18) [back to overview]Plasma Concentration of Diamine Oxidase (DAO) 24 h After the Surgery
NCT03782233 (18) [back to overview]Plasma Concentration of D-lactic Acid Before the Surgery
NCT03782233 (18) [back to overview]Postoperative Exhaust Time
NCT03782233 (18) [back to overview]Surgical Condition Scores Rated by Surgeons (Average Scores)
NCT03782233 (18) [back to overview]Postoperative VAS (48 h After Surgery, Rest State)
NCT03782233 (18) [back to overview]Plasma Concentration of D-lactic Acid 24 h After the Surgery
NCT03782233 (18) [back to overview]Postoperative VAS (48 h After Surgery, Active State)
NCT03782233 (18) [back to overview]Postoperative VAS (24 h After Surgery, Rest State)
NCT03782233 (18) [back to overview]Postoperative VAS (24 h After Surgery, Active State)
NCT03782233 (18) [back to overview]Postoperative VAS (12 h After Surgery, Rest State)
NCT03782233 (18) [back to overview]Postoperative VAS (12 h After Surgery, Active State)
NCT03857750 (2) [back to overview]Onset Time
NCT03857750 (2) [back to overview]Duration of Action
NCT03904550 (1) [back to overview]Time Until Complete Reversal of Neuromuscular Blockade
NCT03939923 (5) [back to overview]Time to Extubation
NCT03939923 (5) [back to overview]Tidal Volume
NCT03939923 (5) [back to overview]Peak Flow Rate
NCT03939923 (5) [back to overview]Blood Pressure (First Measurement of Systolic Blood Pressure Post Reversal)
NCT03939923 (5) [back to overview]Heart Rate
NCT03958201 (2) [back to overview]Incidence of Postoperative Residual Neuromuscular Blockade at Time of Extubation
NCT03958201 (2) [back to overview]Incidence of Severe Postoperative Residual Neuromuscular Blockade at Time of Extubation

Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 80%

The time it takes for the the T4 to T1 ratio to reach 80%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%). (NCT00124735)
Timeframe: after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)

Interventionminutes (Mean)
Rocuronium Bolus Maintenance - Neonate (BN)36.62
Rocuronium Bolus Maintenance - Infants (BI)43.58
Rocuronium Bolus Maintenance - Toddlers (BT)32.39
Rocuronium Bolus Maintenance -Children (BC)20.43
Rocuronium Bolus Maintenance - Adolescents (BA)35.75
Rocuronium Continuous Infusion Maintenance - Neonates (IN)57.83
Rocuronium Continuous Infusion Maintenance - Infants (II)44.75
Rocuronium Continuous Infusion Maintenance - Toddlers (IT)29.47
Rocuronium Continuous Infusion Maintenance - Children (IC)21.82
Rocuronium Continuous Infusion Maintenance - Adolescents (IA)35.45

[back to top]

Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 90%

The time it takes for the the T4 to T1 ratio to reach 90%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%). (NCT00124735)
Timeframe: after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)

Interventionminutes (Mean)
Rocuronium Bolus Maintenance - Neonate (BN)28.25
Rocuronium Bolus Maintenance - Infants (BI)53.66
Rocuronium Bolus Maintenance - Toddlers (BT)45.31
Rocuronium Bolus Maintenance -Children (BC)23.09
Rocuronium Bolus Maintenance - Adolescents (BA)49.25
Rocuronium Continuous Infusion Maintenance - Neonates (IN)52.25
Rocuronium Continuous Infusion Maintenance - Infants (II)50.75
Rocuronium Continuous Infusion Maintenance - Toddlers (IT)37.86
Rocuronium Continuous Infusion Maintenance - Children (IC)28.02
Rocuronium Continuous Infusion Maintenance - Adolescents (IA)38.68

[back to top]

Duration of Recovery of T4/T1 Ratio (TOF Fourth Twitch to First Twitch) 70%

The time it takes for the the T4 to T1 ratio to reach 70%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%). (NCT00124735)
Timeframe: after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)

Interventionminutes (Mean)
Rocuronium Bolus Maintenance - Neonate (BN)29.62
Rocuronium Bolus Maintenance - Infants (BI)33.25
Rocuronium Bolus Maintenance - Toddlers (BT)22.65
Rocuronium Bolus Maintenance -Children (BC)16.19
Rocuronium Bolus Maintenance - Adolescents (BA)28.04
Rocuronium Continuous Infusion Maintenance - Neonates (IN)43.32
Rocuronium Continuous Infusion Maintenance - Infants (II)33.25
Rocuronium Continuous Infusion Maintenance - Toddlers (IT)23.08
Rocuronium Continuous Infusion Maintenance - Children (IC)18.37
Rocuronium Continuous Infusion Maintenance - Adolescents (IA)27.59

[back to top]

Total Dose of Zemuron (Rocuronium) Administered

Total dose from administration of intubating dose to reappearance of T3 (the third twitch of a Train of Four [TOF] stimulation) after the last maintenance bolus dose or discontinuation of Zemuron (rocuronium) infusion (Per protocol [PP] data set) (NCT00124735)
Timeframe: during surgery

Interventionmg/kg (Mean)
Rocuronium Bolus Maintenance - Neonate (BN)0.91
Rocuronium Bolus Maintenance - Infants (BI)0.78
Rocuronium Bolus Maintenance - Toddlers (BT)0.86
Rocuronium Bolus Maintenance -Children (BC)0.81
Rocuronium Bolus Maintenance - Adolescents (BA)0.96
Rocuronium Continuous Infusion Maintenance - Neonates (IN)1.01
Rocuronium Continuous Infusion Maintenance - Infants (II)0.84
Rocuronium Continuous Infusion Maintenance - Toddlers (IT)1.00
Rocuronium Continuous Infusion Maintenance - Children (IC)1.26
Rocuronium Continuous Infusion Maintenance - Adolescents (IA)0.99

[back to top]

Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9

"Mean time from start of MK-8616 administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT00298831)
Timeframe: Up to approximately 30 minutes following administration of study treatment

InterventionMinutes (Mean)
Sugammadex2.32

[back to top]

Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.8

"Mean time from start of MK-8616 administration to recovery of participant T4/T1 ratio to 0.8 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.8 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT00298831)
Timeframe: Up to approximately 15 minutes following administration of study treatment

InterventionMinutes (Mean)
Sugammadex1.80

[back to top]

Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.7

"Mean time from start of MK-8616 administration to recovery of participant T4/T1 ratio to 0.7 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.7 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT00298831)
Timeframe: Up to approximately 10 minutes following administration of study treatment

InterventionMinutes (Mean)
Sugammadex1.50

[back to top]

Clinical Assessments of Recovery - Check for General Muscle Weakness (GMW)

General muscle weakness check was assessed by the investigator. The assessment of general muscle weakness was based on a scale from 0-10, with 0 representing total paralysis, 1 signifying extreme impairment, 9 for close to no impairment, and 10 for normal muscle strength. Scores of 3, 4, 5, etc. denoted increasing muscle strength in approximately 10% increments. Scores of 9 and lower were denoted as GMW. Assessment 1 occurred prior to transfer to the recovery room after extubation and assessment 2 occurred prior to discharge from the recovery room. (NCT00298831)
Timeframe: Up to 24 hours

InterventionParticipants (Count of Participants)
GMW present during Assessment 1GMW present during Assessment 2
Sugammadex49

[back to top]

Clinical Assessments of Recovery - Participant Able to Perform 5-second Head Lift (5SHL)

5-second head lift test was assessment of the ability of the participant to lift the head for 5 seconds and was performed by a blinded safety assessor. Tests were repeated every 15 minutes until the participant could successfully perform the 5-second head-lift. Assessment 1 occurred prior to transfer to the recovery room after extubation and Assessment 2 occurred prior to discharge from the recovery room. (NCT00298831)
Timeframe: Up to 24 hours

InterventionParticipants (Count of Participants)
Able to perform 5SHL during Assessment 1Able to perform 5SHL during Assessment 2
Sugammadex173196

[back to top]

Clinical Assessment of Recovery - Participant's Level of Consciousness

The quality of recovery was assessed by asking the participant 40 questions from a validated Quality of Recovery Questionnaire (QoR-40). Participants were assessed for level of consciousness (i.e., awake and oriented, arousable with minimal stimulation, responsive only to tactile stimulation), if applicable, by asking their name, if they are aware of where they are, and what day it is. Assessment 1 occurred prior to transfer to the recovery room after extubation and Assessment 2 occurred prior to discharge from the recovery room. (NCT00298831)
Timeframe: Up to 24 hours

InterventionParticipants (Count of Participants)
Awake and oriented - Assessment 1Awake and oriented - Assessment 2Arousable with minimal stimulation - Assessment 1Arousable with minimal stimulation - Assessment 2Responsive only to tactile stimulation - Assess. 1Responsive only to tactile stimulation - Assess. 2
Sugammadex138184511280

[back to top]

Number of Participants Exhibiting Desaturation >5%

decrease of >5% in oxygen saturation measured continuously using pulse oxymetry (NCT00355368)
Timeframe: at any time between the start of the intubation sequence and 2min after the completion of intubation

Interventionparticipants (Number)
Succinylcholine73
Rocuronium66

[back to top]

Number of Participants With an Failed First Intubation Attempts

defined as either uncompleted intubation attempt within 90 sec or starting a second intubation attempt (NCT00355368)
Timeframe: within the first 90 sec following the start of induction

Interventionparticipants (Number)
Succinylcholine32
Rocuronium36

[back to top]

Time to Completion of Intubation

time interval between the injection of the induction agent and the first appearance of endtidal CO2 (NCT00355368)
Timeframe: time interval between the injection of the induction agent and the first appearance of endtidal CO2

Interventionseconds (Mean)
Succinylcholine81
Rocuronium95

[back to top]

Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.

"The factors laryngoscopy, vocal cords, and response to intubation are individually rated with a score from 1 (bad intubation conditions)to 3 (excellent intubation conditions)and the resulting three scores are summed up. The maximum score is thus 9 while the minimum score is 3.~Units: measure on a scale" (NCT00355368)
Timeframe: during laryngoscopy and the first minute after completion of intubation

Interventionscore points (Mean)
Succinylcholine8.3
Rocuronium8.2

[back to top]

Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 & T4 refer to the magnitudes (heights) of the first & fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached ≥0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00421148)
Timeframe: From start of sugammadex or palcebo administration to recovery of T4/T1 ratio to 0.9 (ranging from ~0.5 minutes to ~30 minutes from sugammadex or placebo administration)

InterventionMinutes (Mean)
Infants: Placebo20.98
Infants: Sugammadex 0.5 mg/kg3.72
Infants: Sugammadex 1 mg/kg2.42
Infants: Sugammadex 2 mg/kg0.58
Children: Placebo19.57
Children: Sugammadex 0.5 mg/kg5.22
Children: Sugammadex 1 mg/kg3.95
Children: Sugammadex 2 mg/kg1.20
Children: Sugammadex 4 mg/kg1.57
Adolescents: Placebo22.77
Adolescents: Sugammadex 0.5 mg/kg11.97
Adolescents: Sugammadex 1 mg/kg1.77
Adolescents: Sugammadex 2 mg/kg1.87
Adolescents: Sugammadex 4 mg/kg1.08
Adults: Placebo29.48
Adults: Sugammadex 0.5 mg/kg3.77
Adults: Sugammadex 1 mg/kg1.62
Adults: Sugammadex 2 mg/kg1.27
Adults: Sugammadex 4 mg/kg1.37
Infants: Sugammadex 4 mg/kg0.67

[back to top]

Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 & T4 refer to the magnitudes (heights) of the first & fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00421148)
Timeframe: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (ranging from ~0.5 minutes to ~25 minutes from sugammadex or placebo administration)

InterventionMinutes (Mean)
Infants: Placebo17.85
Infants: Sugammadex 0.5 mg/kg2.97
Infants: Sugammadex 1 mg/kg2.03
Infants: Sugammadex 2 mg/kg0.58
Children: Placebo14.20
Children: Sugammadex 0.5 mg/kg3.42
Children: Sugammadex 1 mg/kg1.85
Children: Sugammadex 2 mg/kg0.95
Children: Sugammadex 4 mg/kg0.75
Adolescents: Placebo21.92
Adolescents: Sugammadex 0.5 mg/kg4.92
Adolescents: Sugammadex 1 mg/kg1.35
Adolescents: Sugammadex 2 mg/kg0.98
Adolescents: Sugammadex 4 mg/kg0.87
Adults: Placebo24.77
Adults: Sugammadex 0.5 mg/kg2.22
Adults: Sugammadex 1 mg/kg1.37
Adults: Sugammadex 2 mg/kg1.07
Adults: Sugammadex 4 mg/kg1.27
Infants: Sugammadex 4 mg/kg0.67

[back to top]

Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 & T4 refer to the magnitudes (heights) of the first & fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00421148)
Timeframe: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (ranging from ~0.4 minutes to ~20 minutes from sugammadex or placebo administration)

InterventionMinutes (Mean)
Infants: Placebo14.85
Infants: Sugammadex 0.5 mg/kg2.47
Infants: Sugammadex 1 mg/kg1.78
Infants: Sugammadex 2 mg/kg0.58
Children: Placebo12.32
Children: Sugammadex 0.5 mg/kg2.62
Children: Sugammadex 1 mg/kg1.45
Children: Sugammadex 2 mg/kg0.75
Children: Sugammadex 4 mg/kg0.57
Adolescents: Placebo18.62
Adolescents: Sugammadex 0.5 mg/kg2.77
Adolescents: Sugammadex 1 mg/kg1.07
Adolescents: Sugammadex 2 mg/kg0.95
Adolescents: Sugammadex 4 mg/kg0.83
Adults: Placebo19.65
Adults: Sugammadex 0.5 mg/kg1.62
Adults: Sugammadex 1 mg/kg1.27
Adults: Sugammadex 2 mg/kg0.87
Adults: Sugammadex 4 mg/kg1.12
Infants: Sugammadex 4 mg/kg0.42

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.7. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.7 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 4 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex4.10
Vecuronium+Neostigmine56.17

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.7. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.7 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 2 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex2.27
Rocuronium+Neostigmine37.68

[back to top]

Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine2032
Rocuronium+Sugammadex2634
Vecuronium+Neostigmine2033
Vecuronium+Sugammadex2739

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.9 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 3 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex3.28
Rocuronium+Neostigmine55.50

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.8. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.8 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 5 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex5.55
Vecuronium+Neostigmine67.42

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.8. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.8 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 3 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex2.65
Rocuronium+Neostigmine45.82

[back to top]

Number of Participants Able to Perform a 5-second Head Lift

The number of participants who were able to lift their head for 5 seconds was assessed by the investigator as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine2833
Rocuronium+Sugammadex3334
Vecuronium+Neostigmine2433
Vecuronium+Sugammadex3641

[back to top]

Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine111
Rocuronium+Sugammadex90
Vecuronium+Neostigmine81
Vecuronium+Sugammadex122

[back to top]

Number of Participants Experiencing General Muscle Weakness

The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine53
Rocuronium+Sugammadex32
Vecuronium+Neostigmine23
Vecuronium+Sugammadex41

[back to top]

Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine30
Rocuronium+Sugammadex20
Vecuronium+Neostigmine70
Vecuronium+Sugammadex70

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.9 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 6 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex8.73
Vecuronium+Neostigmine77.80

[back to top]

Number of Participants Experiencing General Muscle Weakness

The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex20
Succinylcholine30

[back to top]

Number of Participants Able to Perform 5-Second Head Lift

The number of participants who were able to lift their head for 5 seconds was assessed as a measure of recovery following neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex1320
Succinylcholine2435

[back to top]

Level of Consciousness: Number of Participants Awake and Oriented

The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness. The clinical level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex819
Succinylcholine1333

[back to top]

Level of Consciousness: Number of Participants Arousable With Minimal Stimulation

The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex71
Succinylcholine152

[back to top]

Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation

The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex50
Succinylcholine70

[back to top]

Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation. (NCT00474253)
Timeframe: Up to 15 minutes after administration of rocuronium + sugammadex or succinylcholine

InterventionMinutes (Mean)
Rocuronium + Sugammadex4.35
Succinylcholine7.15

[back to top]

Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation. (NCT00474253)
Timeframe: Up to 20 minutes after administration of rocuronium + sugammadex or succinylcholine

InterventionMinutes (Mean)
Rocuronium + Sugammadex6.13
Succinylcholine11.03

[back to top]

Level of Consciousness Assessment 1: Prior to Transfer to the Recovery Room Following Extubation

The level of consciousness prior to transfer to the recovery room was determined by the clinician for each participant. Each participants was assigned 1 of 3 potential levels of consciousness: 1) awake and oriented; 2) arousable with minimal stimulation; or 3) responsive only to tactile stimulation. (NCT00475215)
Timeframe: Up to 6 hours (prior to transfer to the recovery room after extubation)

,
InterventionParticipants (Count of Participants)
Awake and orientedArousable with minimal stimulationResponsive only to tactile stimulationMissing data
Rocuronium + Sugammadex 2.0 mg/kg171660
Rocuronium + Sugammadex 4.0 mg/kg221321

[back to top]

Level of Consciousness Assessment 2: Prior to Discharge From the Recovery Room

The level of consciousness prior to discharge from the recovery room was determined by the clinician for each participant. Each participants was assigned 1 of 3 potential levels of consciousness: 1) awake and oriented; 2) arousable with minimal stimulation; or 3) responsive only to tactile stimulation. (NCT00475215)
Timeframe: Up to 6 hours (prior to discharge from the recovery room)

,
InterventionParticipants (Count of Participants)
Awake and orientedArousable with minimal stimulationResponsive only to tactile stimulation
Rocuronium + Sugammadex 2.0 mg/kg3810
Rocuronium + Sugammadex 4.0 mg/kg3800

[back to top]

Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.7 in Participants With or Having a Past History of Pulmonary Disease

The mean time from the start of sugammadex administration to recovery of the T4/T1 ratio to 0.7 was determined. Less time indicates faster recovery from neuromuscular blockade. The ratio of T4 (fourth twitch; amplitude of fourth response to train of four [TOF] stimulation is expressed as percent of control T4) over T1 (first twitch; amplitude of first response to TOF stimulation is expressed as percent of control T1) ranges from 0 (complete loss of T4 twitch response) to 1.0 (complete recovery of T4 twitch response). For TOF stimulation, 4 consecutive square wave supra-maximal stimuli of 0.2 msec duration were delivered at 2 Hz every 15 seconds. Neuromuscular monitoring was performed with the TOF-Watch® SX. (NCT00475215)
Timeframe: Up to 90 minutes

InterventionMinutes (Mean)
Rocuronium + Sugammadex 2.0 mg/kg1.5
Rocuronium + Sugammadex 4.0 mg/kg1.35

[back to top]

Five-Second Head Lift Assessment 2: Prior to Discharge From the Recovery Room

The ability of each cooperative (based on clinician determination) participant to perform a 5-second head lift was determined by the clinician. Participants were rated as either able or not able to complete the head lift task. (NCT00475215)
Timeframe: Up to 6 hours (prior to discharge from the recovery room)

,
InterventionParticipants (Count of Participants)
Able to performNot able to perform
Rocuronium + Sugammadex 2.0 mg/kg390
Rocuronium + Sugammadex 4.0 mg/kg371

[back to top]

Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.8 in Participants With or Having a Past History of Pulmonary Disease

The mean time from the start of sugammadex administration to recovery of the T4/T1 ratio to 0.8 was determined. Less time indicates faster recovery from neuromuscular blockade. The ratio of T4 (fourth twitch; amplitude of fourth response to train of four [TOF] stimulation is expressed as percent of control T4) over T1 (first twitch; amplitude of first response to TOF stimulation is expressed as percent of control T1) ranges from 0 (complete loss of T4 twitch response) to 1.0 (complete recovery of T4 twitch response). For TOF stimulation, 4 consecutive square wave supra-maximal stimuli of 0.2 msec duration were delivered at 2 Hz every 15 seconds. Neuromuscular monitoring was performed with the TOF-Watch® SX. (NCT00475215)
Timeframe: Up to 90 minutes

InterventionMinutes (Mean)
Rocuronium + Sugammadex 2.0 mg/kg1.8
Rocuronium + Sugammadex 4.0 mg/kg1.62

[back to top]

Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.9 in Participants With or Having a Past History of Pulmonary Disease

The mean time from the start of sugammadex administration to recovery of the T4/T1 ratio to 0.9 was determined. Less time indicates faster recovery from neuromuscular blockade. The ratio of T4 (fourth twitch; amplitude of fourth response to train of four [TOF] stimulation is expressed as percent of control T4) over T1 (first twitch; amplitude of first response to TOF stimulation is expressed as percent of control T1) ranges from 0 (complete loss of T4 twitch response) to 1.0 (complete recovery of T4 twitch response). For TOF stimulation, 4 consecutive square wave supra-maximal stimuli of 0.2 msec duration were delivered at 2 Hz every 15 seconds. Neuromuscular monitoring was performed with the TOF-Watch® SX. (NCT00475215)
Timeframe: Up to 90 minutes

InterventionMinutes (Mean)
Rocuronium + Sugammadex 2.0 mg/kg2.42
Rocuronium + Sugammadex 4.0 mg/kg2.1

[back to top]

General Muscle Weakness Assessment 1: Prior to Transfer to the Recovery Room Following Extubation

Each cooperative (based on clinician determination) participant was assessed by a clinician to determine if there was muscle weakness. Participants were rated as having or not having muscle weakness by the clinician. (NCT00475215)
Timeframe: Up to 6 hours (prior to transfer to the recovery room after extubation)

,
InterventionParticipants (Count of Participants)
Muscle WeaknessNo Muscle Weakness
Rocuronium + Sugammadex 2.0 mg/kg325
Rocuronium + Sugammadex 4.0 mg/kg430

[back to top]

Percentage of Participants Experiencing ≥1 Adverse Event(s) (AE)

The percentage of participants experiencing ≥1 AE(s) was determined for each arm. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT00475215)
Timeframe: Up to 7 days

InterventionPercentage of Participants (Number)
Rocuronium + Sugammadex 2.0 mg/kg97.4
Rocuronium + Sugammadex 4.0 mg/kg94.7

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an Adverse Event (AE)

The percentage of participants discontinuing from study treatment due to an AE was determined for each arm. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT00475215)
Timeframe: Up to 7 days

InterventionPercentage of Participants (Number)
Rocuronium + Sugammadex 2.0 mg/kg0
Rocuronium + Sugammadex 4.0 mg/kg0

[back to top]

General Muscle Weakness Assessment 2: Prior to Discharge From the Recovery Room

Each cooperative (based on clinician determination) participant was assessed by a clinician to determine if there was muscle weakness. Participants were rated as having or not having muscle weakness by the clinician. (NCT00475215)
Timeframe: Up to 6 hours (prior to discharge from the recovery room)

,
InterventionParticipants (Count of Participants)
Muscle WeaknessNo Muscle Weakness
Rocuronium + Sugammadex 2.0 mg/kg435
Rocuronium + Sugammadex 4.0 mg/kg632

[back to top]

Five-Second Head Lift Assessment 1: Prior to Transfer to the Recovery Room Following Extubation

The ability of each cooperative (based on clinician determination) participant to perform a 5-second head lift was determined by the clinician. Participants were rated as either able or not able to complete the head lift task. (NCT00475215)
Timeframe: Up to 6 hours (prior to transfer to the recovery room after extubation)

,
InterventionParticipants (Count of Participants)
Able to performNot able to perform
Rocuronium + Sugammadex 2.0 mg/kg235
Rocuronium + Sugammadex 4.0 mg/kg295

[back to top]

Number of Participants Experiencing an Adverse Event

The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product. (NCT00535743)
Timeframe: Up to 7 days following administration of study treatment

InterventionParticipants (Count of Participants)
Arm A. Placebo; 3 Min After 1 mg/kg Esmeron®5
Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®5
Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®7
Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®7
Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®8
Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®7
Arm G. Placebo; 15 Min After 1 mg/kg Esmeron®2
Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®4
Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®3
Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®4
Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®3
Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®4
Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron®3
Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®5
Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®7
Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®5
Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®6
Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®9
Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron®3
Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®2
Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®4
Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1
Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®3
Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®3

[back to top]

Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.7

"Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.7 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of NMB present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.7 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT00535743)
Timeframe: Up to 180 minutes following administration of study treatment

Interventionminutes (Mean)
Arm A. Placebo; 3 Min After 1 mg/kg Esmeron®91.58
Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®36.43
Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®4.55
Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.58
Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.13
Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.27
Arm G. Placebo; 15 Min After 1 mg/kg Esmeron®81.70
Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®5.28
Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®3.28
Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®1.25
Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®1.28
Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®0.93
Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron®122.90
Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®54.43
Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®7.45
Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®2.42
Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®1.62
Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®1.18
Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron®111.37
Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®24.15
Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®3.08
Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.58
Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.67
Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.22

[back to top]

Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.8

"Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.8 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of NMB present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.8 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT00535743)
Timeframe: Up to 200 minutes following administration of study treatment

Interventionminutes (Mean)
Arm A. Placebo; 3 Min After 1 mg/kg Esmeron®98.23
Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®40.00
Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®5.90
Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.87
Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.57
Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.43
Arm G. Placebo; 15 Min After 1 mg/kg Esmeron®91.53
Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®6.23
Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®4.10
Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®1.45
Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®1.33
Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®0.93
Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron®129.85
Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®60.85
Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®8.52
Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®2.80
Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®1.73
Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®1.20
Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron®121.03
Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®33.95
Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®4.42
Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.98
Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.72
Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.27

[back to top]

Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9

"Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT00535743)
Timeframe: Up to 240 minutes following administration of study treatment

Interventionminutes (Mean)
Arm A. Placebo; 3 Min After 1 mg/kg Esmeron®108.43
Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®44.73
Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®6.93
Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®2.40
Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®2.42
Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron®1.77
Arm G. Placebo; 15 Min After 1 mg/kg Esmeron®127.37
Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®8.53
Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®5.47
Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®1.85
Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®1.78
Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron®0.93
Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron®122.98
Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®65.67
Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®13.78
Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®3.23
Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®2.08
Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron®1.32
Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron®139.62
Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®42.20
Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®5.97
Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®2.33
Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®1.77
Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron®4.73

[back to top]

Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00552617)
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)

InterventionMinutes (Mean)
Rocuronium + Placebo75.85
Rocuronium + 0.5 mg/kg Sugammadex6.25
Rocuronium + 1.0 mg/kg Sugammadex2.62
Rocuronium + 2.0 mg/kg Sugammadex1.28
Rocuronium + 4.0 mg/kg Sugammadex1.15
Vecuronium + Placebo64.33
Vecuronium + 0.5 mg/kg Sugammadex25.65
Vecuronium + 1.0 mg/kg Sugammadex3.10
Vecuronium + 2.0 mg/kg Sugammadex5.83
Vecuronium + 4.0 mg/kg Sugammadex2.12

[back to top]

Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00552617)
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)

InterventionMinutes (Mean)
Rocuronium + Placebo96.30
Rocuronium + 0.5 mg/kg Sugammadex16.30
Rocuronium + 1.0 mg/kg Sugammadex4.62
Rocuronium + 2.0 mg/kg Sugammadex1.43
Rocuronium + 4.0 mg/kg Sugammadex1.50
Vecuronium + Placebo79.02
Vecuronium + 0.5 mg/kg Sugammadex35.50
Vecuronium + 1.0 mg/kg Sugammadex5.07
Vecuronium + 2.0 mg/kg Sugammadex3.42
Vecuronium + 4.0 mg/kg Sugammadex3.03

[back to top]

Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00552617)
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)

InterventionMinutes (Mean)
Rocuronium + Placebo65.67
Rocuronium + 0.5 mg/kg Sugammadex3.08
Rocuronium + 1.0 mg/kg Sugammadex2.08
Rocuronium + 2.0 mg/kg Sugammadex1.12
Rocuronium + 4.0 mg/kg Sugammadex1.02
Vecuronium + Placebo58.12
Vecuronium + 0.5 mg/kg Sugammadex12.57
Vecuronium + 1.0 mg/kg Sugammadex2.35
Vecuronium + 2.0 mg/kg Sugammadex2.00
Vecuronium + 4.0 mg/kg Sugammadex1.70

[back to top]

Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 ratio (expressed as a decimal from 0 [loss of T4] up to 1.0 [no NMB]) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 ratio to 0.8 indicates a faster recovery from NMB. (NCT00559468)
Timeframe: Up to 3 minutes after sugammadex administration

Interventionminutes (Mean)
Sugammadex + Sevoflurane1.20
Sugammadex + Propofol1.12

[back to top]

Mean Time From Start Administration of Sugammadex to Recovery of Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train of Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 ratio (expressed as a decimal from 0 [loss of T4] up to 1.0 [no NMB]) indicates the extent of recovery from NMB. In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 ratio to 0.9 indicates a faster recovery from NMB. (NCT00559468)
Timeframe: Up to 3 minutes after sugammadex administration

Interventionminutes (Mean)
Sugammadex + Sevoflurane1.45
Sugammadex + Propofol1.32

[back to top]

Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 ratio (expressed as a decimal from 0 [loss of T4] up to 1.0 [no NMB]) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 ratio to 0.7 indicates a faster recovery from NMB. (NCT00559468)
Timeframe: Up to 3 minutes after sugammadex administration

Interventionminutes (Mean)
Sugammadex + Sevoflurane1.07
Sugammadex + Propofol1.02

[back to top]

Clearance of Rocuronium by Dialysis as Measured by the Reduction Ratio (RR)

Starting on Day 1 dialysis was performed on four separate occasions using a Fresenius 40008H hemodialyzer, with a hemodiafilter standard helixone membrane FX 600. Dialysate samples were collected before, and after hemodialysis, with concentrations of rocuronium determined using a liquid chromatographic assay with mass spectrometric detection. The clearance of rocuronium at each dialysis session was calculated by measuring the ratio of plasma concentration at the end of dialysis, average duration of 6 hours, compared with that immediately before the start of dialysis, called the RR. (NCT00656799)
Timeframe: Up to Day 7

InterventionReduction Ratio (Mean)
First Dialysis (n=5)Second Dialysis (n=6)Third Dialysis (n=4)Fourth Dialysis (n=4)
Sugammadex0.7500.6250.5210.458

[back to top]

Time From Start of Administration of Sugammadex to Recovery of T4/T1 Ratio to 0.9

Neuromuscular function was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing the magnitudes (heights) of the first twitch (T1) and fourth twitch (T4) response at the adductor pollicis muscle with a TOF-Watch® SX. Stimulation continued until the T4/T1 ratio reached at least 0.9. Higher T4/T1 ratios represent greater recovery from neuromuscular blockade; with a value of 1.0 representing full recovery. (NCT00656799)
Timeframe: Day 1

InterventionMinutes (Geometric Mean)
Sugammadex5.11

[back to top]

Time From Start of Administration of Sugammadex to Recovery of T4/T1 Ratio to 0.7

Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing the magnitudes (heights) of the T1 and T4 response at the adductor pollicis muscle with a TOF-Watch® SX. Stimulation continued until the T4/T1 ratio reached at least 0.7. Higher T4/T1 ratios represent greater recovery from neuromuscular blockade; with a value of 1.0 representing full recovery. (NCT00656799)
Timeframe: Day 1

InterventionMinutes (Geometric Mean)
Sugammadex3.41

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

A SAE is any untoward medical occurrence that at any dose results in the following: death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or is a congenital anomaly/birth defect (NCT00656799)
Timeframe: Up to day 7

Interventionparticipants (Number)
Sugammadex2

[back to top]

Number of Participants With Reoccurrence of Neuromuscular Blockade at Day 1

Neuromuscular function was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing the magnitudes (heights) of the first twitch (T1) and fourth twitch (T4) response at the adductor pollicis muscle with a TOF-Watch® SX. Stimulation continued until the T4/T1 ratio reached at least 0.9. Higher T4/T1 ratios represent greater recovery from neuromuscular blockade; with a value of 1.0 representing full recovery. Reoccurrence of neuromuscular blockade is defined as a decline in the T4/T1 ratio from >= 0.9 to < 0.8 in at least three consecutive measurements. (NCT00656799)
Timeframe: Day 1

Interventionparticipants (Number)
Sugammadex0

[back to top]

Number of Participants With Pregnancies at 30 Days Post-dose

Pregnancies reported by means of a Pregnancy Reporting Form, consist of pregnant female participants or pregnant female partners of male participants (NCT00656799)
Timeframe: Up to 30 days post -dose

Interventionparticipants (Number)
Sugammadex0

[back to top]

Number of Participants With Pre-treatment Adverse Events (AEs)

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body, whether or not related to the use of a product. (NCT00656799)
Timeframe: Screening up to Day 1

Interventionparticipants (Number)
Sugammadex1

[back to top]

Number of Participants With Medical Device (Near) Incidents

A medical device (near) incident is defined as an occurrence due to inaccurate or inadequate labeling/instructions, or information supplied with a medical device; or malfunction, deterioration or recall of a medical device that could lead to death or serious deterioration in health. (NCT00656799)
Timeframe: Up to day 7

Interventionparticipants (Number)
Sugammadex0

[back to top]

Number of Participants With Events Due to Possible Interaction of Sugammadex With Endo-/Exogenous Compounds Other Than Rocuronium

Evidence of AEs due to possible interaction of sugammadex with endogenous compounds or with exogenous compounds other than rocuronium (NCT00656799)
Timeframe: Day 1

Interventionparticipants (Number)
Sugammadex0

[back to top]

Time From Start of Administration of Sugammadex to Recovery of T4/T1 Ratio to 0.8

Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing the magnitudes (heights) of the T1 and T4 response at the adductor pollicis muscle with a TOF-Watch® SX. Stimulation continued until the T4/T1 ratio reached at least 0.8. Higher T4/T1 ratios represent greater recovery from neuromuscular blockade; with a value of 1.0 representing full recovery. (NCT00656799)
Timeframe: Day 1

InterventionMinutes (Geometric Mean)
Sugammadex4.05

[back to top]

Vital Sign: Mean Systolic Blood Pressure

Systolic blood pressure was measured at the following time points: screening, before rocuronium treatment, before sugammadex treatment, at 2, 5, 10, 20 minutes post-sugammadex treatment, and the day after surgery (NCT00656799)
Timeframe: Screening up to 1 day after surgery

Interventionmm Hg (Mean)
ScreeningPre-RocuroniumBaseline pre-sugammadex2 minutes post-sugammadex5 minutes post-sugammadex10 minutes post-sugammadex30 minutes post-sugammadxPost-anesthetic
Sugammadex124.2106.3105.5105.0103.298.092.8146.3

[back to top]

Vital Sign: Mean Diastolic Blood Pressure

Diastolic blood pressure was measured at the following time points: screening, before rocuronium treatment, before sugammadex treatment, at 2, 5, 10, 20 minutes post-sugammadex treatment, and the day after surgery (NCT00656799)
Timeframe: Screening up to 1 day after surgery

Interventionmm Hg (Mean)
ScreeningPre-RocuroniumBaseline pre-sugammadex2 minutes post-sugammadex5 minutes post-sugammadex10 minutes post-sugammadex30 minutes post-sugammadexPost-anesthetic
Sugammadex58.251.245.246.544.546.843.767.8

[back to top]

Rate of Clearance of Sugammadex From Dialysate

Starting on Day 1 dialysis was performed on four separate occasions using a Fresenius 40008H hemodialyzer, with a hemodiafilter standard helixone membrane FX 600. Dialysate samples were collected from a port in the outflow of the dialyzer before, during and after an average of 6 hours of hemodialysis. The concentrations of sugammadex were determined using a liquid chromatographic assay with mass spectrometric detection. The clearance rate from dialysate at each dialysis session was assessed by averaging across all available collection time points.The data from the fourth dialysis are not presented as they were not calculable. (NCT00656799)
Timeframe: Up to day 7

InterventionmL/min (Mean)
First Dialysis (n=5)Second Dialysis (n=6)Third Dialysis (n=4)
Sugammadex63.065.166.8

[back to top]

Vital Sign: Mean Heart Rate

Heart rate was measured at the following time points: screening, before rocuronium treatment, before sugammadex treatment, at 2, 5, 10, 20 minutes post-sugammadex treatment, and the day after surgery (NCT00656799)
Timeframe: Screening up to 1 day after surgery

InterventionBeats per minute (Mean)
ScreeningPre-RocuroniumBaseline pre-sugammadex2 minutes post-sugammadex5 minutes post-sugammadex10 minutes post-sugammadex30 minutes post-sugammadexPost-anesthetic
Sugammadex81.778.083.781.080.580.277.871.8

[back to top]

Rate of Clearance of Sugammadex From Blood

Starting on Day 1 dialysis was performed on four separate occasions using a Fresenius 40008H hemodialyzer, with a hemodiafilter standard helixone membrane FX 600. Blood samples were collected from ports in the arterial and venous tubing of the dialyzer before, during and after an average of 6 hours of hemodialysis. The concentrations of sugammadex were determined using a liquid chromatographic assay with mass spectrometric detection. The clearance rate from blood at each dialysis session was assessed by averaging across all available collection time points. (NCT00656799)
Timeframe: Up to day 7

InterventionmL/min (Mean)
First Dialysis (n=5)Second Dialysis (n=6)Third Dialysis (n=4)Fourth Dialysis (n=4)
Sugammadex79.176.572.483.4

[back to top]

Rate of Clearance of Rocuronium From Dialysate

Starting on Day 1 dialysis was performed on four separate occasions using a Fresenius 40008H hemodialyzer, with a hemodiafilter standard helixone membrane FX 600. Dialysate samples were collected from a port in the outflow of the dialyzer before, during and after an average of 6 hours of hemodialysis. The concentrations of rocuronium were determined using a liquid chromatographic assay with mass spectrometric detection. The clearance rate from dialysate at each dialysis session was assessed by averaging across all available collection time points. (NCT00656799)
Timeframe: Up to Day 7

InterventionmL/min (Mean)
First Dialysis (n=5)Second Dialysis (n=6)Third Dialysis (n=4)Fourth Dialysis (n=4)
Sugammadex75.197.211095.3

[back to top]

Rate of Clearance of Rocuronium From Blood

Starting on Day 1 dialysis was performed on four separate occasions using a Fresenius 40008H hemodialyzer, with a hemodiafilter standard helixone membrane FX 600. Blood samples were collected from ports in the arterial and venous tubing of the dialyzer before, during and after an average of 6 hours of hemodialysis. The concentrations of rocuronium were determined using a liquid chromatographic assay with mass spectrometric detection. The clearance rate from blood at each dialysis session was assessed by averaging across all available collection time points. (NCT00656799)
Timeframe: Up to Day 7

InterventionmL/min (Mean)
First Dialysis (n=5)Second Dialysis (n=6)Third Dialysis (n=4)Fourth Dialysis (n=3)
Sugammadex80.286.394.194.8

[back to top]

Number of Participants With Physical Examinations

Physical examinations were to be conducted at screening, on Day 1 and 7 days after surgery (NCT00656799)
Timeframe: Screening up to day 7

Interventionparticipants (Number)
ScreeningPeri-procedural (Day 1)Day 7
Sugammadex660

[back to top]

Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR)

Starting on Day 1 dialysis was performed on four separate occasions using a Fresenius 40008H hemodialyzer, with a hemodiafilter standard helixone membrane FX 600. Dialysate samples were collected before, and after hemodialysis, with concentrations of sugammadex determined using a liquid chromatographic assay with mass spectrometric detection. The clearance of sugammadex at each dialysis session was calculated by measuring the ratio of plasma concentration at the end of dialysis, average duration of 6 hours, compared with that immediately before the start of dialysis, called the RR. (NCT00656799)
Timeframe: Up to day 7

InterventionReduction Ratio (Mean)
First Dialysis (n=5)Second Dialysis (n=6)Third Dialysis (n=4)Fourth Dialysis (n=4)
Sugammadex0.6870.5660.5160.532

[back to top]

Number of Participants With Post-operative Complications

Post-operative complications include any of the following: procedural pain, nausea, vomiting, incision-site pain, constipation, headache, pyrexia, dizziness and pruritus. (NCT00675792)
Timeframe: Up to 7 days after surgery

Interventionparticipants (Number)
Sugammadex51
Neostigmine49

[back to top]

Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9

Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds, and assessing T1 and T4 twitch response at the adductor pollicis muscle with a TOF-Watch® SX. Nerve stimulation was continued until the T4/T1 ratio, which indicates the extent of recovery from neuromuscular blockade, achieved a ratio of 0.9, with imputed data included. (NCT00675792)
Timeframe: Up to 1 hour after treatment

InterventionMinutes (Mean)
Sugammadex2.53
Neostigmine7.95

[back to top]

Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation

Neuromuscular function was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds, and assessing twitch response at the adductor pollicis muscle with a TOF-Watch® SX. The magnitudes (heights) of the first and fourth twitches (T1 and T4) were used to calculate the T4/T1 ratio, where a higher T4/T1 ratio indicates a greater recovery from neuromuscular blockade, with a value of 1.0 indicating complete recovery. After anesthesia, when neuromuscular function was expected to be fully recovered, tracheal extubation was performed, at which time the T4/T1 ratio was measured, with any missing recovery times imputed. (NCT00675792)
Timeframe: Up to the first 24 hours after tracheal extubation

InterventionT4/T1 Ratio (Mean)
Sugammadex1.02
Neostigmine0.78

[back to top]

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds, and assessing T1 and T4 twitch response at the adductor pollicis muscle with a TOF-Watch® SX. Nerve stimulation was continued until the T4/T1 ratio, which indicates the extent of recovery from neuromuscular blockade, achieved a ratio of 0.7, with imputed data included. (NCT00675792)
Timeframe: Up to 1 hour after treatment

InterventionMinutes (Mean)
Sugammadex1.60
Neostigmine4.98

[back to top]

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds, and assessing T1 and T4 twitch response at the adductor pollicis muscle with a TOF-Watch® SX. Nerve stimulation was continued until the T4/T1 ratio, which indicates the extent of recovery from neuromuscular blockade, achieved a ratio of 0.8, with imputed data included. (NCT00675792)
Timeframe: Up to 1 hour after treatment

InterventionMinutes (Mean)
Sugammadex1.87
Neostigmine6.18

[back to top]

Number of Participants With Evidence of Possible Interaction of Sugammadex With Endogenous Compounds or Exogenous Compounds Other Than Rocuronium Bromide

Evidence of adverse events due to a possible interaction of sugammadex with exogenous compounds or endogenous compounds other than rocuronium was recorded. (NCT00675792)
Timeframe: Up to 7 days after surgery

Interventionparticipants (Number)
Sugammadex0
Neostigmine0

[back to top]

Mean Heart Rate

Heart Rate was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)

,
Interventionbeats per minute (Mean)
ScreeningPre-rocuroniumPre-IMP2 minutes post-IMP (N=65, N=65)5 minutes post-IMP10 minutes post-IMP (N=66, N=66)30 minutes post-IMP (N=65, N=66)Post-anesthetic visit (N=66, N=66)
Neostigmine74.663.668.065.357.156.365.171.9
Sugammadex72.963.468.366.064.967.373.172.7

[back to top]

Mean Diastolic Blood Pressure

Diastolic Blood Pressure was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)

,
Interventionmm Hg (Mean)
ScreeningPre-rocuroniumPre-IMP2 minutes post-IMP (N=65, N=65)5 minutes post-IMP10 minutes post-IMP (N=66, N=66)30 minutes post-IMP (N=65, N=66)Post-anesthetic visit (N=66, N=66)
Neostigmine82.858.372.572.669.268.773.175.2
Sugammadex80.958.272.873.472.471.874.376.7

[back to top]

Monitoring of Clinical Signs of Recovery According to Routine Anesthetic Procedures at the Trial Sites

The monitoring of clinical signs of recovery was to be conducted based on the routine anesthetic procedures at each site. (NCT00724932)
Timeframe: Up to PACU discharge (up to ~4.5 hours)

Interventionparticipants (Number)
SugammadexNA
NeostigmineNA

[back to top]

Number of Female Participants or Partners of Male Participants Who Became Pregnant During Study

Thirty days after administration of IMP, female participants of childbearing potential were asked whether they became pregnant during the trial and male participants were asked whether their partner (if of childbearing potential) became pregnant during the trial. (NCT00724932)
Timeframe: Up to 30 days after IMP administration

Interventionparticipants (Number)
Sugammadex0
Neostigmine0

[back to top]

Number of Participants With Clinical Evidence of Reoccurrence of Neuromuscular Blockade or Residual Neuromuscular Blockade (Routine Oxygen Saturation by Pulse Oximetry and Breath Frequency Measurement)

Clinical evidence of reoccurrence of NMB or residual NMB was assessed by oxygen saturation (by pulse oximetry) and breath frequency measurements as per routine practice after anesthesia and neuromuscular monitoring. (NCT00724932)
Timeframe: Up to 24 hours after IMP administration

Interventionparticipants (Number)
Sugammadex1
Neostigmine0

[back to top]

Number of Participants With Events Due to a Possible Interaction of Sugammadex With Endogenous Compounds or With Exogenous Compounds Other Than Rocuronium

Any evidence of events due to a possible interaction of sugammadex with endogenous compounds or with exogenous compounds other than rocuronium, was to be recorded. (NCT00724932)
Timeframe: Up to 7 days after IMP administration

Interventionparticipants (Number)
Sugammadex Only0

[back to top]

Number of Participants With Reoccurrence of Neuromuscular Blockade Based on the Train-of-Four- (TOF-) Watch® SX Recording (i.e. a Decline in T4/T1 Ratio From >=0.9 to <0.8 in at Least Three Consecutive TOF Values)

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the 1st and 4th twitches, respectively, after TOF stimulation. The T4/T1 Ratio is expressed as a decimal of up to 1.0. A higher ratio indicates greater recovery from NMB. A decline in the T4/T1 ratio from >=0.9 (indicating a recovery from NMB) to <0.8 for at least three consecutive TOF values was considered to be a reoccurrence of NMB. (NCT00724932)
Timeframe: Up to 30 minutes after IMP administration

Interventionparticipants (Number)
Sugammadex0
Neostigmine0

[back to top] [back to top]

Time From Tracheal Extubation to Operating Room Discharge Ready

The time of tracheal extubation was defined as the actual time at which the participant was extubated. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From tracheal extubation to Operating Room discharge ready (up to ~1 minute)

Interventionminutes (Mean)
Sugammadex1
Neostigmine0

[back to top]

Time From Actual Operating Room Discharge to PACU Discharge Ready

The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From actual Operating Room discharge to PACU discharge ready (up to ~30 minutes)

Interventionminutes (Mean)
Sugammadex24
Neostigmine29

[back to top]

Time From Operating Room Admission to Actual Operating Room Discharge

The time of Operating Room admission was defined as the time at which the participant was physically placed into the Operating Room. The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From Operating Room admission to actual Operating Room discharge (up to ~3 hours)

Interventionminutes (Mean)
Sugammadex158
Neostigmine169

[back to top]

Time From Operating Room Admission to Operating Room Discharge Ready

The time of Operating Room admission was defined as the time at which the participant was physically placed into the Operating Room. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of ≥0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From Operating Room admission to Operating Room discharge ready (up to ~3 hours)

Interventionminutes (Mean)
Sugammadex154
Neostigmine165

[back to top]

Time From Operating Room Discharge Ready to Actual Operating Room Discharge

The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From Operating Room discharge ready to actual Operating Room discharge (up to ~5 minutes)

Interventionminutes (Mean)
Sugammadex4
Neostigmine5

[back to top]

Time From Operating Room Discharge Ready to Actual PACU Discharge

The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From Operating Room discharge ready to actual PACU discharge (up to ~4.5 hours)

Interventionminutes (Mean)
Sugammadex268
Neostigmine210

[back to top]

Time From Operating Room Discharge Ready to Post Anesthetic Care Unit (PACU) Discharge Ready

The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From Operating Room discharge ready to PACU discharge ready (up to ~33 minutes)

Interventionminutes (Mean)
Sugammadex28
Neostigmine33

[back to top]

Time From PACU Admit to Actual PACU Discharge

The time of PACU admit was defined as the actual time the participant was admitted to the PACU. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From PACU admit to actual PACU discharge (up to ~4.3 hours)

Interventionminutes (Mean)
Sugammadex260
Neostigmine203

[back to top]

Time From Start of Administration of the Last Dose of Rocuronium to Recovery of the T4/T1 Ratio to 0.5, 0.6, 0.7, 0.8 and 0.9

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of last dose of rocuronium to recovery of T4/T1 Ratio to 0.5, 0.6, 0.7, 0.8 and 0.9 (ranging from ~12 minutes to ~36 minutes)

,
Interventionminutes (Geometric Mean)
Recovery of T4/T1 ratio to 0.5Recovery of T4/T1 ratio to 0.6Recovery of T4/T1 ratio to 0.7Recovery of T4/T1 ratio to 0.8Recovery of T4/T1 ratio to 0.9 (N=65, N=61)
Neostigmine30.030.731.633.235.2
Sugammadex11.711.912.112.513.3

[back to top]

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.8 (ranging from ~2 minutes to ~6 minutes)

Interventionminutes (Geometric Mean)
Sugammadex1.9
Neostigmine5.6

[back to top]

Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 ratio to 0.9 (ranging from ~2 minutes to ~9 minutes)

Interventionminutes (Geometric Mean)
Sugammadex2.4
Neostigmine8.4

[back to top]

Time From Start of Administration of the Last Dose of Rocuronium to the Time of 1-2 PTC in the 4.0 mg.Kg-1 Sugammadex Group

The time of 1-2 PTC refers to when 1-2 twitches are generated after tetanic stimulation. Time to 1-2 PTC is the time point of the last single twitch >0 or baseline (in case of noise or direct stimulation) within the sequence of a PTC measurement. 1-2 PTC was the target depth of NMB at which sugammadex was to be administered. (NCT00724932)
Timeframe: From last dose of rocuronium to 1-2 PTC (up to ~9 minutes)

Interventionminutes (Geometric Mean)
Sugammadex Only8.9

[back to top]

Time From Start of Administration of the Last Dose of Rocuronium to the Time of Reappearance of T2 in the 50 μg.Kg-1 Neostigmine Group

The time of reappearance of T2 refers to when the second twitch reappears after TOF stimulation. Reappearance of T2 was the target depth of NMB at which neostigmine was to be administered. (NCT00724932)
Timeframe: From last dose of rocuronium to reappearance of T2 (up to ~26 minutes)

Interventionminutes (Geometric Mean)
Neostigmine Only25.6

[back to top]

Time From PACU Admit to PACU Discharge Ready

The time of PACU admit was defined as the actual time the participant was admitted to the PACU. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From PACU admit to PACU discharge ready (up to ~25 minutes)

Interventionminutes (Mean)
Sugammadex20
Neostigmine25

[back to top]

Time From Start of IMP Administration to Operating Room Discharge Ready

The time of IMP administration was defined as the actual time at which IMP administration was started. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From start of IMP administration to Operating Room discharge ready (up to ~21 minutes)

Interventionminutes (Mean)
Sugammadex15
Neostigmine21

[back to top]

Time From Start of IMP Administration to Tracheal Extubation

The time of IMP administration was defined as the actual time at which IMP administration was started. The time of tracheal extubation was defined as the actual time at which the participant was extubated. (NCT00724932)
Timeframe: From start of IMP administration to tracheal extubation (up to ~21 minutes)

Interventionminutes (Mean)
Sugammadex14
Neostigmine21

[back to top]

Mean Systolic Blood Pressure

Systolic Blood Pressure was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)

,
Interventionmm Hg (Mean)
ScreeningPre-rocuroniumPre-IMP2 minutes post-IMP (N=65, N=65)5 minutes post-IMP10 minutes post-IMP (N=66, N=66)30 minutes post-IMP (N=65, N=66)Post-anesthetic visit (N=66, N=66)
Neostigmine133.9101.6121.3122.5118.0119.3131.7125.4
Sugammadex132.798.2122.1122.5122.6124.0132.9127.3

[back to top]

Number of Participants Who Experienced Pre-treatment Non-serious Adverse Events (AEs) and Post-treatment Non-serious AEs

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 7 days after last dose IMP. Pre-treatment refers to the period from signing of the informed consent up to start of IMP administration. Post-treatment refers to the period from start of IMP administration to 7 days after IMP administration. (NCT00724932)
Timeframe: From signing of informed consent to end of trial (7 days after surgery)

,
Interventionparticipants (Number)
Pre-treatment non-serious AEPost-treatment non-serious AE
Neostigmine3465
Sugammadex3865

[back to top]

Number of Participants Who Experienced Pre-treatment Serious Adverse Events (SAEs) and Post-treatment SAEs

"An SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.~Participants were monitored for occurrence SAEs for up to 7 days after last dose IMP. Pre-treatment refers to the period from signing of the informed consent up to start of IMP administration. Post-treatment refers to the period from start of IMP administration to 7 days after IMP administration." (NCT00724932)
Timeframe: From signing of informed consent to end of trial (7 days after surgery)

,
Interventionparticipants (Number)
Pre-treatment SAEPost-treatment SAE
Neostigmine06
Sugammadex14

[back to top]

Time From Start of IMP Administration to Actual Operating Room Discharge

The time of IMP administration was defined as the actual time at which IMP administration was started. The time of Operating Room discharge was defined as the actual time at which the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From start of IMP administration to actual Operating Room discharge (up to ~26 minutes)

Interventionminutes (Mean)
Sugammadex19
Neostigmine26

[back to top]

Time From Actual Operating Room Discharge to Actual PACU Discharge

The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From actual Operating Room discharge to actual PACU discharge (up to ~4.4 hours)

Interventionminutes (Mean)
Sugammadex264
Neostigmine207

[back to top]

Time From Tracheal Extubation to Actual Operating Room Discharge

The time of tracheal extubation was defined as the actual time at which the participant was extubated. The time of Operating Room discharge was defined as the actual time at which the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From tracheal extubation to actual OR discharge (up to ~5 minutes)

Interventionminutes (Mean)
Sugammadex5
Neostigmine5

[back to top]

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.5 and 0.6

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). Faster times to recovery of the T4/T1 Ratios to 0.5 and 0.6 indicate faster recoveries from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.5 and 0.6 (ranging from ~1 minute to ~4 minutes)

,
Interventionminutes (Geometric Mean)
Recovery of T4/T1 Ratio to 0.5Recovery of T4/T1 Ratio to 0.6
Neostigmine2.83.4
Sugammadex1.31.5

[back to top]

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.7 (ranging from ~2 minutes to ~5 minutes)

Interventionminutes (Geometric Mean)
Sugammadex1.6
Neostigmine4.1

[back to top]

Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 2 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.09
Succinylcholine0.19

[back to top]

Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 10 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.01
Succinylcholine0.32

[back to top]

Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex

"Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 10 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.07

[back to top]

Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 15 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.02
Succinylcholine0.33

[back to top]

Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex

"Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 15 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.07

[back to top]

Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium

Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery. (NCT00751179)
Timeframe: Start of administration of sugammadex to recovery from neuromuscular blockade (Up to approximately 6 minutes)

InterventionMinutes (Geometric Mean)
Rocuronium - Sugammadex1.79

[back to top]

Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex

"Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 2 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.02

[back to top]

Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 5 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.06
Succinylcholine0.30

[back to top]

Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex

"Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 5 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.02

[back to top]

Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups

"Only AEs which occurred following administration of sugammadex or succinylcholine are included. AEs in the rocuronium - sugammadex group occurring after rocuronium but before sugammadex administration are considered pretreatment events and are not included. The AE reporting interval included the entire intubation/surgical period for the succinylcholine group (since succinylcholine was administered just prior to intubation/commencement of surgery) but not for the rocuronium - sugammadex group (since sugammadex was administered at the end of the surgical procedure)." (NCT00751179)
Timeframe: Up to 7 days post dose

Interventionparticipants (Number)
Rocuronium - Sugammadex60
Succinylcholine75

[back to top]

Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine

Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until recovery of T1 of 90% of baseline and full recovery of neuromuscular function occurred as determined by the anesthesiologist as per routine clinical practice. (NCT00751179)
Timeframe: Start of administration of succinylcholine to recovery from neuromuscular blockade (Up to approximately 18 minutes)

InterventionMinutes (Geometric Mean)
Succinylcholine10.76

[back to top]

Time From Anesthetic Discontinuation to First Ability to Swallow

At 2 minutes after first response to command (T1), the patient was asked to swallow 20 mL of water from a paper cup, and an observer blinded to anesthetic assignment assessed the ability to swallow based on transit of water to the posterior pharynx (absence of pooling or drooling) and absence of cough or gag (indicating misdirection of the water bolus into the laryngeal inlet). This test was repeated at 6, 14, 22, 30 and 60 minutes after the time of first response to command. (NCT01199237)
Timeframe: up to 60 minutes after T1

InterventionSeconds (Mean)
Sevoflurane1275
Desflurane718

[back to top]

Time From Potent Inhaled Anesthetic Discontinuation to First Response to Command (T1)

"At the conclusion of surgery, after the patient's potent inhaled anesthetic was discontinued, the commands open your eyes and squeeze my hand were given at 30-second intervals. The time at which patient first appropriately response to both commands was noted as T1." (NCT01199237)
Timeframe: Up to 1 hour post-operative

Interventionseconds (Mean)
Sevoflurane623
Desflurane343

[back to top]

Nausea and Vomiting

Patients were asked to rate their experience of nausea and vomiting on a 0-10 verbal analog scale, with 0 being absence and 10 being the worst imaginable (NCT01199237)
Timeframe: 30 minutes after T1

,
Interventionunits on a scale (Mean)
NauseaVomiting
Desflurane1.3590
Sevoflurane0.3850

[back to top]

Recovery of Ability to Swallow After Neostigmine/Glycopyrrolate Antagonism of Rocuronium Paralysis.

The patient is judged by the primary anesthetist to be awake at time T1. At 2 minutes after T1, the patient was asked to swallow 20mL of water from a paper cup, and a blinded observer judged the ability to swallow based on transit of water to the posterior pharynx (absence of pooling or drooling) and absence of cough or gag. (NCT01199237)
Timeframe: At 2 minutes after response to command (T1).

,
Interventionparticipants (Number)
able to swallow at T1+2 minutesunable to swallow at T1+2 minutes
Desflurane256
Sevoflurane1610

[back to top]

Nausea and Vomiting

Patients were asked to rate their experience of nausea and vomiting on a 0-10 verbal analog scale, with 0 being absence and 10 being the worst imaginable (NCT01199237)
Timeframe: 60 minutes after T1

,
Interventionunits on a scale (Mean)
NauseaVomiting
Desflurane1.3330.026
Sevoflurane0.2630

[back to top]

Regional Cerebral Oxygen Satuation (rSO2)

definitive values of regional cerebral oxygen saturation(rSO2,%) values are described as mean (SD) (NCT01436799)
Timeframe: 1, 3, 5, 7, and 9 min after the beach chair position

,
Interventionpercentage of rSO2 (%) (Mean)
1min after beach chair position3min after beach chair position5min after beach chair position7min after beach chair position9min after beach chair position
Desflurane77.47675.275.174
Propofol72.5707068.567.8

[back to top]

Optimal Dose of Neuromuscular Blocking Agent During ECT

The optimal dose of muscle neuromuscular blocking is defined as the lowest dose of either compound that predicts 'acceptable' control of muscle strength during ECT. Assessment of the primary end point is based on a dichotomous scale 'acceptable' and 'not acceptable' control of muscle strength during ECT, and the two assessors will be blinded to the dose of neuromuscular blocking agent. The optimal dose was identified for each subject, and results were reported as the average of all lowest doses collected in the study. (NCT01441960)
Timeframe: Up to six weeks following inclusion

Interventionmg.kg-1 (Mean)
NMBA: Sux0.85
NMBA- Rocuronium0.41

[back to top]

Compound Specific Differences in Time to Recovery From Neuromuscular Blockade

The investigators defined the compound specific differences in time to recovery from neuromuscular blockade - i.e., recovery of spontaneous breathing and recovery of the twitch height to baseline. (NCT01441960)
Timeframe: Up to six weeks following inclusion

Interventionminutes (Mean)
Succinylchline9.7
Rocuronium19.5

[back to top]

Differences in Seizure Duration Between Compounds

Observational reports suggest that differences in seizure duration might exist depending on the neuromuscular blocking agents used to accomplish muscle strength control during ECT. (NCT01441960)
Timeframe: Up to six weeks following inclusion

InterventionSeconds (Mean)
Succinylcholine27
Rocuronium31

[back to top]

The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups

"The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group.~The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses." (NCT01450813)
Timeframe: Six minutes after the dose of rocuronium with laryngoscopy at 3 minutes after the study intervention

Interventionunits on a scale (Mean)
Group 12.40
Group 21.39
Group 30.48
Group 40.17

[back to top]

The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups

Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups (NCT01450813)
Timeframe: Maintenance Anesthesia

Interventionunits on a scale (Mean)
Remifentanil 2ng/ml1.73
Remifentanil 8 ng/ml1.38

[back to top]

The Percentage of Patients With Optimal Surgical Space Conditions ( 1 at a 4-step Scale) Assessed at the Time During Surgery, When View Was Less

"The surgical space conditions (4-stage scale) assessed at the time during surgery, when view was less. The laparoscopies were performed by experienced surgeons, whom were asked to evaluate surgical space conditions with a 4-point scale : Grade 1 (optimal) = optimal surgical space conditions; Grade 2 (good) = non-optimal conditions, but an intervention was not considered; Grade 3 (acceptable) = an intervention was considered in order to improve surgical space; Grade 4 (poor) = inadequate conditions and an intervention was necessary in order to ensure acceptable surgical space." (NCT01523886)
Timeframe: From surgical incision to last suture has been placed, an expected average of 30 minutes

Interventionpercentage of patients (Number)
Deep Neuromuscular Blockade28
Moderate Neuromuscular Blockade4

[back to top]

Nausea and Vomiting

"Using a yes - no questionnaire, the patients will be asked whether they are nauseated or not or whether they vomited. In fact yes indicates the nr of participants.~No statistical analysis was performed." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionparticipants (Number)
Moderate/Normal Surgical Block0
Deep Surgical Block0

[back to top]

Post-operative Pain

"Using a 10 cm visual analogue score pain relief score will be measured. 0 = no pain 10 = most severe pain~No statistical analysis was performed!" (NCT01631149)
Timeframe: measurements are made in the recovery room following surgery for an average prior of 1 hour

Interventionunits on a scale (0-10 cm) (Mean)
Moderate/Normal Surgical Block2.6
Deep Surgical Block2.1

[back to top]

Surgical Rating Scale

"During the procedure, the surgical condition will be scored by the surgeon using a 5-point surgical rating scale. In order to reduce variability in the surgical rating all surgeries will be performed by one single surgeon. The rating scale will be a 5-point ordinal scale ranging from 1 = poor condition to 5 = optimal surgical conditions. The surgeon will score the condition at 15 minute intervals. In case of a sudden change in surgical conditions additional scores will be added to the case record form. If conditions are poor (score 1 or 2), muscle relaxation will be increased, a score of 1 will be used.~In each subject the scores over time were averaged and a comparison between treatments was performed using a t-test" (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (1-5) (Mean)
Moderate/Normal Surgical Block4
Deep Surgical Block4.7

[back to top]

Postoperative Sedation Score

"Using a 5-point sedation scale, sedation levels will be obtained throughout the postoperative period.~0 = wide awake 5= severely sedated, The sedation data were averaged over time." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (0-5) (Mean)
Moderate/Normal Surgical Block2.0
Deep Surgical Block1.3

[back to top]

Breathing

"In the recovery room the respiratory rate will be measured continuously using the Respir8 respiratory rate monitor. The data will be recorded on the CRF at 15 min intervals.~Breathing rate units are number of breaths as measured in 1 min.~Comparison by t-test: NS between treatments" (NCT01631149)
Timeframe: Measurements will be made during the stay in the recovery room for an average period of 3 hours

Interventionbreaths per min (Mean)
Moderate/Normal Surgical Block14.5
Deep Surgical Block14.5

[back to top]

Shoulder Pain

"Number of participants with shoulder pain or discomfort (VAS > 20) in the shoulder region within 14 days after operation.~VAS 0-100: Visual analouge scale for assessment of pain ranging from no pain (value 0) to worst kind of pain (value 100)." (NCT01722097)
Timeframe: within 14 days

Interventionparticipants (Number)
Deep Neuromuscular Blockade14
Moderate Neuromuscular Blockade30

[back to top]

Pain (Assessed on a 0-100 Visual Analouge Scale (VAS): 0 no Pain, 100 Worst Kind of Pain)

"Pain (shoulder-, incisional-, abdominal - and overall pain) estimated as area under the curve (AUC) from 0 till 4 days after operation.~Pain (shoulder-, incisional-, abdominal - and overall pain) estimated as area under the curve (AUC) from 0 till 14 days after operation.~Pain was assessed: preoperatively, at arrival to the postanesthesia care unit, 2 hours after surgery, 4 hours after surgery, 8 hours after surgery, at discharge from hospital, and once daily at day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 after surgery." (NCT01722097)
Timeframe: within 14 days

,
Interventionunits on a scale*days (Median)
VAS shoulder pain 4 days AUCVAS shoulder pain 14 days AUCVAS incisional pain 4 days AUCVAS incisional pain 14 days AUCVAS abdominal pain 4 days AUCVAS abdominal pain 14 days AUCVAS overall pain 4 days AUCVAS overall pain 14 days AUC
Deep Neuromuscular Blockade16.427.688.4144.6102.4190.8101.7190.2
Moderate Neuromuscular Blockade28.536.3102.2150.8114.1215.5129.8256.9

[back to top]

Number of Times Participant's Movements or Increased Muscle Tone Interfered With the Surgical Conditions During Laparoscopy: By Depth of NMB (Standard, Deep)

"At the end of the procedure the surgeon responds to the following question: How many times did patient's movements (coughing, bucking, hiccup) or increased muscle tone (resistance, difficulty to close fasciae or skin) interfere with your surgery?" (NCT01728584)
Timeframe: During surgery, approximate duration of 1-2 hours (Day 1)

Interventioninstances of occurrence that interfered (Least Squares Mean)
Standard NMB0.92
Deep NMB0.32

[back to top]

Score on Surgeon's Assessment of Overall Satisfaction With the Visibility of the Surgical Field: By Depth of NMB (Standard, Deep)

"At the end of the procedure the surgeon responds to the following question, using an 11-point scale from 0 (poor, unacceptable visibility) to 10 (excellent): How satisfied were you overall with the visual field during the surgery you just performed? If at any time the surgeon requests a rescue intervention, the surgeon will rate his overall satisfaction with the visibility of the surgical field according to his opinion, but if a rescue intervention has been applied, that individual participant will be counted with a score of zero in the analysis." (NCT01728584)
Timeframe: End of surgery (Day 1)

Interventionscore on a scale (Least Squares Mean)
Standard NMB6.88
Deep NMB7.80

[back to top]

Score on Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions: By Treatment Arm

"At the end of the procedure the surgeon responds to the following question, using an 11-point scale from 0 (poor, needed intervention) to 10 (excellent): How satisfied were you overall with the surgical conditions related to anesthesia and pneumoperitoneum during the surgery you just performed? If at any time the surgeon requests a rescue intervention, the overall assessment of surgical conditions should be rated as 0 (=poor, needed intervention). The surgeon will rate the surgical conditions according to his opinion but if a rescue intervention has been applied, that individual participant will be counted with a score of zero in the analysis." (NCT01728584)
Timeframe: End of surgery (Day 1)

Interventionscore on a acale (Least Squares Mean)
Standard NMB and Standard Insufflation Pressure8.65
Standard NMB and Low Insufflation Pressure4.99
Deep NMB and Standard Insufflation Pressure9.09
Deep NMB and Low Insufflation Pressure6.69

[back to top]

Score on Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions: By Depth of NMB (Standard, Deep) and Insufflation Pressure (Standard, Low)

"At the end of the procedure the surgeon responds to the following question, using an 11-point scale from 0 (poor, needed intervention) to 10 (excellent): How satisfied were you overall with the surgical conditions related to anesthesia and pneumoperitoneum during the surgery you just performed? If at any time the surgeon requests a rescue intervention, the overall assessment of surgical conditions should be rated as 0 (=poor, needed intervention). The surgeon will rate the surgical conditions according to his opinion but if a rescue intervention has been applied, that individual participant will be counted with a score of zero in the analysis." (NCT01728584)
Timeframe: End of surgery (Day 1)

Interventionscore on a scale (Least Squares Mean)
Standard NMB6.83
Deep NMB7.92
Standard Insufflation Pressure8.89
Low Insufflation Pressure5.87

[back to top]

Participant's Overall Average Pain Score in the First 24 Hours After Administration of Sugammadex: By Depth of NMB (Standard, Deep) and Insufflation Pressure (Standard, Low)

Participants rated pain at 1, 2, 4, 24 and 48 hours after the administration of sugammadex on day of surgery (Day 1), and daily from Day 3 to Day 8. Pain rating was made using an 11-point scale from 0 (no pain) to 10 (severe pain). Separate ratings were made for overall pain at rest, pain when provoked (e.g., due to participant transition from lying to sitting position) and shoulder pain at rest. The participant's overall average pain score within 24 hours after sugammadex was the average of all pain assessments (including all 3 pain types assessed) at 1, 2, 4 and 24 hours after sugammadex dose. (NCT01728584)
Timeframe: Up to 24 hours after administration of sugammadex on Day 1

Interventionscore on a scale (Least Squares Mean)
Standard NMB2.48
Deep NMB2.83
Standard Insufflation Pressure2.74
Low Insufflation Pressure2.57

[back to top]

Participant's Overall Average Pain Score in the First 24 Hours After Administration of Sugammadex: By Treatment Arm

Participants rated pain at 1, 2, 4, 24 and 48 hours after the administration of sugammadex on day of surgery (Day 1), and daily from Day 3 to Day 8. Pain rating was made using an 11-point scale from 0 (no pain) to 10 (severe pain). Separate ratings were made for overall pain at rest, pain when provoked (e.g., due to participant transition from lying to sitting position) and shoulder pain at rest. The participant's overall average pain score within 24 hours after sugammadex was the average of all pain assessments (including all 3 pain types assessed) at 1, 2, 4 and 24 hours after sugammadex dose. (NCT01728584)
Timeframe: Up to 24 hours after administration of sugammadex on Day 1

Interventionscore on a scale (Least Squares Mean)
Standard NMB and Standard Insufflation Pressure2.42
Standard NMB and Low Insufflation Pressure2.62
Deep NMB and Standard Insufflation Pressure3.06
Deep NMB and Low Insufflation Pressure2.57

[back to top]

Number of Participants With Rescue Actions Performed During Surgery in Order to Improve Insufficient Surgical Conditions: By Treatment Arm

"During procedure, surgeon (who was blinded to random assignment) could request that unblinded anesthetist change the randomized treatment conditions (called a rescue intervention), if surgeon considered surgical conditions to be unacceptable. This was to be done systematically as follows: If the participant is on standard NMB, the preferred rescue intervention should be to increase the NMB to a depth of 1-2 PTCs; for such a participant the second option (if participant is also on low insufflation pressure) should be the increase of insufflation pressure by 4 mm Hg. If the participant is already on deep NMB, the preferred option should be (if participant is also on low insufflation pressure) the increase of insufflation pressure by 4 mm Hg. The unblinded anesthetist recorded any rescue actions performed. This measure presents the number of participants: with any rescue action performed, with rescue change in depth of NMB, with rescue change in insufflation pressure level." (NCT01728584)
Timeframe: During surgery, approximate duration of 1-2 hours (Day 1)

,,,
Interventionparticipants (Number)
Number with rescue action performedNumber with rescue change in depth of NMBNumber with rescue change in pressure level
Deep NMB and Low Insufflation Pressure505
Deep NMB and Standard Insufflation Pressure000
Standard NMB and Low Insufflation Pressure756
Standard NMB and Standard Insufflation Pressure000

[back to top]

Score on Surgeon's Assessment of the Effect Participant's Movements During Surgery Had on the Overall Surgical Procedure: By Depth of NMB (Standard, Deep)

"At the end of the procedure the surgeon responds to the following question, using an 11-point scale from 0 (extremely disruptive) to 10 (not disruptive): How did the patient movements described above disrupt your surgical performance? This refers to participant movements during surgery." (NCT01728584)
Timeframe: End of surgery (Day 1)

Interventionscore on a scale (Least Squares Mean)
Standard NMB9.21
Deep NMB9.94

[back to top]

Score on Surgeon's Assessment of the Overall Adequacy of Insufflation Pressure During Surgery: By Depth of NMB (Standard, Deep)

"At the end of the procedure the surgeon responds to the following question, using an 11-point scale from 0 (poor, unacceptable insufflation pressure, required intervention) to 10 (excellent): How do you rate the overall adequacy of insufflation pressure during the surgery you just performed?" (NCT01728584)
Timeframe: End of surgery (Day 1)

Interventionscore on a scale (Least Squares Mean)
Standard NMB6.73
Deep NMB7.86

[back to top]

Score on Surgeon's Assessment of the Overall Adequacy of Muscle Relaxation During Surgery: By Depth of NMB (Standard, Deep)

"At the end of the procedure the surgeon responds to the following question, using an 11-point scale from 0 (poor, unacceptable muscle relaxation, required intervention) to 10 (excellent): How do you rate the overall adequacy of muscle relaxation during the surgery you just performed?" (NCT01728584)
Timeframe: End of surgery (Day 1)

Interventionscore on a scale (Least Squares Mean)
Standard NMB8.05
Deep NMB8.87

[back to top]

Number of Participants Using Pain/Analgesic Medication During Post Operative Period: By Treatment Arm

Post operative use of pain/analgesic medication by participant through Day 8 was recorded. (NCT01728584)
Timeframe: Up to Day 8

,,,
Interventionparticipants using pain medication (Number)
Within 3 hours post surgery3 to 24 hours post surgery24 to 48 hours post surgeryBetween 48 hours and end of Day 5On Day 6, 7 or 8
Deep NMB and Low Insufflation Pressure2424231710
Deep NMB and Standard Insufflation Pressure3738352925
Standard NMB and Low Insufflation Pressure2121222014
Standard NMB and Standard Insufflation Pressure3126262719

[back to top]

Participant's Daily Assessment of Overall Pain at Rest During Post Operative Period: By Treatment Arm

Participants rated pain at 1, 2, 4, 24 and 48 hours after the administration of sugammadex on day of surgery (Day 1), and daily (in the morning) from Day 3 to Day 8. Pain rating was made using an 11-point scale from 0 (no pain) to 10 (severe pain). Separate ratings were made for overall pain at rest, pain when provoked (e.g., due to participant transition from lying to sitting position) and shoulder pain at rest. This measure summarizes the assessment of overall pain at rest for the study days following the surgery. (NCT01728584)
Timeframe: Days 2 to 8

,,,
Interventionscore on a scale (Mean)
24 hours after sugammadex dose (n=29, 22, 38, 25)48 hours after sugammadex dose (n=27, 22, 33, 23)Day 3 (N=22, 20, 30, 17)Day 4 (N=28, 20, 37, 23)Day 5 (N=27, 21, 38, 24)Day 6 (N=27, 20, 35, 24)Day 7 (N=27, 21, 34, 22)Day 8 (N=28, 21, 35, 21)
Deep NMB and Low Insufflation Pressure2.481.832.001.040.920.750.590.43
Deep NMB and Standard Insufflation Pressure2.241.731.871.761.451.311.180.94
Standard NMB and Low Insufflation Pressure2.231.411.651.051.000.850.950.81
Standard NMB and Standard Insufflation Pressure1.661.220.860.890.890.560.480.54

[back to top]

Participant's Daily Assessment of Provoked Pain During Post Operative Period: By Treatment Arm

Participants rated pain at 1, 2, 4, 24 and 48 hours after the administration of sugammadex on day of surgery (Day 1), and daily (in the morning) from Day 3 to Day 8. Pain rating was made using an 11-point scale from 0 (no pain) to 10 (severe pain). Separate ratings were made for overall pain at rest, pain when provoked (e.g., due to participant transition from lying to sitting position) and shoulder pain at rest. This measure summarizes the assessment of provoked pain for the study days following the surgery. (NCT01728584)
Timeframe: Days 2 to 8

,,,
Interventionscore on a scale (Mean)
24 hours after sugammadex dose (n=29, 22, 38, 25)48 hours after sugammadex dose (n=27, 22, 33, 23)Day 3 (N=22, 20, 30, 17)Day 4 (N=28, 20, 37, 23)Day 5 (N=27, 21, 38, 24)Day 6 (N=27, 20, 35, 24)Day 7 (N=27, 21, 34, 22)Day 8 (N=28, 21, 35, 21)
Deep NMB and Low Insufflation Pressure3.762.913.241.911.711.421.230.81
Deep NMB and Standard Insufflation Pressure3.682.942.973.052.582.512.211.91
Standard NMB and Low Insufflation Pressure3.272.142.501.851.901.401.521.38
Standard NMB and Standard Insufflation Pressure3.382.672.232.251.931.701.371.21

[back to top]

Participant's Daily Assessment of Shoulder Pain During Post Operative Period: By Treatment Arm

Participants rated pain at 1, 2, 4, 24 and 48 hours after the administration of sugammadex on day of surgery (Day 1), and daily (in the morning) from Day 3 to Day 8. Pain rating was made using an 11-point scale from 0 (no pain) to 10 (severe pain). Separate ratings were made for overall pain at rest, pain when provoked (e.g., due to participant transition from lying to sitting position) and shoulder pain at rest. This measure summarizes the assessment of shoulder pain for the study days following the surgery. (NCT01728584)
Timeframe: Days 2 to 8

,,,
Interventionscore on a scale (Mean)
24 hours after sugammadex dose (n=29, 22, 38, 25)48 hours after sugammadex dose (n=27, 22, 33, 23)Day 3 (N=22, 20, 30, 17)Day 4 (N=28, 20, 37, 23)Day 5 (N=27, 21, 38, 24)Day 6 (N=27, 20, 35, 24)Day 7 (N=27, 21, 34, 22)Day 8 (N=28, 21, 35, 21)
Deep NMB and Low Insufflation Pressure1.400.960.880.610.250.210.230.14
Deep NMB and Standard Insufflation Pressure1.050.760.670.700.680.630.680.66
Standard NMB and Low Insufflation Pressure1.180.640.800.550.430.150.140.24
Standard NMB and Standard Insufflation Pressure1.000.410.180.320.000.000.000.04

[back to top]

Number of Intra-abdominal Pressure Rises > 18cmH2O

The number of intra-abdominal pressure rises > 18cmH2O detected by the intra-abdominal CO2 insufflator. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionnumber of intra-abdominal pressure rises (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex0.2
Normal Neuromuscular Blockade, Reversal With Neostigmine0.3

[back to top]

Peak Expiratory Flow

Peak expiratory flow is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex51.3
Normal Neuromuscular Blockade, Reversal With Neostigmine51.5

[back to top]

Duration of Surgery

Measured from the time of first skin incision to completion of skin closure. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionminutes (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex61.3
Normal Neuromuscular Blockade, Reversal With Neostigmine70.6

[back to top]

Subjective Evaluation of the View on the Operating Field by the Surgeon

"At the end of surgery, the view on the operating field will be graded by the surgeon using a 5-point rating scale:~Extremely poor~Poor~Acceptable~Good~Optimal" (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex4.2
Normal Neuromuscular Blockade, Reversal With Neostigmine3.9

[back to top]

Forced Expiratory Volume in 1 Second

Forced expiratory volume in 1 second is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex45.2
Normal Neuromuscular Blockade, Reversal With Neostigmine48.8

[back to top]

Forced Vital Capacity

Forced vital capacity is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex51.9
Normal Neuromuscular Blockade, Reversal With Neostigmine49.0

[back to top]

Present the Percentage of Participants With an Excellent Ease of Intubation Rating

"percentage of participants with an excellent ease of intubation rating based on Scale of 1-4 (1 Being Excellent, 4 Being Poor)," (NCT01749501)
Timeframe: 24 hours after intubation period

Intervention% reported as excellent (Number)
Rocuronium91
Placebo17

[back to top]

Timing of Entire Procedure (Stopwatch)and Recording Number of Attempts to Successful Intubation Recorded.

(NCT01749501)
Timeframe: 24 hours after intubation procedure

Interventionminutes (Mean)
Rocuronium2.94
Placebo4.95

[back to top]

Effect of Anesthetics on the Abdominal Elastance (E) Measured During Insufflation of the Abdomen by

the impact of the following agents on the abdominal elastance (E) : remifentanyl > 0.50 µg/kg/min; sevoflurane 1 MAC and deep neuromuscular block (rocuronium given with PTC < 4). (NCT01930747)
Timeframe: 5 min after reaching 1 MAC or haven given the anesthetics intravenous

InterventionmmHg/liter (Mean)
Deep Neuromuscular Block2.53
Inhalation With 1 MAC Sevoflurane2.71
Remifentanyl2.5

[back to top]

Adverse Events Difference Between the Three Groups

"To compare the major adverse events among the patient groups who receive the different agents listed above in the primary efficacy objective" (NCT01930747)
Timeframe: from zero till 24 hours after recovery of surgery.

InterventionParticipants (Count of Participants)
Deep Neuromuscular Block0
Inhalation With 1 MAC Sevoflurane0
Remifentanyl0

[back to top]

Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen

the impact of the following agents on the pressure at zero volume (PV0): remifentanyl > 0.50 µg/kg/min; sevoflurane 1 MAC and deep neuromuscular block (rocuronium given with PTC < 4). (NCT01930747)
Timeframe: 5 min after reaching 1 MAC or haven given the anesthetics intravenous

InterventionmmHg (Mean)
Deep Neuromuscular Block5.7
Inhalation With 1 MAC Sevoflurane8.29
Remifentanyl6.58

[back to top]

Surgical Conditions During Suturing of the Abdominal Fascia

Optimal (score 1) Good (score 2) Acceptable (score 3) Poor (score 4) (NCT01933425)
Timeframe: 1 hour

,
Interventionparticipants (Number)
Optimal (score 1)Good (score 2)Acceptable (score 3)Poor (score 4)
Deep Neuromuscular Blockade7000
no Neuromuscular Blockade2500

[back to top]

Intraabdominal Distance (Centimeters)

Difference in intraabdominal distance from promontorium to the edge of the trocar in umbilicus at 8 mmHg with and without deep neuromuscular blockade (PTC 0-1). (NCT01933425)
Timeframe: 1 hour

Interventioncentimeters (Median)
Deep Neuromuscular Block8.6
No Neuromuscular Block8.2

[back to top]

Intraabdominal Distance (Centimeters)

Difference in intraabdominal distance from promontorium to the edge of the trocar in umbilicus at 12 mmHg with and without deep neuromuscular blockade (PTC 0-1). (NCT01933425)
Timeframe: 1 hour

Interventioncentimeters (Median)
Deep Neuromuscular Block9.3
No Neuromuscular Block9.0

[back to top]

Induction to Delivery Interval

Induction to delivery interval will be used as primary keypoint for surgical conditions comparison. (NCT01941628)
Timeframe: 24 hrs

Interventionseconds (Mean)
Rocuronium268
Succinylcholine276

[back to top]

Number of Participants With Newborn in Need of Respiratory Support

The number of participants with a newborn in need of respiratory support will be the primary safety measure in comparison of the influence of different neuromuscular blockade levels on newborn adaptation. (NCT01941628)
Timeframe: 24 hours

Interventionparticipants (Number)
Rocuronium0
Succinylcholine0

[back to top]

Peroperative and Postoperative Surgical Complication

A total number of surgical complications evaluated at day 5 after Caesarean delivery. (NCT01941628)
Timeframe: 5 days

Interventionparticipants (Number)
Rocuronium0
Succinylcholine0

[back to top]

Electric Activity of the Intercostal Muscles

(NCT01962298)
Timeframe: From the start of spontaneous breathing till extubation, limited to maximum ten minutes after the onset of spontaneous breathing

Interventionmicrovolt (Median)
Single Rocuronium Dose - Placebo2.4
Single Rocuronium Dose - Sugammadex2.2
Repeated Rocuronium Dose - Neostigmine1.5
Repeated Rocuronium Dose - Sugammadex2.2
Continuous Rocuronium Dose1.8

[back to top]

Electric Activity of the Diaphragm (Microvolts)

(NCT01962298)
Timeframe: From the start of spontaneous breathing till extubation, limited to maximum ten minutes after the onset of spontaneous breathing

Interventionmicrovolt (Median)
Single Rocuronium Dose - Placebo3.7
Single Rocuronium Dose - Sugammadex4.5
Repeated Rocuronium Dose - Neostigmine3.2
Repeated Rocuronium Dose - Sugammadex2.9
Continuous Rocuronium Dose4.4

[back to top]

Cerebral Oximetry (%)

Regional cerebral oxygenation will be assessed continuously during the intraoperative period using NIRS technology. (NCT02025075)
Timeframe: BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum

Interventionpercent cerebral saturation (Mean)
Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep74
Deep Neuromuscular Block (NMB): MODERATE of of Deep-TOF1-Deep73
Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep74
Moderate Neuromuscular Block (NMB): MOD(1st) of TOF1-Deep-TOF175
Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF175
Moderate Neuromuscular Block (NMB): MOD(2nd) of TOF1-Deep-TOF175

[back to top]

Ejection Fraction (%)

To assess cardiac performance, transthoracic echocardiography will be used. Ejection fraction was measured as fractional shortening (FS). FS is the fraction of any diastolic dimension that is lost in systole. FS = 100*(LVEDD - LVESD) / LVEDD, LVEDD = LV end-diastolic dimension (mm); LVESD = LV end-systolic dimension (mm). (NCT02025075)
Timeframe: BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum

Intervention% fractional shortening (Mean)
Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep36
Deep Neuromuscular Block (NMB): MODERATE of of Deep-TOF1-Deep34
Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep35
Moderate Neuromuscular Block (NMB): MOD(1st) of TOF1-Deep-TOF135
Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF136
Moderate Neuromuscular Block (NMB): MOD(2nd) of TOF1-Deep-TOF137

[back to top]

Postoperative Pain

The patient will be inquired about pain with a visual analogue scale (VAS). Pain will be evaluated as incisional pain using VAS (0 = no pain; 100 = worst possible pain). (NCT02025075)
Timeframe: Postoperative Day 1

Interventionunits on a scale (Mean)
Deep Neuromuscular Block (NMB)3.5
Moderate Neuromuscular Block (NMB)3.1

[back to top]

Regional Change in Air Content (Delta Z, %)

We will measure continuous respiratory flows and pressures in the intraoperative period to assess continuously the compliance and resistance of the respiratory system (T1 to T5). In addition, we will use an esophageal balloon to assess esophageal pressures and partition the global mechanical properties of the respiratory system, into their lung and chest wall components (T1 to T5). Regional lung aeration will be assessed for quantification of intraoperative lung recruitment using Electrical Impedance Tomography (EIT) (T0 to T6). Percent change was calculated using electrical impedance measurements obtained at time T0 as reference. (NCT02025075)
Timeframe: BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum

Interventionpercent change (Mean)
Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep14.5
Deep Neuromuscular Block (NMB): MODERATE of of Deep-TOF1-Deep29.0
Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep43.3
Moderate Neuromuscular Block (NMB): MOD(1st) of TOF1-Deep-TOF1-14.0
Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF119.4
Moderate Neuromuscular Block (NMB): MOD(2nd) of TOF1-Deep-TOF129.8

[back to top]

Post-operative Nausea

(NCT02109133)
Timeframe: During 24hours after operation

Interventionevents (Number)
Moderate Neuromuscular Blockade (Moderate NMB Group)4
Deep Neuromuscular Blockade (Deep NMB Group)1

[back to top]

Incidence of Residual Neuromuscular Blockade

(NCT02109133)
Timeframe: During 24hours after operation

Interventionparticipants (Number)
Moderate Neuromuscular Blockade (Moderate NMB Group)0
Deep Neuromuscular Blockade (Deep NMB Group)0

[back to top]

Maximum Intraocular Pressure During RALRP Under Deep Neuromuscular Blockade

maximum intraocular pressure during RALRP under deep neuromuscular blockade after being positioned in the steep Trendelenburg position with CO2 pneumoperitoneum under deep neuromuscular blockade (NCT02109133)
Timeframe: Maximum intraocular pressure was measured at 60 minutes after CO2 pneumoperitoneum in the ST position

InterventionmmHg (Mean)
Moderate Neuromuscular Blockade (Moderate NMB Group)23.3
Deep Neuromuscular Blockade (Deep NMB Group)19.8

[back to top]

Overall Surgical Condition

overall surgical conditions using the 5-point rating scale as previously described: Grade 5 (optimal), optimal surgical conditions; grade 4 (good), nonoptimal conditions, but an intervention is not required; grade 3 (acceptable), wide surgical view, but an intervention can improve surgical conditions, grade 2 (poor), inadequate conditions, there is a visible view, but an intervention is necessary to ensure acceptable surgical conditions; grade 1 (extremely poor), inability to perform surgery; therefore, intervention is necessary. (NCT02109133)
Timeframe: At the end of the Steep trendelenburg position, an average of 1 hour

Interventionunits on a scale (Median)
Moderate Neuromuscular Blockade4.0
Deep Neuromuscular Blockade3.0

[back to top]

Surgical Rating Score

The final score for the surgical conditions of a patient defined as the average of all scores provided during the surgical procedure. (Rated on a 5 point subjective rating scale; 1: extremely poor, 2: poor, 3: acceptable, 4: good, 5: optimal) (NCT02140593)
Timeframe: After randomization every 30 minutes during the operation from first incision to last suture of fascial closure, up to 300 minutes

Interventionunits on a scale (Median)
Standard Neuromuscular Blockade4
Deep Neuromuscular Blockade4.75

[back to top]

The Surgical Rating Score During Fascial Closure

After last suture of fascial closure surgical conditions are rated on a 5 point scale (NCT02140593)
Timeframe: Immediatly after fascial closure

Interventionunits on a scale (Mean)
Standard Neuromuscular Blockade4
Deep Neuromuscular Blockade5

[back to top]

Cardiac Index

"Was obtained from arterial pressure waveform analysis using the FloTrac™ sensor and the Vigileo™ monitor.~Measurements were obtained at (1) T Lateral, (2) T Lat+PP1h, (3) T Lat+PP2h, and (4) EndPP." (NCT02185339)
Timeframe: intraoperative

,
InterventionL/min/m^2 (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group2.42.82.93.0
Moderate Neuromuscular Blockade (Moderate NMB) Group2.42.62.83.1

[back to top]

Estimated Dead Space

Was calculated from arterial blood and expired carbon dioxide analysis. Measurements were obtained at (1) T Lateral, (2) T Lat+PP1h, (3) T Lat+PP2h, and (4) EndPP. (NCT02185339)
Timeframe: intraoperative

,
Intervention% of respiratory dead space (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group11.814.114.112.0
Moderate Neuromuscular Blockade (Moderate NMB) Group11.916.516.414.8

[back to top]

Postoperative Pain

"Postoperative pain was measured by Visual Analogue Scale (VAS). Participants were asked to report their level of pain by pointing to a horizontal line, 10 cm in length. The scale (0-10 scores) was anchored by no pain (score of 0) and pain as bad as it could be (score of 10).~Measurements were made at postoperative (PO) 1h, PO 2h, PO 6h, PO 24h, and PO 48h." (NCT02185339)
Timeframe: Postoperative 2 days

,
InterventionScores on a scale (Mean)
PO 1hPO 2hPO 6hPO 24hPO 48h
Deep Neuromuscular Blockade (Deep NMB) Group5.45.14.32.22.2
Moderate Neuromuscular Blockade (Moderate NMB) Group5.94.94.52.42.4

[back to top]

Pulmonary Shunt

"Was calculated using the formula: pulmonary shunt = (pulmonary capillary oxygen content - arterial oxygen content) / (pulmonary capillary oxygen content - venous oxygen content). Pulmonary capillary oxygen partial pressure is assumed to be equal to alveolar oxygen partial pressure.~Measurements were obtained at (1) T Lateral, (2) T Lat+PP1h, (3) T Lat+PP2h, and (4) EndPP." (NCT02185339)
Timeframe: intraoperative

,
Intervention% of shunt (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group13.212.715.011.9
Moderate Neuromuscular Blockade (Moderate NMB) Group12.413.214.814.1

[back to top]

Stroke Volume Variation

"Was calculated by taking '(maximum stroke volume - minimum stroke volume) / mean stroke volume' over a respiratory cycle using the FloTrac™ sensor and the Vigileo™ monitor.~Measurements were obtained at (1) T Lateral, (2) T Lat+PP1h, (3) T Lat+PP2h, and (4) EndPP." (NCT02185339)
Timeframe: intraoperative

,
Intervention% of mean stroke volume (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group9.211.311.47.3
Moderate Neuromuscular Blockade (Moderate NMB) Group9.312.912.07.9

[back to top]

Surgical Condition

Subjective rating of the view on the operating field was assessed by the surgeon who performed the surgery (optimal condition, good, acceptable, poor, extremely poor) (NCT02185339)
Timeframe: At completion of pneumoperitoneum surgery

,
InterventionParticipants (Number)
Extremely poorPoorAcceptableGoodOptimal
Deep Neuromuscular Blockade (Deep NMB) Group000129
Moderate Neuromuscular Blockade (Moderate NMB) Group011721

[back to top]

Thoracopulmonary Compliance

"Was measured with a patient spirometry monitor through a flow sensor.~Measurements were obtained at the following four time points: (1) 15 min after a patient positioning in lateral decubitus before inducing the pneumoperitoneum (T Lateral); (2) 1 h after pneumoperitoneum induction with the patient in the lateral decubitus position (T Lat+PP1h); (3) 2 h after pneumoperitoneum induction with the patient in the lateral decubitus position (T Lat+PP2h); and (4) at the end of surgery, 15 min after abdominal deflation in the lateral decubitus position (T EndPP)." (NCT02185339)
Timeframe: intraoperative

,
Interventionml/cmH2O (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group51.934.633.654.1
Moderate Neuromuscular Blockade (Moderate NMB) Group52.331.930.852.6

[back to top]

Arterial Oxygen Tension/Inspired Oxygen Fraction

Was calculated from arterial blood oxygen analysis. Measurements were obtained at (1) T Lateral, (2) T Lat+PP1h, (3) T Lat+PP2h, and (4) EndPP. (NCT02185339)
Timeframe: intraoperative

,
InterventionmmHg (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group477467468493
Moderate Neuromuscular Blockade (Moderate NMB) Group483461465487

[back to top]

Arterial to End-tidal Partial Pressure of Carbon Dioxide Difference

Was calculated from arterial blood and expired carbon dioxide analysis. Measurements were obtained at (1) T Lateral, (2) T Lat+PP1h, (3) T Lat+PP2h, and (4) EndPP. (NCT02185339)
Timeframe: intraoperative

,
InterventionmmHg (Mean)
T LateralT Lat+PP1hT Lat+PP2hT EndPP
Deep Neuromuscular Blockade (Deep NMB) Group4.35.85.84.2
Moderate Neuromuscular Blockade (Moderate NMB) Group4.37.17.25.3

[back to top]

Continuous Abdominal Contractions

"Number of patients experiencing episodes with continuous abdominal contractions where the abdomen feels tight but the operation can still proceed (the intestines are gradually displaced near the inner surface of the abdominal wall)" (NCT02247466)
Timeframe: 3 hours

InterventionParticipants (Count of Participants)
Group A - Saline, Assesment, Rocuronium and Assesment0
Group B - Rocuronium, Assesment, Sugammadex and Assesment0

[back to top]

Insufflator Alarms

Insufflator alarms where pneumoperitoneum > 17 mmHg Number of patients experiencing insufflator alarms where pneumoperitoneum > 17 mmHg (NCT02247466)
Timeframe: 3 hours

InterventionParticipants (Count of Participants)
Group A - Saline, Assesment, Rocuronium and Assesment0
Group B - Rocuronium, Assesment, Sugammadex and Assesment0

[back to top]

Operating Time

Duration of operating time (from first incision to last suture) (NCT02247466)
Timeframe: 3 hours

Interventionminutes (Mean)
Group A - Saline, Assesment, Rocuronium and Assesment61
Group B - Rocuronium, Assesment, Sugammadex and Assesment64

[back to top]

Suturing Time

Duration of suturing the hernia (minutes) (NCT02247466)
Timeframe: 3 hours

Interventionminutes (Mean)
Group A - Saline, Assesment, Rocuronium and Assesment10
Group B - Rocuronium, Assesment, Sugammadex and Assesment9

[back to top]

Contractions

Sudden contractions of the abdominal wall during operation (bucking or coughing), number of participants with sudden contractions (NCT02247466)
Timeframe: 3 hours

InterventionParticipants (Count of Participants)
Group A - Saline, Assesment, Rocuronium and Assesment1
Group B - Rocuronium, Assesment, Sugammadex and Assesment0

[back to top]

Change in Lactate Over 24 Hours

Change in median serum lactate level between enrollment and 24-hours after the receipt of study drug. A negative number indicates that the lactate levels were lower at 24 hours compared to their level at receipt of study drug. (NCT02260258)
Timeframe: 24 hours

Interventionmmol/L (Number)
Rocuronium-2.2
Usual Care-2.3

[back to top]

Change in Lactate Over 24 Hours: Effect Estimate

Interaction between allocated treatment and time: ratio of geometric mean differences over 24 hours in log lactate values between the two groups. (NCT02260258)
Timeframe: 24 hours

InterventionRatio (Number)
Effect Estimate1.3

[back to top]

Muscle Weakness Score

"Medical Research Council Scale : Measured for 6 muscle groups (3 in the upper limbs and 3 in the lower limbs). Maximum score is 30 (grade 5 for each group) and minimum is 0 (grade 0 for each group). If muscle group strength was not symmetric bilaterally, higher measurement used. Higher scores indicate better outcomes.~Grade 5: Muscle contracts normally against full resistance. Grade 4: Muscle strength is reduced but muscle contraction can still move joint against resistance.~Grade 3: Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed.~Grade 2: Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.~Grade 1: Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle.~Grade 0: No movement is observed" (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days

InterventionPoints (Median)
Rocuronium30
Usual Care30

[back to top]

Survival

In-hospital survival (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days

InterventionParticipants (Count of Participants)
Rocuronium14
Usual Care14

[back to top]

Time ROSC to Target Temperature

Time from return of spontaneous circulation to target temperature (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days

InterventionHours (Median)
Rocuronium6.8
Usual Care8.3

[back to top]

Length of Intensive Care Unit (ICU) Stay

Length of stay in ICU (NCT02260258)
Timeframe: Length of Stay Truncated at 28 Days

,
Interventiondays (Median)
All patientsICU survivors
Rocuronium6.09.0
Usual Care4.05.0

[back to top]

Mechanical Ventilation Duration

Mechanical Ventilation Duration in Hours (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days

,
InterventionHours (Median)
All patientsSurvivors to extubation
Rocuronium102.0126.3
Usual Care82.766.9

[back to top]

Number of Participants With Rankin Score ≤3

"Modified Rankin scale to assess neurological outcome at discharge. The scale ranges from 0 to 6, and is used for measuring the performance of daily activities. The score is as follows:~0: No symptoms~1: No significant disability (able to carry out all usual activities, despite some symptoms)~2: Slight disability (able to look after own affairs without assistance, but unable to carry out all previous activities)~3: Moderate disability (requires some help, but able to walk unassisted)~4: Moderately severe disability (unable to attend to own bodily needs without assistance, and unable to walk unassisted)~5: Severe disability (requires constant nursing care and attention, bedridden, incontinent)~6: Dead.~Higher cores represent worse outcomes. Good and bad neurological outcome will be defined as a score of 0-3 and 4-6 respectively. This outcome reports the number of patients with a good neurological outcome( modified Rankin score ≤ 3)" (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days

InterventionParticipants (Count of Participants)
Rocuronium11
Usual Care9

[back to top]

Time to Modified Aldrete's Score ≥ 9

Time from Post Anesthesia Care Unit (PACU) arrival to patients were considered fit for discharge from the PACU by Modified Aldrete's score assessment which scale range is from 0-10. Higher value represents a better outcome. (NCT02451202)
Timeframe: Minutes from Post Anesthesia Care Unit (PACU) arrival to patients were considered fit for discharge from the PACU.

InterventionMinutes (Median)
Deep Neuromuscular Blockade Arm27
Moderate Neuromuscular Blockade Arm33

[back to top]

Proportion of Patients Who Have a Clinically Acceptable Surgical Conditions

Proportion of patients who have a excellent and good surgical condition score (NCT02451202)
Timeframe: intraoperative

InterventionProportion of patients (Number)
Moderate Neuromuscular Blockade Arm0.89
Deep Neuromuscular Blockade Arm1

[back to top]

Inspiratory Pressure That Cause Gastric Insufflation

"Difference in the inspiratory pressure that minimized the incidence of gastric insufflation, yet guaranteed a tidal volume of at least 6 ml/kg between the neuromuscular blocker and non-neuromuscular blocker groups.~Gastric insufflation was measured using both gastric ultrasonography and epigastric auscultation." (NCT02471521)
Timeframe: Interval between start of mask ventilation and detection of gastric insufflation, an expected average of 100 sec

InterventioncmH2O (Mean)
Neuromuscular Blocker Group13
Non-neuromuscular Blocker Group13

[back to top]

PQRS Results at 15 and 40 Minutes After Surgery (Taking Into Account the Patient Baseline Values of the PQRS Test Done on the Preanesthetic Visit)

PQRS(Post-operative Quality Recovery Scale) recovery rate at 15 minutes post surgery and PQRS recovery rate at 40 minutes post surgery. Recovery is defined as returning to PQRS baseline values. (NCT02484651)
Timeframe: 15 and 40 minutes after surgery

InterventionParticipants (Count of Participants)
15 minutes7193142615 minutes7193142740 minutes7193142740 minutes71931426
Overall recoveryDid not recovered
Standard Group2
Deep NMB Group5
Standard Group24
Deep NMB Group21
Standard Group0
Deep NMB Group3
Standard Group32
Deep NMB Group27

[back to top]

BIS Signal Variability Using the Measured Standard Deviation During the Maintenance Phase of Anesthesia

"BIS (Bispetral Index of the EEG) sample standard deviation during the maintenance phase of anesthesia was used as a measure of signal variability, maintenance phase is defined as the time between the first time the BIS signal drops below 60 after loss of consciousness, until the time the BIS signal goes above 60 after the propofol infusion is stopped. BIS signal varies between 0 to 100. BIS values near 100 represent an awake clinical state while 0 denotes the maximal effect an isoelectric EEG. The aim was to maintain the BIS value within a target range of 40 to 60. The higher the BIS sample standard deviation the higher the oscillation around the sample mean." (NCT02484651)
Timeframe: Maintenance of anesthesia, an average of 130 minutes

Interventionunits on a scale (Mean)
Standard Group7.6
Deep NMB Group7.8

[back to top]

Required Effect-site Concentrations of Propofol and Remifentanil

"Mean effect-site concentration of propofol required during maintenance of anesthesia (using target controlled infusion).~Mean effect-site concentration of remifentanil required during maintenance of anesthesia (using target controlled infusion)." (NCT02484651)
Timeframe: Maintenance of anesthesia, an average of 130 minutes

,
Interventionng/ml (Mean)
PropofolRemifentanil
Deep NMB Group24502.84
Standard Group30003.26

[back to top]

Operation Time

Time from skin incision to wound dressing assessed up to 8 hours. (NCT02495038)
Timeframe: Intraoperative, an average of 3 hours.

InterventionMinute (Mean)
Intubating Dose, Group I151.8
10% Reduction of Combination of Esmeron® and Nimbex®, Group S147.0
20% Reduction of Combination of Esmeron® and Nimbex®, Group L145.9

[back to top]

Non Invasive Blood Pressure,

"Before induction of anesthesia, non invasive blood pressure was measured for baseline.~And after injection of NMBAs, non invasive blood pressure was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

,,
InterventionmmHg (Mean)
Systolic pressureDiastolic pressure
10% Reduction of Combination of Esmeron® and Nimbex®, Group S128.376.7
20% Reduction of Combination of Esmeron® and Nimbex®, Group L128.474.8
Intubating Dose, Group I128.375.6

[back to top]

Additional Rescue Doses Per Hour Ratio.

Additional Rescue Doses Per Hour Ratio is the number per hour of addition of rescue dose administrated with 10% of initial NMBAs dose. The formula is {(Addition number + 1 / Anesthetic time) x 60}. (NCT02495038)
Timeframe: Intraoperative, an average of 3 hours.

Interventionratio (Mean)
Intubating Dose, Group I1.43455
10% Reduction of Combination of Esmeron® and Nimbex®, Group S1.21014
20% Reduction of Combination of Esmeron® and Nimbex®, Group L0.82128

[back to top]

Anesthetic Time

Time from induction to recovery of anesthesia, asessed up to 3 hours. (NCT02495038)
Timeframe: Intraoperative, an average 4 hours.

InterventionMinute (Mean)
Intubating Dose, Group I163.0
10% Reduction of Combination of Esmeron® and Nimbex®, Group S159.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L161.4

[back to top]

Bispectral Index

"The BIS monitor provides a single dimensionless number, which ranges from 0 (equivalent to EEG silence) to 100. A BIS value between 40 and 60 indicates an appropriate level for general anesthesia, as recommended by the manufacturer.~Before induction of anesthesia, bispectral index was measured for baseline. And after injection of NMBAs, bispectral index was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionBIS score (Mean)
Intubating Dose, Group I46.0
10% Reduction of Combination of Esmeron® and Nimbex®, Group S46.1
20% Reduction of Combination of Esmeron® and Nimbex®, Group L44.3

[back to top]

Body Temperature

"Before induction of anesthesia, body temperature was measured for baseline by oral temperature probe.~And after injection of NMBAs, non invasive blood pressure was measured at 10 min by esophageal temperature probe." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionCelcius degree (Mean)
Intubating Dose, Group I36.3
10% Reduction of Combination of Esmeron® and Nimbex®, Group S36.3
20% Reduction of Combination of Esmeron® and Nimbex®, Group L36.3

[back to top]

Duration 25% of Neuromuscular Blocking Agents(NMBAs)

Time from administration of initial NMBAs to Train-of-four (TOF) ratio >25%, assessed up to 2 hours during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 1 hours

InterventionMinute (Mean)
Intubating Dose, Group I51.3
10% Reduction of Combination of Esmeron® and Nimbex®, Group S47.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L39.4

[back to top]

Onset of Neuromuscular Blocking Agents(NMBAs)

Time from administration of initial NMBAs to Train-of-four (TOF) ratio=0, assessed up to 15 minutes during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 5 minutes

InterventionSecond (Mean)
Intubating Dose, Group I212.8
10% Reduction of Combination of Esmeron® and Nimbex®, Group S230.1
20% Reduction of Combination of Esmeron® and Nimbex®, Group L399.3

[back to top]

Recovery Index of Neuromuscular Blocking Agents(NMBAs)

Time from TOF ratio 25% to 75%, assessed up to 1 hour during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 20 minutes

InterventionMinute (Mean)
Intubating Dose, Group I15.9
10% Reduction of Combination of Esmeron® and Nimbex®, Group S16.2
20% Reduction of Combination of Esmeron® and Nimbex®, Group L14.1

[back to top]

Peripheral Oxygen Saturation

"Before induction of anesthesia, peripheral oxygen saturation was measured for baseline.~And after injection of NMBAs, peripheral oxygen saturation was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionPercentage (Mean)
Intubating Dose, Group I100
10% Reduction of Combination of Esmeron® and Nimbex®, Group S99.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L100

[back to top]

Pain

pain will be scored using numeric rating scale (0-10, with 0 = no pain and 10 = most pain imaginable), at 10 minute intervals at the post anesthesia care unit, but only the mean value will be used in the analysis and reported. (NCT02553629)
Timeframe: postoperative, for up to 2 hours

Interventionunits on a scale (Mean)
Moderate Neuromuscular Block4.4
Deep Neuromuscular Block3.9

[back to top]

Extubation

The investigators will assess the time from the injection of the reversal agent until the time to removal of the endotracheal tune (extubation). (NCT02553629)
Timeframe: intraoperative

Interventionminutes (Mean)
Moderate Neuromuscular Block3
Deep Neuromuscular Block3

[back to top]

Mean Arterial Blood Pressure

"Mean arterial pressure (MAP in mmHg) will be monitored at 10 minute intervals for 2 hours in the post anesthesia care unit.~The data will be averaged per subject and the mean of the mean values are reported." (NCT02553629)
Timeframe: 2 hours postoperative

Interventionmillimeters of mercury (Mean)
Moderate Neuromuscular Block98
Deep Neuromuscular Block101

[back to top]

Respiration

"Respiration will be measured by counting the respiratory rate at 10 min interval for 2 hours in the post anesthesia care unit. The breaths per min (unit 1/min) will be logged.~The data were averaged per subject and the mean of the mean data are reported." (NCT02553629)
Timeframe: 2 hours postoperative

Interventionbreaths per minute (Mean)
Moderate Neuromuscular Block12.7
Deep Neuromuscular Block12.6

[back to top]

Surgical Rating

"During a procedure, the surgical condition will be scored by one surgeon using a 5-point surgical rating. This will be done at 10 min intervals from the start of surgery until the end of surgery scale. The rating scale is a 5-point ordinal scale ranging from 1 = poor condition to 5 = optimal surgical conditions. The mean difference in ratings between procedures under deep neuromuscular block and those during moderate neuromuscular block will be evaluated.~The rating scale will be averaged for each subject and the mean values will be reported." (NCT02553629)
Timeframe: intraoperative

Interventionunits on a scale (Mean)
Moderate Neuromuscular Block4.2
Deep Neuromuscular Block4.8

[back to top]

Postoperative Opioid Requirement

The participants will be given iv fentanyl or hydromorphone after surgery. They will also be given po oxycodone. The investigators will collect data on the amount of opioid that is required after surgery. This will be reported as morphine equivalents using the morphine equivalent calculator at: (NCT02703909)
Timeframe: day of surgery until hospital discharge (approximately 2-3 days)

Interventionmorphine equivalents (Mean)
Opioid Requirement-Subjects Who Had IP of 10 mm During Surgery48.8
Opioid Requirement -Subjects Who Had P of 15 mm During Surgery56.7

[back to top]

Surgeon Satisfaction Scale

The surgeon will grade his satisfaction with the surgical conditions using a 5 point scale with 1 - extremely poor; 2 - poor; 3 - acceptable; 4. good; 5 - optimal surgical conditions (NCT02703909)
Timeframe: day of surgery

InterventionScores on a scale (Mean)
Moderate NMB + 10 mm IP2.7
Moderate NMB + 15 mm IP4.1
Deep NMB + 10 mm IP3.1
Deep NMB + 15 mm IP4.6

[back to top]

Number and Percentage of Subjects With Success at Low (10 mm) Insufflation Pressure

The patients will be randomized to an initial insufflation pressure of 10 or 15 mm hg. If the surgeons are not satisfied with the initial operating conditions, the insufflating pressure will be increase to 15 mm Hg (if not already at that level). This will be reported as the percentage of patients who were able to have their entire surgery performed at an insufflation pressure of 10 mm Hg. (NCT02703909)
Timeframe: day of surgery

InterventionParticipants (Count of Participants)
Moderate NMB + 10 mm IP10
Moderate NMB + 15 mm IP0
Deep NMB + 10 mm IP14
Deep NMB + 15 mm IP0

[back to top]

The Degree of Bleeding

2.The degree of bleeding of each patient scaled by surgeons (Intraoperative scale for assessment of operating condition of surgical field: 0 - No bleeding, 1 - Slight bleeding - no suctioning of blood required, 2 - Slight bleeding - occasional suctioning required but not threatened the operative field, 3 - Slight-bleeding - frequent suctioning of blood was required that threatens the operative field a few seconds after suctioning, 4 - Moderate bleeding - frequent suctioning of blood was required which threatens the operative field directly after suctioning, 5 - Severe bleeding - continuous suctioning of blood was required which severely threatened the operative field make the surgery not possible). (NCT02724111)
Timeframe: Continuously observed during the whole period of surgery, up to 3 hours

InterventionScores on a scale (NRS; 0-5) (Mean)
Deep Neuromuscular Blockade1.8
Restricted Neuromuscular Blockade3.3

[back to top]

Adverse Events : The Postoperative Nausea and Vomiting Occurrence in Subject

The occurrence of any adverse events was recorded in the post-anesthesia care unit (PACU) and a ward during the postoperative 24 hours. (NCT02724111)
Timeframe: during the postoperative 24 hours

InterventionParticipants (Count of Participants)
Deep Neuromuscular Blockade11
Restricted Neuromuscular Blockade8

[back to top]

Mean Value of Peak Inspiratory Pressure

This outcome is the mean value of the peak inspiratory pressure measured at each 15 minute during the anesthesia, which can reflect the degree of the tone of respiratory muscles. As muscle tone increases, airway pressure usually increases due to increased tone of abdominal muscle and respiratory muscles including diaphragm. The longer the surgery goes, the higher the airway pressure gets. Also, as neurospinal surgeries are operated in the prone position, the potential for increased airway pressure is high. As airway pressure gets higher, intrathoracic pressure and intraabdominal pressure also become higher. These consequences may bring about similar results with detrimental effects derived from marked increase in intraabdominal pressure in laparoscopic abdominal surgeries (NCT02724111)
Timeframe: Every 15 minutes during anesthesia, up to 3 hours

InterventioncmH2O (Mean)
Deep Neuromuscular Blockade18.4
Restricted Neuromuscular Blockade20.2

[back to top]

Mean Value of Pressure of Back Muscle Retractor

Mean value of pressure of back muscle retractor placed in the operating site (recorded every 15 minutes during the placement of the retractor): measured by the pressure probe placed between the retractor and the back muscle. (NCT02724111)
Timeframe: Every 15 minutes at the period of the retractor placement during surgery, up to 2 hours

InterventionmmHg (Mean)
Deep Neuromuscular Blockade81.2
Restricted Neuromuscular Blockade100

[back to top]

Overall Satisfaction of Surgeons for the Surgical Condition

Overall satisfaction of surgeons for the surgical condition will be assessed by the surgeons who perform surgery using numerical rating scale (NRS; 1-10) after surgery (1, worst; 10, best). (NCT02724111)
Timeframe: After surgery

InterventionScores on a scale (NRS; 1-10) (Mean)
Deep Neuromuscular Blockade8
Restricted Neuromuscular Blockade3.1

[back to top]

Recovery Time (Time to Reach Sedation Score 5 at Postanesthesia Care Unit (PACU).

the time to reach sedation score 5 (the Observer's Assessment of Alertness/ Sedation (OAA/S) score; awake, 5 to unresponsive, 1) at PACU (NCT02724111)
Timeframe: every 10 min for 1 hour at PACU.

Interventionminute (Mean)
Deep Neuromuscular Blockade10.5
Restricted Neuromuscular Blockade17

[back to top]

The Muscle Tone

The muscle tone of each patient at the screw insertion through the pedicle of spine during surgery scaled by surgeons (1: muscle tone is good, suitable for surgery; 2: muscle tone is moderate, but do not affect the operation; 3: muscle tone is hard, making the operation difficult.). (NCT02724111)
Timeframe: at the screw insertion through the pedicle of spine during surgery

InterventionScores on a scale (NRS; 1-3) (Mean)
Deep Neuromuscular Blockade1.3
Restricted Neuromuscular Blockade2.5

[back to top]

The Number of Body Movements

The number of body movements (including cough or any diaphragm movement) observed during the surgery. (NCT02724111)
Timeframe: At the occurrence of the event during surgery, up to 3 hours

Interventionnumber of event (Mean)
Deep Neuromuscular Blockade0
Restricted Neuromuscular Blockade2

[back to top]

Abdominal Insufflation Pressure

To compare surgical operating condition by Abdominal Insufflation Pressure in patients undergoing laparoscopic procedures using deep NMB versus moderate NMB (NCT02812186)
Timeframe: Intra-operative, from intubation time to extubation time

InterventionmmHg (Median)
Deep NMB15
Moderate NMB15

[back to top]

Peak Airway Pressures

To determine if a deep NMB can lead to lower peak airway pressures in patients undergoing laparoscopic procedures when compared to a moderate NMB (NCT02812186)
Timeframe: Intra-operative, from intubation time to extubation time

,
Interventioncm H2O (Median)
MeanMaximum
Deep NMB25.528
Moderate NMB28.330

[back to top]

Surgical Rating Scale

"To compare surgical operating condition by Surgical Rating Scale (SRS) in patients undergoing laparoscopic procedures using deep NMB versus moderate NMB~Surgical Rating Score scores are on a 1-5 scale with 1 = extremely poor conditions, 2 = poor conditions, 3 = adequate conditions, 4 = good conditions, 5= excellent conditions. Higher scores mean a better outcome." (NCT02812186)
Timeframe: Intra-operative, from intubation time to extubation time

Interventionunits on a scale (Median)
Deep NMB5
ModerateNMB5

[back to top]

Cumulative Use of Rocuronium

Total amount of rocuronium administered during surgery (NCT02838134)
Timeframe: Day 0: once, up to 240 minutes

Interventionmg (Mean)
Group A: Deep Neuromuscular Blockade184.6
Group B: Moderate Neuromuscular Blockade67.0

[back to top]

Conversion

Number of Participants with conversion to open or hand-assisted donor nephrectomy (NCT02838134)
Timeframe: Day 0: once, up to 240 minutes

InterventionParticipants (Count of Participants)
Group A: Deep Neuromuscular Blockade0
Group B: Moderate Neuromuscular Blockade2

[back to top]

Pain Scores

Total amount of pain 4 weeks after surgery Likert scale from 0 to 10. Higher scores represent more pain (worse outcome). (NCT02838134)
Timeframe: once, 4 weeks after surgery

Interventionscore on a scale (Mean)
Group A: Deep Neuromuscular Blockade1.88
Group B: Moderate Neuromuscular Blockade1.85

[back to top]

Surgical Conditions

"Surgical rating score, concerning the quality of the surgical field, scored with the surgical rating scale (SRS) A likert scale from 1 to 5. Higher scores represent better outcomes.~= extremely poor conditions~= poor conditions~= acceptable conditions~=good conditions~= optimal conditions" (NCT02838134)
Timeframe: Day 0: Intraoperative, average of scores up to 240 minutes (assessed each 15 minutes)

Interventionscore on a scale (Mean)
Group A: Deep Neuromuscular Blockade4.8
Group B: Moderate Neuromuscular Blockade4.7

[back to top]

Total Score of the Quality of Recovery-40 Questionnaire

The QoR-40 is a validated assessment tool for measuring a patient's self-assessed quality of recovery after surgery. It consists of 40 questions measuring 5 dimensions: patient support, comfort, emotions, physical independence and pain. Each item is rated on a scale of 1 to 5, giving a minimal score of 40 and a maximum score of 200. Higher values represent a better outcome. (NCT02838134)
Timeframe: Day 2: 48 hours after detubation

Interventionscore on a scale (Mean)
Group A: Deep Neuromuscular Blockade175.6
Group B: Moderate Neuromuscular Blockade175.3

[back to top]

Total Score of the Quality of Recovery-40 Questionnaire (QoR-40)

The QoR-40 is a validated assessment tool for measuring a patient's self-assessed quality of recovery after surgery. It consists of 40 questions measuring 5 dimensions: patient support, comfort, emotions, physical independence and pain. Each item is rated on a scale of 1 to 5, giving a minimal score of 40 and a maximum score of 200. Higher values represent a better outcome (NCT02838134)
Timeframe: Day 1: 24 hours after detubation

Interventionscore on a scale (Mean)
Group A: Deep Neuromuscular Blockade169.3
Group B: Moderate Neuromuscular Blockade169.5

[back to top]

Warm Ischemia Time

Intraoperative parameter measuring the time (in minutes) between dissection of the renal artery and flushing of the kidney after retrieval (NCT02838134)
Timeframe: Day 0: once, up to 240 minutes

Interventionminutes (Mean)
Group A: Deep Neuromuscular Blockade3.6
Group B: Moderate Neuromuscular Blockade3.9

[back to top]

Discharge Criteria

Scoring the following criteria: adequate pain control with oral medication, passage of flatus or defecation, intake of solid food tolerated, patient is mobilized and independent and patient accepts discharge. (NCT02838134)
Timeframe: 24 and 48 hours after detubation

,
InterventionParticipants (Count of Participants)
reached all criteria after 24hoursreached all criteria after 48 hours
Group A: Deep Neuromuscular Blockade1324
Group B: Moderate Neuromuscular Blockade1529

[back to top]

Postoperative Pain

"components of pain scores after 1 hour, 6 hours, on postoperative day 1 (POD1) and postoperative day 2 (POD2).~Likert scale from 0 to 10. Higher scores represent more pain." (NCT02838134)
Timeframe: Day 0: 1h, 6h, day 1: 24h and day 2: 48 hours (and if still admitted 72h) after detubation

,
Interventionscore on a scale (Mean)
Overall_1h (PACU)Referred pain_1h (PACU)overall_6hReferred pain_6hOverall_POD1Referred pain+POD1Overall_POD2Referred pain_POD2
Group A: Deep Neuromuscular Blockade4.00.03.70.75.02.54.62.4
Group B: Moderate Neuromuscular Blockade4.310.34.51.05.63.24.93.3

[back to top]

Postoperative Complications

Number of participants with postoperative complications that occurred up to 8 weeks after surgery (NCT02838134)
Timeframe: 24 and 48 hours (and if still admitted 72h) after detubation and 4 and 8 weeks after surgery

,
InterventionParticipants (Count of Participants)
during hospital stay30 days after surgery60 days after surgery
Group A: Deep Neuromuscular Blockade279
Group B: Moderate Neuromuscular Blockade455

[back to top]

Length of Pneumoperitoneum

Intraoperative parameter of duration of pneumoperitoneum (NCT02838134)
Timeframe: Day 0: once, up to 240 minutes

Interventionminutes (Mean)
Group A: Deep Neuromuscular Blockade122.8
Group B: Moderate Neuromuscular Blockade113.8

[back to top]

Intra-operative Complications

Number of Participants with Complications which occurred during surgery (NCT02838134)
Timeframe: Day 0: once, up to 240 minutes

InterventionParticipants (Count of Participants)
Group A: Deep Neuromuscular Blockade1
Group B: Moderate Neuromuscular Blockade6

[back to top]

Estimated Blood Loss

Intraoperative parameter (NCT02838134)
Timeframe: Day 0: once, up to 240 minutes

Interventionml (Mean)
Group A: Deep Neuromuscular Blockade60.2
Group B: Moderate Neuromuscular Blockade69.1

[back to top]

Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA

The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation. (NCT02914119)
Timeframe: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours

InterventionTrain-of-four ratio (Median)
Eligible Patients0.97

[back to top]

Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively

(NCT02914119)
Timeframe: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes

InterventionMinutes (Median)
Eligible Patients97

[back to top]

Incidence of Postoperative Residual Curarization

the number of participant with Postoperative residual curarization (PORC, TOF ratio < 0.9 ) (NCT03039543)
Timeframe: at the arrival of postoperative post-anesthesia care unit (PACU), an average of 5 minutes

InterventionParticipants (Count of Participants)
Moderate Neuromuscular Blockade0
Deep Neuromuscular Blockade0

[back to top]

Number of Participants Attaining a 5 (Optimal) Surgical Condition Score

"5-point surgical condition scale was evaluated as follows.~Extremely poor~unable to work because of coughing or because of the inability to obtain a endoscopic view because of inadequate muscle relaxation. Additional neuromuscular blocking agents (NMB) must be given.~Poor~severely hampered by inadequate muscle relaxation with continuous muscle contractions, movements, or both with the hazard of tissue damage. Additional NMB is needed.~Acceptable~a wide endoscopic view but bladder contractions, movements, or both occur regularly causing some interference with the surgeon's work. There is the need for additional NMB to prevent deterioration.~Good~a wide endoscopic working field with sporadic muscle contractions, movements, or both. No immediate need for additional NMB unless there is the fear of deterioration.~Optimal~a wide endoscopic working field without any movement or contractions. No additional NMB is needed." (NCT03039543)
Timeframe: immediately following the operation, an average of 5 minutes

InterventionParticipants (Count of Participants)
Moderate Neuromuscular Blockade16
Deep Neuromuscular Blockade38

[back to top]

Other Postoperative Adverse Events

Pain, postoperative nausea and vomiting, dry mouth, Postoperative bladder discomfort (NCT03039543)
Timeframe: During PACU stay (An average of 15 minutes)

InterventionParticipants (Count of Participants)
Moderate Neuromuscular Blockade0
Deep Neuromuscular Blockade0

[back to top]

Recovery Time (PACU Discharge)

time needed to reach a modified Aldrete score of 9 (NCT03039543)
Timeframe: During PACU stay (An average of 15 minutes)

Interventionminutes (Mean)
Moderate Neuromuscular Blockade15
Deep Neuromuscular Blockade15

[back to top]

the Incidence of Desaturation

Respiratory complication such as desaturation (SpO2 < 90%) were recorded during PACU stay. (NCT03039543)
Timeframe: During PACU stay (An average of 15 minutes)

InterventionParticipants (Count of Participants)
Moderate Neuromuscular Blockade0
Deep Neuromuscular Blockade0

[back to top]

Number Patients With Increased Risk of Falling

Based on TUG time measurements of patients below are the numbers of patients with an increased risk of falling. (NCT03063255)
Timeframe: Changes from baseline (pre-op) to 72 hours post-operative

Interventionparticipants (Number)
Obturator Block28
Neuromuscular Block29

[back to top]

Number of Patients With Incidence of Leg Weakness

Test the strength of subject's lower extremity muscles on the timed up and go (TUG) test and determine how many patients had increased leg weakness. (NCT03063255)
Timeframe: Changes from baseline (pre-op) to 72 hours post-operative

InterventionParticipants (Count of Participants)
Obturator Block27
Neuromuscular Block22

[back to top]

Number of Patients With Incidence of Intraoperative Adductor Spasm

Nerve Integrity Monitor will be used to detect adductor spasm and below are listed the numbers or patients with increased incidence of adductor spasm. (NCT03063255)
Timeframe: intraoperative

InterventionParticipants (Count of Participants)
Obturator Block1
Neuromuscular Block5

[back to top]

PostOperative Complications

To determine if Sugammadex can improve post-operative complications for outpatient bladder procedures such as bladder perforation, nausea, vomiting, post-operative intubation and hospital admittance secondary to respiratory complications which was assessed uring follow ups on post-operative day 1 (POD1) and post-operative day 7 (POD7) looking for immediate postoperative complications such as bladder perforation, nausea, vomiting, postoperative intubation and hospital admittance secondary to respiratory complications and readmission within a week post-procedure for any other cause. (NCT03138967)
Timeframe: Post-operatively, up to 7 days

InterventionParticipants (Count of Participants)
Suggamadex or Treatment Group5
Neostigime/Glycopyrrolate or Standard of Care Group7

[back to top]

Muscle Recovery Time

The primary outcome is to determine if Sugammadex can improve muscle recovery time, measured by time from administration of neuromuscular blockade reversal to train-of-four ratio of 0.9 in outpatient bladder procedures. It was assessed in the intraoperative period measuring the time from administration of reversal agent to TOF of 0.9 in minutes. (NCT03138967)
Timeframe: Intraoperatively, up to 3 hours

Interventionminutes (Mean)
Suggamadex or Treatment Group2
Neostigime/Glycopyrrolate or Standard of Care Group9.24

[back to top]

Overall Recovery Time

To determine if Sugammadex can improve overall recovery time, measured by time from end of surgery to the time patient met Discharge Criteria. (NCT03138967)
Timeframe: Up to 3 hours after end of surgery

Interventionhours (Mean)
Suggamadex or Treatment Group2.0847
Neostigime/Glycopyrrolate or Standard of Care Group2.4727

[back to top]

Intraoperative Hemodynamic Conditions

Perioperative average blood pressure will be reported, mean blood pressure ranging from 65 tot 110 millimeters mercury is considered normal (NCT03170661)
Timeframe: Perioperative measurements at 15 minute interval (on average during 3 hours)

Interventionmillimeters mercury (Median)
Moderate Neuromuscular Block84
Deep Neuromuscular Block85

[back to top]

Intraoperative Nociception Level

"The median and full range of the average nociception level index will be reported.~The nociception level index consist of Ta multiparameter nonlinear combination of heart rate, heart rate variability, amplitude of the finger photoplethysmogram, skin conductance level, fluctuations in skin conductance, and their time derivatives, derived from random forest regression. Random forest is an algorithmic modeling approach that enables combining multiple parameters of different origin and discovering their complex nonlinear interactions. Normal range is between 10-20; 0 indicates no nociceptive events (in example, pain stimuli), 100 indicates severe painful stimuli." (NCT03170661)
Timeframe: Perioperative measurements at 15 minute interval (on average during 3 hours)

Interventionscore on a scale (Median)
Moderate Neuromuscular Block11
Deep Neuromuscular Block13

[back to top]

Leiden Surgical Rating Scale

During the on average 3 hour procedure, the surgical condition will be scored by the surgeon using a 5-point surgical rating scale at 15 minute intervals(1: poor ; 5: optimal) Mean and standard deviation of the average of all leiden surgical rating scale will be reported. (NCT03170661)
Timeframe: during surgery

Interventionscore on a scale (Mean)
Moderate Neuromuscular Block4.8
Deep Neuromuscular Block4.8

[back to top]

Postoperative Measurements and Outcomes; Pain Scores

"Postoperative measurements and outcomes of during PACU stay, all scores are reported as means and standard deviation of the average over the follow up period~-mean pain scores (numeric rating scale; 0 no pain - 10 worst pain imaginable)" (NCT03170661)
Timeframe: During post-anesthetic care unit stay (average stay 2 hours) at 15 minute intervals

Interventionunits on a scale (Mean)
Moderate Neuromuscular Block2.9
Deep Neuromuscular Block3.2

[back to top]

Postoperative Measurements and Outcomes; Saturation

"Postoperative measurements and outcomes of during PACU stay, all scores are reported as means and standard deviation of the average over the follow up period~-blood oxygen saturation in percent levels between 95-100 are considered normal" (NCT03170661)
Timeframe: During post-anesthetic care unit stay (average stay 2 hours) at 15 minute intervals

Interventionpercentage of blood oxygen saturation (Mean)
Moderate Neuromuscular Block98
Deep Neuromuscular Block98

[back to top]

Postoperative Measurements and Outcomes; Sedation Levels

"Postoperative measurements and outcomes of during PACU stay, all scores are reported as means and standard deviation of the average over the follow up period~-ramsay sedation levels (0 = normal alertness, eyes open, responds normal to command 1 = drowsy with open eyes, closed and opened on command 2 = drowsy with closed eyes, opened in response to light auditory stimulus 3 = eyes closed, opened in response to rubbing the shoulder or a loud auditory stimulus 4 = eyes closed and opened only briefly in response to touching the subject 5 = eyes closed, unarousable by touch, aroused by painful 6 = unarousable by pain)" (NCT03170661)
Timeframe: During post-anesthetic care unit stay (average stay 2 hours) at 15 minute intervals

Interventionunits on a scale (Mean)
Moderate Neuromuscular Block0.9
Deep Neuromuscular Block1.0

[back to top]

Mean Visual Analogue Scale (VAS) Score for Wound Pain at Post Anesthesia Care Unit (PACU)

The patient was administered intravenous oxycodone 2 mg (body weight <80 kg) or 3 mg (>80 kg) every 10 min until the visual analogue scale (VAS) assessments showed that the pain intensity had decreased to <3 at rest and <5 on wound compression. At this point, the minimum effective analgesic dose (MEAD) of oxycodone was determined. The range of VAS is 0-10 (0 = no pain; 10 = most severe pain). (NCT03266419)
Timeframe: Through study period in post anesthesia care unit (PACU), an average of about 1 hour

Interventionmm (Mean)
Deep NMB Using Rocuronium6.1
Moderate NMB Using Rocuronium6.1

[back to top]

Minimum Effective Analgesic Dose (MEAD) of Oxycodone at Postoperative Care Unit (PACU)

The patient was administered intravenous oxycodone 2 mg (body weight <80 kg) or 3 mg (>80 kg) every 10 min until the VAS (visual analogue scale)assessments showed that the pain intensity had decreased to <3 at rest and <5 on wound compression. At this point, MEAD of oxycodone was determined. The range of VAS is 0-10 (0 = no pain; 10 = most severe pain). (NCT03266419)
Timeframe: Through study period in PACU (post anesthesia care unit), up to 2 hours

Interventionmg (Median)
Deep NMB Using Rocuronium8.0
Moderate NMB Using Rocuronium8.0

[back to top]

Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI. (NCT03346057)
Timeframe: Up to 7 days

,,,
InterventionPercentage of Participants (Number)
With one or more ECIsAdjudicated HypersensitivityAdjudicated AnaphylaxisClinically Relevant BradycardiaClinically Relevant TachycardiaOther Clinically Relevant Cardiac ArrhythmiaDrug Induced Liver Injury
Neostigmine + Glycopyrrolate3.90.00.02.00.02.00.0
Sugammadex 16 mg/kg7.40.00.00.05.91.50.0
Sugammadex 2 mg/kg1.90.00.00.01.90.00.0
Sugammadex 4 mg/kg5.60.00.02.81.90.90.0

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events

The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg6.7
Sugammadex 4 mg/kg9.3
Sugammadex 16 mg/kg8.8
Neostigmine + Glycopyrrolate21.6

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events

The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate <60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg1.0
Sugammadex 4 mg/kg1.9
Sugammadex 16 mg/kg7.4
Neostigmine + Glycopyrrolate7.8

[back to top]

Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events

The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg1.0
Sugammadex 4 mg/kg0.0
Sugammadex 16 mg/kg1.5
Neostigmine + Glycopyrrolate2.0

[back to top]

Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. (NCT03346057)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg94.3
Sugammadex 4 mg/kg88.8
Sugammadex 16 mg/kg92.6
Neostigmine + Glycopyrrolate88.2

[back to top]

Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose. (NCT03346057)
Timeframe: Up to 7 days

InterventionPercentage of Participants (Number)
Sugammadex 2 mg/kg11.4
Sugammadex 4 mg/kg7.5
Sugammadex 16 mg/kg10.3
Neostigmine + Glycopyrrolate5.9

[back to top]

Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.8: Geometric Mean Analysis

The efficacy analysis of TTR of participant TOF ratio to ≥0.8 was performed by estimating the geometric mean of TTR within each treatment group. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.8 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 69 minutes

InterventionMinutes (Geometric Mean)
Sugammadex 2 mg/kg ABW1.6
Sugammadex 4 mg/kg ABW1.5
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.5
Sugammadex 2 mg/kg IBW2.5
Sugammadex 4 mg/kg IBW2.6
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.5
Neostigmine/Glycopyrrolate16.6

[back to top]

Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.7: Geometric Mean Analysis

The efficacy analysis of TTR of participant TOF ratio to ≥0.7 was performed by estimating the geometric mean of TTR within each treatment group. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.7 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 61 minutes

InterventionMinutes (Geometric Mean)
Sugammadex 2 mg/kg ABW1.4
Sugammadex 4 mg/kg ABW1.3
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.4
Sugammadex 2 mg/kg IBW2.1
Sugammadex 4 mg/kg IBW2.0
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.1
Neostigmine/Glycopyrrolate10.9

[back to top]

Percentage of Participants With Prolonged (>10 Minutes) Time to Recovery (TTR) of the Train Of Four (TOF) Ratio to ≥0.9

Following administration of study intervention, the percentage of participants experiencing prolonged (>10 minutes) recovery to a TOF ratio ≥0.9 was calculated. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.9 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 76 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW7.9
Sugammadex 4 mg/kg ABW2.7
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)5.3
Sugammadex 2 mg/kg IBW5.4
Sugammadex 4 mg/kg IBW0.0
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.7
Neostigmine/Glycopyrrolate84.2

[back to top]

Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events

The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events were identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias are defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachyarrhythmia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not be considered an AE, as determined by investigator judgment. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 35 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW0.0
Sugammadex 4 mg/kg ABW0.0
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)0.0
Sugammadex 2 mg/kg IBW2.6
Sugammadex 4 mg/kg IBW0.0
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)1.4
Neostigmine/Glycopyrrolate2.6

[back to top]

Percentage of Participants Experiencing an Event of Clinical Interest (ECI) After Administration of Study Intervention

The percentage of participants experiencing an ECI following administration of study intervention was monitored. ECIs are a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW0.0
Sugammadex 4 mg/kg ABW2.6
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.3
Sugammadex 2 mg/kg IBW2.6
Sugammadex 4 mg/kg IBW2.8
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.7
Neostigmine/Glycopyrrolate2.6

[back to top]

Percentage of Participants Experiencing an Adverse Event (AE) After Administration of Study Intervention

The percentage of participants experiencing an AE following administration of study intervention was monitored. An AE is any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening (i.e. any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study treatment is also considered an AE. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW94.7
Sugammadex 4 mg/kg ABW86.8
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)90.8
Sugammadex 2 mg/kg IBW94.7
Sugammadex 4 mg/kg IBW91.7
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)93.2
Neostigmine/Glycopyrrolate89.5

[back to top]

Percentage of Participants Experiencing a Serious Adverse Event (SAE) After Administration of Study Intervention

The percentage of participants experiencing an SAE following administration of study intervention was monitored. An SAE is an adverse event that: results in death; is life threatening; results in persistent or significant disability or incapacity; results in or prolongs a hospitalization; is a congenital anomaly or birth defect; is a cancer; or may jeopardize the participant, potentially requiring medical or surgical intervention. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW2.6
Sugammadex 4 mg/kg ABW0.0
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.3
Sugammadex 2 mg/kg IBW5.3
Sugammadex 4 mg/kg IBW8.3
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)6.8
Neostigmine/Glycopyrrolate7.9

[back to top]

Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.9: Secondary Geometric Mean Analysis

The secondary efficacy analysis of TTR of participant TOF ratio to ≥0.9 was performed by estimating the geometric mean of TTR within each treatment group. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.9 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 76 minutes

InterventionMinutes (Geometric Mean)
Sugammadex 2 mg/kg ABW2.0
Sugammadex 4 mg/kg ABW1.9
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)2.0
Sugammadex 2 mg/kg IBW3.2
Sugammadex 4 mg/kg IBW3.5
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)3.3
Neostigmine/Glycopyrrolate23.1

[back to top]

Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis

The primary efficacy analysis of TTR of TOF ratio to ≥0.9 was performed by estimating event rates within each treatment group using the Kaplan-Meier method. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.9 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 76 minutes

InterventionMinutes (Median)
Sugammadex 2 mg/kg ABW1.7
Sugammadex 4 mg/kg ABW1.8
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.8
Sugammadex 2 mg/kg IBW3.4
Sugammadex 4 mg/kg IBW3.3
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)3.3
Neostigmine/Glycopyrrolate34.5

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events

The percentage of participants experiencing treatment-emergent bradycardia events were identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia is defined as a heart rate <60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not be considered an adverse event (AE), as determined by investigator judgment. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 35 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW5.3
Sugammadex 4 mg/kg ABW5.3
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)5.3
Sugammadex 2 mg/kg IBW2.6
Sugammadex 4 mg/kg IBW5.6
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)4.1
Neostigmine/Glycopyrrolate2.6

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events

The percentage of participants experiencing treatment-emergent sinus tachycardia events were identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not be considered an AE, as determined by investigator judgment. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 35 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW10.5
Sugammadex 4 mg/kg ABW13.2
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)11.8
Sugammadex 2 mg/kg IBW7.9
Sugammadex 4 mg/kg IBW2.8
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)5.4
Neostigmine/Glycopyrrolate7.9

[back to top]

Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9

"Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units minutes:seconds (mm:ss), was reformatted to be presented in the single unit of minutes (min)." (NCT03519854)
Timeframe: Up to 70 minutes following administration of study treatment

Interventionminutes (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®52.05
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®22.73
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®4.93
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®6.25
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®1.85
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®1.83
Arm G. Placebo; Given 5 Minutes After Esmeron®51.67
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®27.35
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®8.88
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®2.28
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®2.13
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®1.45
Arm M. Placebo; Given 15 Minutes After Esmeron®35.58
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®6.53
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®2.73
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®2.05
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®2.08
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®1.35

[back to top]

Mean Heart Rate at Baseline

Mean heart rate at baseline was assessed. Baseline heart rate was defined as the heart rate measured under stable anesthesia prior to administration of study treatment. (NCT03519854)
Timeframe: Up to 45 minutes prior to study treatment administration

Interventionbeats per minute (bpm) (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®61.0
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®62.0
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®63.5
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®68.0
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®68.2
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®69.8
Arm G. Placebo; Given 5 Minutes After Esmeron®68.0
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®56.7
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®64.2
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®64.7
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®69.7
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®57.5
Arm M. Placebo; Given 15 Minutes After Esmeron®63.0
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®62.7
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®65.3
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®64.2
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®66.5
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®68.5

[back to top]

Mean Heart Rate at 30 Minutes Following Administration of Study Treatment

Mean heart rate at 30 minutes following administration of study treatment was assessed. (NCT03519854)
Timeframe: 30 minutes following administration of study treatment

Interventionbpm (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®77.8
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®62.0
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®72.0
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®72.5
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®76.7
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®66.6
Arm G. Placebo; Given 5 Minutes After Esmeron®77.3
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®63.0
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®69.7
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®72.5
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®66.5
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®60.0
Arm M. Placebo; Given 15 Minutes After Esmeron®65.7
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®66.8
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®65.3
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®63.5
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®64.7
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®66.0

[back to top]

Mean Heart Rate at 2 Minutes Following Administration of Study Treatment

Mean heart rate at 2 minutes following administration of study treatment was assessed. (NCT03519854)
Timeframe: 2 minutes following administration of study treatment

Interventionbpm (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®76.7
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®73.0
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®84.5
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®72.7
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®86.2
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®74.8
Arm G. Placebo; Given 5 Minutes After Esmeron®84.0
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®61.3
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®70.8
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®66.2
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®69.8
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®67.8
Arm M. Placebo; Given 15 Minutes After Esmeron®59.0
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®71.2
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®77.2
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®62.8
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®65.4
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®64.3

[back to top]

Mean Corrected QT Interval (QTc) at Baseline

Mean QTc interval at baseline was assessed. Baseline QTc interval was defined as the QTc interval measured under stable anesthesia prior to administration of study treatment. The baseline QTc interval is corrected for participant heart rate at baseline prior to study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate. (NCT03519854)
Timeframe: Up to 45 minutes prior to study treatment administration

Interventionmilliseconds (msec) (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®418
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®396
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®418
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®404
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®417
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®416
Arm G. Placebo; Given 5 Minutes After Esmeron®400
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®415
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®405
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®416
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®408
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®411
Arm M. Placebo; Given 15 Minutes After Esmeron®392
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®410
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®398
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®398
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®398
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®406

[back to top]

Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment

Mean QTc interval at 2 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 2 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate. (NCT03519854)
Timeframe: 2 minutes following administration of study treatment

Interventionmsec (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®420
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®406
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®422
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®406
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®427
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®416
Arm G. Placebo; Given 5 Minutes After Esmeron®400
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®420
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®412
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®419
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®410
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®416
Arm M. Placebo; Given 15 Minutes After Esmeron®401
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®419
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®406
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®416
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®410
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®416

[back to top]

Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment

Mean QTc interval at 30 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 30 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate. (NCT03519854)
Timeframe: 30 minutes following administration of study treatment

Interventionmsec (Mean)
Arm A. Placebo; Given 3 Minutes After Esmeron®418
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®416
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®427
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®415
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®433
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®424
Arm G. Placebo; Given 5 Minutes After Esmeron®392
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®420
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®425
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®413
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®400
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®422
Arm M. Placebo; Given 15 Minutes After Esmeron®400
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®418
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®408
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®421
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®411
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®418

[back to top]

Number of Participants Experiencing an Adverse Event

The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product. (NCT03519854)
Timeframe: Up to 7 days following administration of study treatment

InterventionParticipants (Count of Participants)
Arm A. Placebo; Given 3 Minutes After Esmeron®0
Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®5
Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®1
Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®4
Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®4
Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®5
Arm G. Placebo; Given 5 Minutes After Esmeron®2
Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®2
Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®1
Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®3
Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®2
Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®2
Arm M. Placebo; Given 15 Minutes After Esmeron®0
Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®4
Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®4
Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®1
Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®1
Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®3

[back to top]

Percentage of Participants Experiencing ≥1 Adverse Events (AEs)

The percentage of participants experiencing ≥1 AEs was determined. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. (NCT03519867)
Timeframe: Up to 7 days following MK-8616 administration

InterventionPercentage of Participants (Number)
1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg100.0
2) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg100.0
3) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg60.0
4) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg66.7
5) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg80.0
6) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg100.0
7) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg100.0
8) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg100.0
9) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg66.7
10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg50.0

[back to top]

Time From Start of Administration of MK-8616 to Recovery T4/T1 Ratio to 0.9

The mean time from the start of MK-8616 administration to recovery T4/T1 ratio of 0.9 was determined. Less time indicates faster recovery from NMB. The ratio of T4 (fourth twitch; amplitude of fourth response to train of four [TOF] stimulation is expressed as percent of control T4) over T1 (first twitch; amplitude of first response to TOF stimulation is expressed as percent of control T1) ranges from 0 (complete loss of T4 twitch response) to 1.0 (complete recovery of T4 twitch response). For TOF stimulation, 4 consecutive square wave supra-maximal stimuli of 0.2 msec duration were delivered at 2 Hz every 15 seconds. Neuromuscular monitoring was performed with the TOF-Watch® SX. (NCT03519867)
Timeframe: Up to 90 minutes

InterventionMinutes (Mean)
1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg44.18
2) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg19.08
3) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg5.38
4) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg3.32
5) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg1.53
6) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg20.57
7) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg11.52
8) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg4.33
9) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg1.92
10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg0.98

[back to top]

Recovery Time of T1 to 90% Baseline

The time of neuromuscular recovery from sugammadex 4mg/kg dose reversal rocuronium at 0.6 mg/kg compared with traditionally used succinylcholine in electroconvulsive therapy (ECT). (NCT03532178)
Timeframe: 30 minutes

Interventionminutes (Mean)
Muscle Relaxant #16.79
Muscle Relaxant #210.97

[back to top]

Number of Participants With Treatment or Emergent Adverse Events of the Drugs

To document the side-effect profiles of sugammadex reversal of rocuronium and succhinylcholine in the ECT patient population (NCT03532178)
Timeframe: 24 hours after the procedure

,
InterventionParticipants (Count of Participants)
NauseaMyalgiaHeadache
Rocuronium + Sugammadex117
Succinylcholine + Normal Saline329

[back to top]

Additional Post Op Pain

post-operative pain: measured on a 0 (no pain) -10 (worst) numeric rating scale (NRS) at 6hrs, 12hrs, 2 weeks, and 2 months. A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 6hrs, 12hrs, 2weeks, 2 months

,
Interventionscore on a scale (Median)
6 Hrs12 hrs2 weeks2 months
Non-Opioid Intervention0.000.820
Observational241.30.7

[back to top]

Simple Shoulder Test

Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Weeks

Interventionscore on a scale (Median)
Observational2.0
Non-Opioid Intervention2.0

[back to top]

Simple Shoulder Test

Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Months

Interventionscore on a scale (Median)
Observational6
Non-Opioid Intervention6

[back to top]

Post Op Pain

Pain at patient discharge or 24-hours, whichever comes first - measured on a 0 (no pain) -10 (worst possible pain) numeric rating scale (NRS). A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 24 hours

Interventionscore on a scale (Median)
Observational3.0
Non-Opioid Intervention2.0

[back to top]

ASES

American Shoulder and Elbow Surgeons (ASES) Shoulder Score for pain and function. Range 0-100. Low score = worse shoulder condition. Function, disability, and pain subscores (all ranges 0-50), and are summed for total ASES score. (NCT03540030)
Timeframe: 2 Weeks

Interventionunits on a scale (Median)
Observational54.3
Non-Opioid Intervention54.2

[back to top]

Morphine Use

Morphine milli-equivalents In-hospital post-operative. Continuous scale of MME, no defined better/worse. Measured as number and dose of medications taken. For example, if the patient received an opioid, the drug and dose was recorded and converted to MME. A time frame of when to assess opioid use in-hospital post-operative was not used but was a continuous monitor for rescue opioid from in-hospital post-operative through discharge. (NCT03540030)
Timeframe: In-hospital Stay

InterventionMorphine milli-equivalents (Median)
Observational45.0
Non-Opioid Intervention19.0

[back to top]

Falls

rate of falls (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention4274
Observational4242

[back to top]

Falls

rate of falls (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention5300
Observational1272

[back to top]

Nausea

rate of nausea (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention1300
Observational0282

[back to top]

Nausea

rate of nausea (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention1340
Observational5232

[back to top]

Pain Satisfaction

Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention2924
Observational2352

[back to top]

Pain Satisfaction

Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention3410
Observational2712

[back to top]

Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore

quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Months

,
Interventionscore on a scale (Median)
PCSMCS
Non-Opioid Intervention40.360.8
Observational38.458.7

[back to top]

Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore

quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Weeks

,
Interventionscore on a scale (Median)
PCSMCS
Non-Opioid Intervention35.059.1
Observational36.756.3

[back to top]

Constipation

rate of constipation (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention13220
Observational1992

[back to top]

Constipation

rate of constipation (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention4274
Observational7212

[back to top]

Incidence of Postoperative Severe Residual Neuromuscular Blockade at Time of Tracheal Extubation

Postoperative severe residual neuromuscular blockade is measured by a Train-of-four ratio <0.7 as measured by acceleromyography. (NCT03543826)
Timeframe: Within two minutes of time of extubation.

InterventionParticipants (Count of Participants)
Subjects Undergoing Orthopedic or Abdominal Surgery1

[back to top]

Incidence of Postoperative Severe Residual Neuromuscular Blockade at Time of Arrival to the Post-anesthesia Care Unit.

Postoperative severe residual neuromuscular blockade is measured by a Train-of-four ratio <0.7 as measured by acceleromyography. (NCT03543826)
Timeframe: Within five minutes of arrival to the post-anesthesia care unit.

InterventionParticipants (Count of Participants)
Subjects Undergoing Orthopedic or Abdominal Surgery2

[back to top]

Incidence of Postoperative Residual Neuromuscular Blockade at Time of Tracheal Extubation.

Postoperative residual neuromuscular blockade is measured by a Train-of-four ratio <0.9 as measured by acceleromyography. (NCT03543826)
Timeframe: Within two minutes of time of extubation.

InterventionParticipants (Count of Participants)
Subjects Undergoing Orthopedic or Abdominal Surgery14

[back to top]

Incidence of Postoperative Residual Neuromuscular Blockade at Time of Arrival to the Post-anesthesia Care Unit.

Postoperative residual neuromuscular blockade is measured by a Train-of-four ratio <0.9 as measured by acceleromyography. (NCT03543826)
Timeframe: Within five minutes of arrival to the post-anesthesia care unit.

InterventionParticipants (Count of Participants)
Subjects Undergoing Orthopedic or Abdominal Surgery5

[back to top]

Relative Abundance of Intestinal Microbiota

Intestinal microbiota is one of the factors related to the recovery of intestinal function. It can be analyzed by 16S rRNA sequencing of the postoperative feces. (NCT03782233)
Timeframe: the first time of defecation after operation

,
Interventionpercentage of all intestinal microbiota (Median)
Class-DeltaproteobacteriaClass-FlavobacteriiaOrder-DesulfovibrionalesOrder-FlavobacterialesFamily-[Tissierellaceae]Family-FusobacteriaceaeFamily-DesulfovibrionaceaeFamily-[Weeksellaceae]Genus-BlautiaGenus-DialisterGenus-CollinsellaGenus-FusobacteriumGenus-BilophilaGenus-AggregatibacterGenus-MegasphaeraGenus-NeisseriaGenus-SelenomonasGenus-RoseburiaGenus-TG5
Deep Neuromuscular Blockade(Group D)0.001048342432100.008149378906500.00213624495600.00053406123900.008149378906500.00970211250880.00021758050470.00243294564440.00053406123900.005063691747700.000059340138000.0000197800460
Moderate Neuromuscular Blockade (Group M)0.00104834243210.0000197800460.00104834243210.000039560.00011868027530.01960202547670.00102856238620.0000197800460.00247250573620.004272489912100.01960202547670.00100878234030.00071208165200.00197800458890.0000197800460.00003956009200.000019780045

[back to top]

16s rRNA Sequencing of Postoperative Feces

"Alpha and Beta diversity; relative abundance of gut microbiota. Alpha diversity includes Chao 1 index, Shannon index, and Simpson index. A higher value of Chao 1 index corresponds to more abundant number of microbiota. A higher value of Shannon index corresponds to more abundance. And A higher value of Simpson index corresponds to less diversity.~Bata diversity was assessed by PCoA analysis. A three dimensional scatter plot was presented to visualize the similarities and differences between the two groups." (NCT03782233)
Timeframe: the first time of defecation after operation

,
Interventionscore on a scale (Mean)
alpha diversity - Chao1alpha diversity - Shannon indexalpha diversity - Simpson index
Deep Neuromuscular Blockade Group (Group D)763.74.930.9
Moderate Neuromuscular Blockade Group (Group M)599.34.150.83

[back to top]

Total Number of Operational Taxonomic Units (OUTs) of Intestinal Microbiota

"Intestinal microbiota was analyzed by 16S rRNA sequencing. To be specific, first, DNA was extracted and quantified. Bacterial 16S rRNA genes of the V3-V4 region were amplified from extracted DNA using the barcoded primers (5'- CCTACGGRRBGCASCAGKVRVGAAT-3') and (5'- GGACTACNVGGGTWTCTAATCC-3'). PCR reactions were performed and the PCR mixture applied to the PCR amplifier. Then, the PCR products were checked for size and specificity by agarose gel electrophoresis and purified. Finally, high-throughput sequencing was performed using the Illumina MiSeq platform.~The raw reads were filtered to remove low quality sequences and the filtered data were further merged into tags by FLASH(Version 1.2.7). Then the Uchime algorithm in Usearch software was applied to remove chimeric tags. Resulting tags for each sample were clustered into operational taxonomic units(OTUs) at the level of 97% similarity.~Higher values represent a more abundant amount of bacteria in gut." (NCT03782233)
Timeframe: the first time of defecation after operation

Interventionunits (Number)
Deep Neuromuscular Blockade(Group D)1695
Moderate Neuromuscular Blockade (Group M)1287

[back to top]

Duration of Surgery

Time from the first dose of anesthetic to the end of the surgery (NCT03782233)
Timeframe: From the first dose of anesthetic to the end of the surgery

Interventionminutes (Mean)
Deep Neuromuscular Blockade(Group D)155.0
Moderate Neuromuscular Blockade (Group M)174.6

[back to top]

Duration of Postoperative Hospital Stay

Duration from the day of surgery to the day the patient discharged from the hospital (NCT03782233)
Timeframe: from the end of surgery to the time of being discharged from hospital

Interventiondays (Mean)
Deep Neuromuscular Blockade(Group D)9.2
Moderate Neuromuscular Blockade (Group M)9.1

[back to top]

Duration of CO2 Pneumoperitoneum

Time from the beginning to the end of CO2 pneumoperitoneum (NCT03782233)
Timeframe: from the beginning to the end of CO2 pneumoperitoneum

Interventionminute (Mean)
Deep Neuromuscular Blockade(Group D)132.3
Moderate Neuromuscular Blockade (Group M)147.0

[back to top]

Plasma Concentration of Diamine Oxidase (DAO) Before the Surgery

The level of DAO can indicate the damage to the gastrointestinal barrier . (NCT03782233)
Timeframe: 1 day Before the Surgery

InterventionU/L (Mean)
Deep Neuromuscular Blockade(Group D)15.5
Moderate Neuromuscular Blockade (Group M)16.4

[back to top]

Plasma Concentration of Diamine Oxidase (DAO) 24 h After the Surgery

The level of DAO can indicate the damage to the gastrointestinal barrier . (NCT03782233)
Timeframe: 24 h after the Surgery

InterventionU/L (Mean)
Deep Neuromuscular Blockade(Group D)18.1
Moderate Neuromuscular Blockade (Group M)26.5

[back to top]

Plasma Concentration of D-lactic Acid Before the Surgery

The level of D-lactic acid can indicate the damage to the gastrointestinal barrier . (NCT03782233)
Timeframe: 1 day before the surgery

Interventionng/ml (Mean)
Deep Neuromuscular Blockade(Group D)1100.4
Moderate Neuromuscular Blockade (Group M)1087.8

[back to top]

Postoperative Exhaust Time

It's a regular measurement to evaluate the function of gastrointestinal tract . It is calculated from the end of the operation to the time of exhaust. (NCT03782233)
Timeframe: It is calculated from the end of the operation to the time of exhaust.

Interventionhour (Mean)
Deep Neuromuscular Blockade(Group D)58.9
Moderate Neuromuscular Blockade (Group M)70.5

[back to top]

Surgical Condition Scores Rated by Surgeons (Average Scores)

evaluation of the surgical condition by 5 point scale: 5 points: optimal; 4 points: good; 3 points: acceptable; 2 points: poor; 1 point: extremely poor. (NCT03782233)
Timeframe: during surgery

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade(Group D)4.6
Moderate Neuromuscular Blockade (Group M)3.2

[back to top]

Postoperative VAS (48 h After Surgery, Rest State)

VAS pain score: 0 - completely painless, 10 - unbearable pain. (NCT03782233)
Timeframe: 48 h after surgery

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade(Group D)0.4
Moderate Neuromuscular Blockade (Group M)0.7

[back to top]

Plasma Concentration of D-lactic Acid 24 h After the Surgery

The level of D-lactic acid can indicate the damage to the gastrointestinal barrier . (NCT03782233)
Timeframe: 24 h after the surgery

Interventionng/ml (Mean)
Deep Neuromuscular Blockade(Group D)1230.7
Moderate Neuromuscular Blockade (Group M)1297.5

[back to top]

Postoperative VAS (48 h After Surgery, Active State)

VAS pain score: 0 - completely painless, 10 - unbearable pain. (NCT03782233)
Timeframe: 48 h after surgery

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade(Group D)1.5
Moderate Neuromuscular Blockade (Group M)1.5

[back to top]

Postoperative VAS (24 h After Surgery, Rest State)

VAS pain score: 0 - completely painless, 10 - unbearable pain. (NCT03782233)
Timeframe: 24 h after surgery

Interventionpoints (Mean)
Deep Neuromuscular Blockade(Group D)1.3
Moderate Neuromuscular Blockade (Group M)1.5

[back to top]

Postoperative VAS (24 h After Surgery, Active State)

VAS pain score: 0 - completely painless, 10 - unbearable pain. (NCT03782233)
Timeframe: 24 h after surgery

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade(Group D)2.7
Moderate Neuromuscular Blockade (Group M)3.1

[back to top]

Postoperative VAS (12 h After Surgery, Rest State)

VAS pain score: 0 - completely painless, 10 - unbearable pain. (NCT03782233)
Timeframe: 12 h after surgery

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade(Group D)2.2
Moderate Neuromuscular Blockade (Group M)2.1

[back to top]

Postoperative VAS (12 h After Surgery, Active State)

VAS pain score: 0 - completely painless, 10 - unbearable pain. (NCT03782233)
Timeframe: 12 h after surgery

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade(Group D)3.6
Moderate Neuromuscular Blockade (Group M)3.8

[back to top]

Onset Time

"The time from the end of rocuronium injection to train-of-four (TOF) count of 0 monitored by acceleromyography.~The ulnar nerve was stimulated during the monitoring." (NCT03857750)
Timeframe: Day 0, after induction of anesthesia

Interventionseconds (Median)
Elderly (>80 Years)135
Younger (18-40 Years)90

[back to top]

Duration of Action

Time from end of rocuronium injection to TOF ratio >0.9. When the ratio between the first and last stimulation in TOF is above 90 %. (NCT03857750)
Timeframe: Day 0, after induction of anesthesia

Interventionminutes (Median)
Elderly (>80 Years)81
Younger (18-40 Years)53

[back to top]

Time Until Complete Reversal of Neuromuscular Blockade

Measure how long it takes to return from a TOF of 2 to a TOF ≥ 0.9. (NCT03904550)
Timeframe: In the operating room, the amount of time after administration of the reversal syringe to reach recovery of neuromuscular function (TOFR ≥ 90%) assessed up to 30 minutes.

InterventionMinutes (Mean)
Cisatracurium + Neostigmine14.8
Rocuronium + Sugammadex3.5

[back to top]

Time to Extubation

"Time to extubation: West Virginia University Hospitals use an electronic medical record (EMR) to chart procedure stop. The definition for time to extubation is from the time the investigators chart procedure stop to the time of extubation." (NCT03939923)
Timeframe: 0 minutes of study drug to 3 days after study drug administration

InterventionMinutes (Mean)
Neostigmine/Glycopyrrolate10.4
Sugammadex6

[back to top]

Tidal Volume

Tidal volume post-reversal prior to extubation (NCT03939923)
Timeframe: between 30 minutes to 1 hour after extubation

InterventionLiters (Mean)
Neostigmine/Glycopyrrolate1.16
Sugammadex1.0975

[back to top]

Peak Flow Rate

Peak flow rate - measured by peak flow meter post-extubation at 30-60 mins (NCT03939923)
Timeframe: 30-60 minutes post-extubation

InterventionL/min (Mean)
Neostigmine/Glycopyrrolate1.4609
Sugammadex1.416

[back to top]

Blood Pressure (First Measurement of Systolic Blood Pressure Post Reversal)

Blood pressure; measure of systolic blood pressure of subject is obtained post-reversal prior to extubation of trachea (NCT03939923)
Timeframe: 0 minutes to 2 hours after study drug administration

InterventionmmHg (Mean)
Neostigmine/Glycopyrrolate105.6
Sugammadex112.1

[back to top]

Heart Rate

Heart rate post-reversal prior to extubation (NCT03939923)
Timeframe: 0 minutes to 2 hours after study drug administration

Interventionbeats per minute (Mean)
Neostigmine/Glycopyrrolate81.5385
Sugammadex81.1622

[back to top]

Incidence of Postoperative Residual Neuromuscular Blockade at Time of Extubation

Train-of-four ratio <0.9 as measured by electromyography or <1.0 measured by acceleromyography (NCT03958201)
Timeframe: Within two minutes of extubation

InterventionParticipants (Count of Participants)
Subjects Undergoing Elective Surgery Involving the Intraoperative Use of Rocuronium0

[back to top]

Incidence of Severe Postoperative Residual Neuromuscular Blockade at Time of Extubation

Train-of-four ratio <0.7 as measured by electromyography (NCT03958201)
Timeframe: Within two minutes of extubation

InterventionParticipants (Count of Participants)
Subjects Undergoing Elective Surgery Involving the Intraoperative Use of Rocuronium0

[back to top]